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Abstract 
The HCV p7 protein is a viroporin that acts to increase endosomal pH to preserve the 
infectivity of nascent virions. Previous work has identified several key residues in p7 
that are critical for its function. A number of compounds have been found to inhibit p7 
activity in vitro and genotype variation in the p7 sequence is known to have significant 
effects on p7 inhibitor sensitivity. This study aimed to further our understanding of the 
role of p7 during HCV infection. The effects of six naturally-occurring p7 variants, 
within a single genotype, isolated from 5 patients of varying disease severity were 
investigated. 
It was found in in vitro liposome assays that the patient polymorphisms caused a wide 
variation in p7 channel activity. The previously-observed low-pH activation in J4 p7 
was also observed in JFH1 p7, but not in H77 p7; this showed a ‘V’ shaped activation 
profile, with its lowest activity at pH 6.7 and peak activity at pH 6.2 and 7.4. Four of 
the patient isolates shared the same activation pattern as H77; two with non-
synonymous mutations of S21P and Y31H displaying low-pH activation. In virus, the 
Y31H mutant was the only Seattle variant to show a significant reduction in the 
production of infectious virus.  
JFH1 intracellular virions have previously been shown to be sensitive to transient 
exposure to reduced pH, while secreted virions were insensitive to such changes. In 
this study, it is shown that H77 secreted virions are sensitive to transient reductions in 
pH, while the Seattle isolate viruses showed reduced pH sensitivity. The Y31H isolate 
also showed increased sensitivity to the p7 inhibitor rimantadine.  
In conclusion, this study found that natural polymorphisms in p7 within a single 
genotype can cause significant changes in p7 activity. These changes did not show 
any correlation with the severity of disease in the original patients.   
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1.1 Viral hepatitis 
Viral hepatitis, where a virus primarily infects the liver, can be caused by a number of 
viruses from different virus families. High numbers of hepatitis cases following blood 
transfusion were noted after such procedures became common during the 20th 
century, and the causative agents were sought (Starr, 2000). Most cases are caused 
by the hepatitis viruses A-E, but it is estimated that up to 20% of cases of viral 
hepatitis are caused by other agents (Leary et al., 1996).  
1.1.1 Hepatitis A 
Hepatitis A (HAV) is a non-enveloped virus with a single, positive stranded RNA 
genome, classified in the Picornaviridae family, in the genus Hepatovirus. It is 
transmitted through the faeco-oral route and causes sporadic outbreaks of potentially 
severe acute hepatitis. The disease typically lasts for 6-8 weeks, with jaundice a 
common symptom of liver infection. A formalin-inactivated vaccine has significantly 
reduced the incidence of infection (Martin & Lemon, 2006) 
1.1.2 Hepatitis B 
Hepatitis B virus (HBV) is a DNA virus of the family Hepadnaviridae that can cause a 
chronic infection of the liver. Transmission of the virus occurs through blood and 
bodily fluids. Prior to routine screening of blood donations, HBV accounted for a large 
proportion of cases of post-transfusion hepatitis. In most adult cases, HBV causes an 
acute infection, with a 1% risk of developing fulminant hepatitis and a 25% risk of 
developing a chronic infection. Acute HBV infection is slower to progress than HAV, is 
typically non-cytopathic and shows relatively mild symptoms. Chronic HBV has a risk 
of long-term liver damage that can cause cirrhosis or hepatocellular carcinoma 
(Hollinger & Liang, 2001). The virus coat proteins are capable of forming empty virus 
particles; this property allowed the development of a vaccine based on self-assembled 
empty particles. Routine vaccination of children against HBV is now performed in over 
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160 countries, and the incidence rates of acute HBV in the USA fell by 85% between 
1990 and 2006 (Liaw & Chu, 2009).  
1.1.3 Hepatitis delta virus 
Hepatitis delta virus (HDV) is a satellite virus of HBV of the genus Deltavirus, with a 
single stranded negative-sense RNA genome that produces sufficient proteins to 
replicate the genome and form a viral capsid. HDV requires the envelope 
glycoproteins from HBV to produce infectious virus particles. The progression of HDV 
infection is similar to HBV, with transmission via blood and bodily fluids. Patients 
chronically infected with both HBV and HDV show more rapid progression of liver 
disease (Polish et al., 1993).  
1.1.4 Hepatitis E 
Hepatitis E virus (HEV), like HAV, is a small, non-enveloped single-stranded positive 
sense RNA virus transmitted via the faeco-oral route. It was previously classified in 
the Calicivirus family, but has since been reclassified into the new Hepevirus family. 
HEV is endemic in southeast and central Asia, where it is transmitted through 
contaminated water. Development of a chronic HEV infection is extremely rare and 
most acute infections are self-resolving. HEV has an approximate mortality rate of 1%, 
but this increases in certain at-risk groups including pregnant women (Krawczynski, 
1993).  
1.1.5 Hepatitis G 
Hepatitis G virus (HGV), also known as GB virus C (GBVC), has been classified 
among the Flaviridae family and can chronically infect humans through blood 
products, vertical transmission and sexual contact. It is a close relative of HCV with 
~30% sequence homology and infects hepatocytes, but shows no known pathogenic 
effects (Stapleton et al., 2004). It is related to GB virus A, one of two viruses (GBVA 
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and GBVB) originally identified from a patient with acute viral hepatitis after the patient 
sera was passaged in tamarins. 
1.2 Hepatitis C virus 
1.2.1 Discovery 
Blood transfusion was developed in the early 20th century, and the Second World War 
saw a large increase in the use of blood products. With this expansion in usage, there 
was a notable incidence of hepatitis in patients following transfusion (Starr, 2000). 
Hepatitis A and B were identified and screening methods were developed to prevent 
contamination of the blood supply, but a third cause was known to exist that could not 
be identified; this was named chronic non-A non-B hepatitis (Tobler & Busch, 1997). A 
partial genome of HCV was isolated by the Chiron Corporation in 1989 (Choo et al., 
1989). From this partial genome many of the viral proteins were identified, and 
antigens expressed that allowed the development of an enzyme-linked 
immunosorbent assay for virus detection (ELISA). This test was used to screen blood 
donations from 1990 onwards (Tobler & Busch, 1997). 
1.2.2 Global prevalence and distribution of HCV 
The WHO estimates that the worldwide prevalence of HCV is 3% of the total 
population. There are seven major genotypes of HCV, with various subtypes, and an 
uneven geographical distribution (Negro & Alberti, 2011; Lavanchy, 2009). Fig 1.1 
shows the genotype distribution and estimated prevalence in each country, where 
known. Genotype 1A (GT1A) is the most prevalent strain in North America and 
Europe, followed by GT 1B. GT 2A and 2B are distributed worldwide, but are most 
prevalent in Japan and northern Italy. GT 3 is the most common strain in the Indian 
subcontinent. GT 4 is the most common genotype in Africa and the Middle East, and 
has a high degree of genetic diversity. GTs 5 and 6 are rare, and found in limited 
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geographical areas: mainly South Africa and the Hong Kong area respectively 
(Hoofnagle, 2002). 
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Figure 1.1 Global prevalence and genotype distribution of HCV 
HCV prevalence by country is shown where known. Green = below 1% prevalence, blue = 1-1.9%, yellow = 2-2.9%, red = greater than 3%, 
grey = unknown. Genotype distribution by country is shown in pie charts. Taken from Negro and Alberti, 2011 
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1.2.3 Transmission, progression and treatment of HCV  
1.2.3.1 Transmission 
HCV is transmitted through contact with infected blood. In the developed world, the 
most common risk factor for HCV infection is intravenous drug use (IDU), which is 
responsible for over 50% of cases. Prevalence of HCV among intravenous drug users 
can be as high as 60%, with the largest risk factor being the length of time the 
individual has been injecting drugs (Hope et al., 2001). Whilst the sharing of syringes 
has declined due to increased awareness of the risk of HIV, HCV may also be 
transmitted through the shared use of drug preparation equipment, and transmission 
via intranasal inhalation of cocaine using shared straws has been documented (Clarke 
& Kulasegaram, 2006).  
Historically, blood transfusions were responsible for the majority of HCV cases. 
Screening of blood donations was initiated as soon as testing was made available in 
1990, and transmission via this route has been almost completely eliminated. 
Transmission to or from healthcare workers via sharp injuries or mucous membrane 
splash injuries has been well documented, and the risk of infection from a single 
percutaneous exposure is estimated to be 1.8%. As well as infected blood products, 
iatrogenic transmission has also been documented from medical devices such as 
endoscopes (Clarke & Kulasegaram, 2006). In the developing world, safe procedures 
may not always be followed due to a lack of resources and needles, surgical tools and 
other equipment may be reused multiple times, increasing the risk of transmission 
(Shepard et al., 2005). Egypt has the highest known rate of HCV infection in the world 
as a result of inadequate sterilisation of equipment during treatment for the parasite 
schistosomiasis during the second half of the 20th century (Strickland et al., 2002).  
Tattooing is another potential risk factor, but the increased awareness of HIV has 
resulted in needles and other paraphernalia no longer being reused between clients, 
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and thus professional tattooing carries no increased risk of HCV. Non-professional 
tattooing, especially that carried out in prisons, does carry an increased risk of HCV 
(Tohme & Holmberg, 2012). 
Sexual transmission of HCV is extremely rare, with almost no transmissions 
documented in discordant heterosexual couples (where one partner is infected and 
the other is not) (Vandelli et al., 2004). A marginal increase in risk for those with 
multiple sexual partners has been suggested, but may be attributed to other risk-
associated behaviour, including drug use. The only factor significantly known to 
enhance the risk of sexual transmission is HIV infection, which increases the risk for 
both HIV+ heterosexual women and HIV+ men who have sex with men (MSM). The 
statistics on sexual transmission may be complicated by the reliance on self-reporting 
of intravenous drug use as well as sexual behaviour; one Italian study of discordant 
heterosexual couples that documented transmission later found that this was due to 
the sharing of needles between the couple rather than sexual transmission (Tohme & 
Holmberg, 2010).  
Vertical transmission of HCV from mother to child during birth occurs in less than 10% 
of cases in HIV-negative mothers, which rises in cases of HIV co-infection. A major 
risk factor for both groups is the level of HCV viraemia, with almost all transmissions 
occurring in mothers with viraemia levels greater than 106 copies per ml (Thomas et 
al., 1998b). HIV+ mothers typically had higher levels of HCV viraemia which may 
account for some of the increase rate of vertical transmission, but there is still a higher 
risk of transmission in HIV+ mothers even when HCV viraemia levels are taken into 
account (Pappalardo, 2003). 
Other possible transmission routes have been documented in case studies, but these 
are likely to be extremely rare. They include traditional shaving techniques, tick bites, 
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shared use of toothbrushes and biting between children (Clarke & Kulasegaram, 
2006). 
1.2.3.2 Acute infection 
Acute HCV infection has few symptoms, with those reported being mild, such as 
fatigue (Merican et al., 1993), and often passing entirely undetected. Work in 
chimpanzees, and the few detected cases of early infections in humans, has found 
that HCV RNA becomes detectable within days of infection accompanied by up to a 
10-fold increase in serum levels of liver aminotransferase enzymes (Hoofnagle, 2002), 
but seroconversion can take up to 12 weeks (Maheshwari et al., 2008). Clearance of 
the virus without seroconversion has been documented (Post et al., 2004). At the end 
of the acute phase of infection, viral RNA drops to very low levels and either becomes 
undetectable in the case of viral clearance, or a chronic infection develops where the 
RNA levels increase once again, although typically to a much lower level than during 
acute infection (Mondelli et al., 2005).  
Rarely, acute infection may result in potentially life-threatening fulminant hepatitis. It is 
of note that the laboratory strain of HCV, Japanese Fulminant Hepatitis 1 (JFH1), 
originated from a case of fulminant hepatitis in Japan (Wakita et al., 2005). 
1.2.3.3 Chronic infection 
In approximately 85% of cases HCV will develop into a chronic infection and, once 
established, spontaneous clearance of the chronic infection is rare (Yokosuka et al., 
1999). The initial immune response to the acute infection will generally be effective at 
reducing the viral load but, as chronic infection becomes established, viral loads 
increase, although typically to lower levels than usually observed during initial acute 
infection. HCV infection is largely asymptomatic, with many infections going 
undetected until the development of liver disease. Analysis of patient data has shown 
that the risk of developing cirrhosis within 20 years of infection is 10-20% (Seeff, 
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2002). The viral load and genotype have been shown not to correlate with the level of 
liver disease, with one exception; genotype 3 HCV displays increased progression to 
hepatocellular carcinoma (HCC)  (Nkontchou et al., 2011).  
1.2.3.4 HIV co-infection 
The prevalence of HIV and HCV co-infection is linked to blood-borne transmission, 
with an estimated population of 4-5 million co-infected out of an estimated total of 33.4 
million with chronic HCV (Alter, 2006). Those co-infected with HIV often show higher 
viral titres and are more likely to develop cirrhosis or HCC (Giordano et al., 2004; Soto 
et al., 1997). Rates of vertical transmission are also increased with HIV co-infection 
(Pappalardo, 2003). Even with the immunosuppressive effect of HIV infection, some 
cases of spontaneous clearance of HCV are still observed (Vogel & Rockstroh, 2010). 
Quasispecies variation in HCV within patients is also reduced when patients are co-
infected with HIV, possibly as a result of the reduced selection from the immune 
system with the overall reduction in immune response due to HIV (Li et al., 2011).  
1.2.3.5 Disease progression and pathology 
It is thought that the role of HCV in liver pathology is indirect as there is no correlation 
between viral load and the severity of the disease, with pathology resulting from 
damage to the liver rather than any direct cytopathic effect of the virus. The only 
directly cytopathic effect shown for the virus is an association between liver steatosis 
and GT3 (Kumar et al., 2002). Liver fibrosis is reversible and may recede if HCV 
treatment achieves a sustained virological response (SVR), but cirrhosis is 
irreversible. Once the liver has become cirrhotic, it is classified as either 
compensated, where the liver remains functional; or decompensated, where liver 
function is impaired. HCC is a rare outcome of HCV infection, but represents a 
significant healthcare burden. 
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The link between HCV and HCC is not clear, but some viral proteins have been 
shown to interact with cellular factors that prevent apoptosis and promote oncogenic 
signalling, and this may increase the risk of HCC development.  
The more advanced the stage of fibrosis, the less likely that treatment will effectively 
clear the virus. Liver damage as a result of HCV infection is currently the leading 
cause for liver transplantation in North America and Europe, and thus represents a 
significant healthcare burden (Keeffe, 2001).  
Liver transplantation remains the only option for advanced liver failure caused by 
HCV. Newly transplanted livers are rapidly re-infected with HCV from reservoirs 
elsewhere in the body, and the immunosuppression required for transplantation 
makes clearance of the virus with drug treatment unlikely. Trials are currently 
underway with newly developed drugs in transplant patients.  
1.2.3.6 Diagnosis  
HCV is not routinely tested for in the general population, but risk factors such as 
having been a recipient of blood products prior to the introduction of screening and 
having been an IDU indicate populations likely to require testing. There are two 
methods for detecting HCV infection: serological tests detecting the presence of 
antibodies to the virus, and nucleic acid detection methods that can determine the 
presence and number of viral RNA genome copies (Krajden, 2000). The serological 
tests, based on ELISA technology, are dependent on seroconversion. If the person 
was infected too recently to have seroconverted, or is immunocompromised or 
immunosuppressed, then this test may generate false negative results. The nucleic 
acid detection methods, based on RT-PCR technology for the qualitative tests and Q-
RT-PCR for the quantitative tests were, until recently, less sensitive than the 
serological methods but have now equalled them (Ghany et al., 2009). The 
quantitative methods can be used during on-going treatment to assess the level of 
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viraemia by measuring the number of infectious units (IUs) in the blood, and can be 
used to determine if treatment has achieved an SVR. The serological tests, combined 
with the nucleic acid tests, can be used to determine if the patient is infected with 
HCV. A positive antibody but negative nucleic acid test can show that the patient was 
infected but has managed to clear the virus, and a negative serology test with a 
positive nucleic acid test suggests a patient may only recently have been exposed to 
the virus and has not yet generated a serological response, or is 
immunocompromised (Ghany et al., 2009).  
1.2.3.7 Treatment 
Until recently, treatment of HCV was limited to dual therapy with pegylated interferon 
(IFN), a cytokine that stimulates the anti-viral response, and ribavirin (Rib), a broad-
spectrum nucleoside-analogue anti-viral discovered during screening of nucleoside 
analogue compounds for activity against viruses (Lau et al., 2002). The treatment is 
successful if an SVR is achieved where the immune system is able to clear the virus 
and no virus is detectable by RT-PCR during and after treatment. The efficacy of this 
therapy varies by genotype. Genotype 1 is the least responsive with an SVR obtained 
in less than 50% of patients after 48 weeks of drug therapy (Pawlotsky, 2006). The 
efficacy of the treatment is also affected by the length of time the patient was infected 
prior to treatment, with those with more advanced liver pathology showing a reduced 
response to treatment. A number of side effects, such as fatigue and nausea, can 
additionally lead to early discontinuation of treatment prior to achieving an SVR; this 
can be particularly problematic among more vulnerable populations such as IDUs.  
Two newly developed anti-virals, boceprevir and telapravir, act by inhibiting the viral 
protease NS3/NS4A. These drugs have been included in the IFN/Rib treatment 
regimen. Data from clinical trials displayed an improvement in the SVR in patients with 
genotype 1 HCV from 48% for those on IFN/Rib alone to 70% with telaprevir triple 
therapy. Boceprevir showed an improvement from an SVR of 40% with standard 
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IFN/Rib treatment to 67% with boceprevir triple therapy (Poordad et al., 2011). 
However, both drugs were associated with an increase in the number of reported side 
effects and showed higher treatment dropout rates compared with standard IFN/Rib 
therapy (Jacobson et al., 2011; Poordad et al., 2011). 
Resistance mutations were also observed during the trial phases, particularly where 
the drugs were tested as single treatments rather than as triple therapy with IFN/Rib. 
These resistance mutations were found to still exist in the quasispecies pool several 
years after protease inhibitor monotherapy, indicating that these mutations do not 
cause significant impairment of the virus (Susser et al., 2011).  
There are also a number of direct-acting antivirals targeted at other HCV proteins 
currently undergoing clinical trials. These include BMS-790052, a replication-complex 
inhibitor that acts to inhibit viral replication via a currently unknown mechanism (Gao 
et al., 2010), and a number of replication inhibitors targeting NS5B, the RNA-
dependent RNA polymerase (RdRp) (Legrand-Abravanel et al., 2010).  
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1.3 Viroporins 
1.3.1 Viroporins - a varied group of virus proteins that form channels in 
membranes 
Viroporins are a diverse group of proteins found in many different virus families, 
including both RNA and DNA viruses, which act to increase membrane permeability. 
They are small proteins, ranging in size from approximately 60-100 residues. There is 
poor sequence homology between viroporins from different virus families, but they do 
share some biochemical and functional characteristics: at least one hydrophobic 
domain allowing close association with or insertion into membranes. Many viroporins 
form SDS-resistant oligomers, with structural analysis confirming the homo-
oligomerisation into channels. Some viroporins have been shown to be able to 
substitute or trans-complement one another, but in many cases the additional roles 
the proteins may have in the virus life-cycle, often mediated by extramembrane 
domains, may not allow one viroporin to substitute for another. For example, the 
cytoplasmic domain of influenza A M2 is dispensable for channel formation and 
function but contains an amphipathic helix that mediates membrane scission of the 
budding virion (Rossman et al., 2010).  
Whilst some viroporins regulate pH in intracellular compartments; some release 
intracellular calcium ions from storage; and others, primarily those of non-enveloped 
viruses, disrupt the plasma membrane in order to aid cell lysis and virus release. A 
classification system for viroporins was recently proposed, shown in Fig. 1.2, 
classifying the proteins on the basis of the number of membrane-spanning domains 
and orientation of the protein (Nieva et al., 2012). 
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Figure 1.2 Proposed viroporin classification system 
Panel (a): Class I viroporins have a single membrane-spanning domain. The A and B 
subclasses contain proteins that are inserted into the membrane with either a lumenal 
amino terminus and cytosolic carboxyl terminus (class IA) or a cytosolic amino 
terminus and lumenal carboxyl terminus (class IB). In addition, class IA members are 
usually phosphorylated at the C terminus. Known viroporins of each subclass are 
shown. Panel (b): Class II viroporins form helix–turn–helix hairpin motifs that span the 
membrane. Subclass A members have lumenal N and C termini, whereas members of 
subclass B have cytosolic N and C termini. Known viroporins of each subclass are 
shown. CoV, coronavirus; HCV, hepatitis C virus; HRSV, human respiratory syncytial 
virus; IAV, influenza A virus; PV, poliovirus. Taken from Nieva et al, 2012. 
 
 
 
 
 
Figure 1.3 IAV M2 gating mechanism 
Cartoon of the gating mechanism of IAV M2, depicting two of the 4 TMDs as cylinders 
with side-chains shown for His37 and Trp41. Protonation of His37 due to a decrease 
in pH(ext) results in a conformational change in Trp41 that opens the channel and 
allows proton influx. Adapted from Schnell and Chou, 2008. 
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1.3.2 Influenza A M2 protein 
IAV M2 is a 97-residue integral membrane protein that forms tetramers (Sugrue & 
Hay, 1991; Lamb et al., 1985), is incorporated into the virion (Zebedee & Lamb, 1988) 
and has roles in assembly, egress and entry of the virus (Pinto & Lamb, 2006). It has 
a 23-residue ectodomain, a single transmembrane span of 19 residues and a 
cytoplasmic domain of 55 residues. M2 is expressed abundantly in the cell, with a 
large proportion of the expressed protein found at the plasma membrane (Lamb et al., 
1985). It is also found in other cellular lipid fractions associated with the virus 
glycoproteins haemagglutinin (HA) and neuraminidase (NA) (Lamb et al., 1985).  
The ectodomain is required for incorporation of the protein into the virion (Park et al., 
1998), and is exposed at the plasma membrane where binding by monoclonal 
antibodies restricts the number of infectious virus particles produced (Zebedee & 
Lamb, 1988). The highly-conserved cytoplasmic domain interacts with the M1 protein 
during virus particle formation (McCown & Pekosz, 2006). An amphipathic helix in the 
cytoplasmic domain of M2 has been shown to mediate membrane scission at the neck 
of the budding virion independently of the ESCRT pathway (Rossman et al., 2010), by 
inducing membrane curvature (Wang et al., 2012). Both the ectodomain and the 
cytoplasmic domain show post-translational modifications, with the ectodomain having 
a disulphide linkage and the cytoplasmic domain palmitoylation and phosphorylation 
sites. However, none of these modifications significantly affect the ion channel activity 
of the protein (Holsinger et al., 1995) and none are absolutely required for viral 
replication. Mutational analysis has shown that the loss of palmitoylation reduces 
virulence but does not stop virus replication (Grantham et al., 2009), phosphorylation 
of the cytoplasmic domain is not required for virus infectivity (Thomas et al., 1998a), 
and the disulphide bonds stabilise M2 but do not affect the replication of the virus 
either in vitro or in animal studies (Castrucci et al., 1997). 
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The transmembrane region of M2 mediates the proton channel activity of the protein, 
with the minimal truncation of the protein that is still able to form a fully functioning and 
selective ion channel comprising residues 22-61 (Ma et al., 2009). The proton channel 
activity of M2 is required at two stages of the virus life cycle. Firstly, it is required 
during trafficking of HA and NA through the trans-Golgi to prevent endosomal 
acidification that would cause the HA to undergo a conformational change to the low-
pH conformation, which renders the protein unable to mediate membrane fusion 
during virus entry. Secondly, during virus entry, once the virion has endocytosed into 
the cell, M2 allows the influx of protons from the acidifying endosome into the virion, 
destabilising the capsid and allowing the virus to uncoat (Pinto & Lamb, 2006).  
The structure of the M2 proton channel has been characterised using X-ray 
crystallography and NMR techniques. The channel has been shown to have 3 
constriction points: valine 27 (V27), histidine 37 (H37) and tryptophan 41 (W41). At 
neutral pH in solid-state NMR using the TM domain in a cholesterol-rich virus mimetic 
membrane, the 4 lumenal histidine side groups form a π-stacked ring that breaks the 
‘water-wire’ through the channel lumen.  
A cartoon of the IAV M2 gating mechanism is shown in Fig. 1.3. H37 has been shown 
to act as the proton sensor that mediates both the opening and the proton selectivity 
of the channel, as mutation of this residue to either glycine or glutamic acid in 
Xenopus laevis oocytes showed channel conductance that was unresponsive to 
changes in pH, and the H37E mutation was also able to conduct chloride ions (Wang 
et al., 1995). Solid-state NMR of the TM domain has shown that protonation of a 
minimum of 2 of the 4 histidine side chains causes the imidazolium groups to repel 
each other, causing backbone rearrangements that open the pore of the channel and 
allow the formation of a continuous H-bonded ‘water-wire’ through the lumen of the 
channel that allows the transport of protons (Hu et al., 2010). Rather than allowing 
free flow of aqueous material through the channel, protons may be conducted through 
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the channel by means of a shuttling exchange across the lumenal protonated histidine 
residue (Acharya et al., 2010), by ring-flip assisted imidazole deprotonation as the 
transport mechanism (Hu et al., 2010). This shuttling exchange model explains the 
high proton selectivity of the channel, and the only other ions to show even partial 
conductance are, like protons, monovalent cations. W41 acts as a gate, blocking the 
passage of ions through the lumen of the channel. It interacts with protonated H37 by 
means of cation-π associations between the imidazole and indole side-groups, and 
solid state NMR has shown that W41 has increased torsional fluctuations when H37 is 
protonated at low pH suggesting it is allowing the passage of protons by rotating the 
indole sidegroup (Williams et al., 2013). 
When H37 is unprotonated, W41 forms a gate that blocks entry to the channel from 
that end, mediating the directionality of proton transport. When pHout is low, the 
solution has access to H37 and the reduced pH in the water pocket can allow 
protonation and opening of the channel (Fig. 1.3). With W41 blocking pHint, the 
reduction of pH on that side of the membrane does not reach H37 in the lumen of the 
pore due to the blocking effect of the 4 indole rings.  
The adamantane drugs amantadine and rimantadine were used to treat IAV infections 
(Wingfield et al., 1969), and resistance mutations identified M2 as the viral protein 
affected (Hay et al., 1985). Resistance mutations can arise within 5-7 days of 
adamantane treatment, mapping to the transmembrane region of the protein, and are 
single nucleotide changes leading to an amino acid substitution at any of 4 sites: 
residues 26, 27, 30, and 31 (Suzuki et al., 2003). Many influenza strains developed 
resistance following monotherapy with these drugs (Weinstock & Zuccotti, 2006), and 
the majority of circulating influenza A strains, including the recent H1N1 swine 
pandemic, are now resistant (Wang et al., 2009). Structural analysis of amantadine 
has identified two possible binding sites for the drug: in the lumen of the pore directly 
blocking the passage of protons through the channel (Stouffer et al., 2008), or on the 
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lipid side of the channel preventing the structural rearrangements that lead to channel 
opening (Schnell & Chou, 2008). Further work has identified both arrangements as 
being possible, but with the pore-binding model showing a higher binding affinity than 
the lipid-side binding, measured by surface plasmon resonance (SPR) (Rosenberg & 
Casarotto, 2010). 
1.3.3 HIV Vpu protein 
HIV Vpu is a 16 kDa, 81-residue integral membrane phosphoprotein that is conserved 
among HIV1 strains but is not present in HIV2 (Cohen et al., 1988; Strebel et al., 
1988). It has a short ectoplasmic domain, an uncleaved leader domain that acts as a 
transmembrane anchor and a longer cytoplasmic domain (Maldarelli et al., 1993). 
Unlike IAV M2 it is not present in the virion, but it does have two major roles in the 
virus life cycle. Firstly, it aids the virus in immune evasion by causing the rapid 
degradation of CD4, a role which is dependent on the phosphorylation of the C-
terminal cytoplasmic domain (Paul & Jabbar, 1997), downregulating the expression of 
MHC class I (Kerkau et al., 1997) and also inhibiting NFκB activation (Bour et al., 
2001; Akari et al., 2001). The second major role of Vpu in the virus lifecycle is to 
improve the efficiency of virus budding (Terwilliger et al., 1989). These two major 
functions are performed by different domains of the protein. Mutational analysis that 
scrambled the TM domain but left the cytoplasmic domain intact found that the 
cytoplasmic domain was responsible for the immune modulations, while truncation 
analysis found that the TM domain alone enhanced virion release (Schubert et al., 
1996). While the C-terminal cytoplasmic domain is not required for oligomerisation of 
the TM domain, it has been found to stabilise the protein (Ma et al., 2002). Molecular 
modelling has identified the likely oligomer as a pentamer formed of left-handed 
helical bundles (Kukol & Arkin, 1999). Structural data has shown a pore structure with 
a water-filled pore restricted by tryptophan residues at position 22, with serine 
residues lining the base of the pore (Montal, 2003). 
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The TM domain of Vpu was found to have ion channel activity in several systems: 
artificial lipid membranes (Ewart et al., 1996), an E. coli permeability assay (Gonzalez 
& Carrasco, 1998) and in Xenopus laevis oocytes (Schubert & Ferrer-Montiel, 1996). 
The oocyte experiments also identified the channel as being selective for monovalent 
cations (Schubert & Ferrer-Montiel, 1996). Of the previously-used viroporin inhibitors, 
it was found that amiloride derivatives, but not amiloride itself or amantadine, were 
effective at reducing the conductance of the channel in vitro, as well as reducing the 
efficiency of virus budding (Lemaitre et al., 2004; Ewart et al., 2002) 
1.3.4 Respiratory syncytial virus SH protein 
Human respiratory syncytial virus (hRSV) causes pneumonia in infants. The small 
hydrophobic (SH) protein is a 64-residue protein with a hydrophobic stretch sufficient 
for a single span across a membrane. It is redundant for replication of the virus in 
tissue culture (Bukreyev et al., 1997) but in animal models, including chimpanzees, its 
deletion results in reduced viral titres (Jin et al., 2000; Whitehead et al., 1999). It has 
been shown to form pentamers in detergent micelles, with the TM domain forming an 
α-helix (Gan et al., 2012), and EM visualisation of SH oligomers in membranes found 
structures consistent with pentamers or hexamers (Carter et al., 2010). 
The hypothesised role of the SH protein in the virus lifecycle may be to inhibit TNFα 
signalling (Fuentes et al., 2007), but it has also been shown to have viroporin activity 
in black lipid membranes, bacterial permeability assays and liposome assays (Carter 
et al., 2010; Gan et al., 2008; Perez et al., 1997). The TM domain alone was shown to 
be selective for monovalent cations, and showed low-pH activation (Gan et al., 2008). 
Mutation of two histidine residues in SH, one in the TM domain (H22) and one in the 
C-terminus (H51), found that mutation of both abrogated pH activation, but single 
mutations of each to alanine still showed some increased activity in response to 
reduced pH (Gan et al., 2012). There is also a tryptophan at position 15 that has been 
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suggested to interact with H22 to mediate the pH gating in a manner similar to IAV 
M2, but this has yet to be investigated further (Carter et al., 2010). 
1.3.5 Enterovirus 2B protein 
The 2B protein is found in all members of the enteroviridae virus family, including 
poliovirus. It is an approximately 97 residue protein that localises primarily to the ER 
and Golgi, with a smaller fraction going to the plasma membrane and mitochondria 
(Madan et al., 2008; de Jong et al., 2003; van Kuppeveld et al., 1997; Sandoval & 
Carrasco, 1997). Poliovirus 2B has two hydrophobic domains (Agirre et al., 2002), 
HR1 and HR2, of which the first forms a cationic amphipathic α-helix. Mutation of HR1 
has been shown to prevent 2B-induced membrane permeabilisation (Barco & 
Carrasco, 1998; van Kuppeveld et al., 1997; Aldabe et al., 1996). This membrane 
permeabilisation is required by the virus for virion release and RNA replication (Van 
Kuppeveld et al., 1996). The second hydrophobic domain has been shown to stabilise 
the tetramer via inter-helix interactions. These domains have been shown to fold into 
α-helices that fold to form a hairpin structure (Martínez-Gil et al., 2011). 
Expression of enterovirus 2B has been shown to permeabilise the plasma membrane 
to allow the usually non-permeant molecule hygromycin B to enter both bacterial and 
mammalian cells (Aldabe et al., 1996; Lama & Carrasco, 1992). HR2 has tryptophan 
residues that have been shown to be important for membrane permeability, and may 
potentially have a role in gating the channel (de Jong et al., 2004). 
As part of its uncleaved precursor 2BC, 2B causes the accumulation of vesicles to 
form replication complexes. Mutation of the loop residues between HR1 and HR2 has 
been shown to reduce replication of the virus, but does not affect 2B oligomerisation 
or its ability to permeabilise membranes (de Jong et al., 2004). 
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1.3.6 Human papillomavirus E5 protein 
HPV is a non-enveloped DNA virus with many different strains, and the majority of 
research has focused on the cancer-causing strains, such as HPV16. The E5 protein 
of HPV16 is a highly hydrophobic 83-residue protein (Halbert & Galloway, 1988) with 
a predicted membrane topology of an N-terminus in the ER lumen and C terminus in 
the cytoplasm, with the hydrophobic part of the protein forming 3 transmembrane 
spans (Krawczyk et al., 2010). It has been shown to be present as a dimer in cervical 
tissue samples (Kell et al., 1994), and analysis of truncation mutants showed that the 
hydrophobic regions of the protein were able to interact to form oligomers (Gieswein 
et al., 2003). E5 localises to the ER, early endosomes, lysosomes and the perinuclear 
region (Lewis et al., 2008), with overexpression studies often showing a localisation to 
the Golgi as an artefact.  
E5 has been shown to prevent endosomal acidification, a function not necessarily 
mediated by viroporin activity: E5 has been shown to directly interact with vATPase 
and thus may be inhibiting the acidification by blocking its function (Straight et al., 
1995). The hypothesised role for this is to prevent dissociation of EGFR from its ligand 
during EGFR trafficking through the acidic late-endosome to lysosome compartments, 
thus enhancing EGFR signalling, but this is controversial (Suprynowicz et al., 2010).  
The viroporin activity of E5 was shown in liposome dye-release assays, and it was 
also shown to form pore structures by electron microscopy (Wetherill et al., 2012). 
This channel does not show any change in activity in response to changes in pH, and 
lacks any protonatable histidine residues in the channel lumen. Thus, the primary 
function of E5 is not thought to be proton conductance but rather release of 
intracellular calcium stores, thought to be important for some aspects of the virus life 
cycle.  
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1.3.7 Alphavirus 6k protein 
Alphavirus 6k, present in all members of the alphavirus genus, is a 60-residue protein 
with a single transmembrane span (Melton et al., 2002). Low sequence homology in 
6k between different members of the genus renders it specific to each virus, as 
substitution of 6k between viruses abrogates infectivity. It colocalises with the 
envelope spike proteins in the ER and plasma membrane (Schlesinger et al., 1993), 
and an acylated form of the protein is present in the virion (Lusa et al., 1991). 
6K has been shown not to be required for genome replication, particle formation or the 
transport of glycoproteins to the plasma membrane (Loewy et al., 1995), but appears 
to have a role in budding of the virus as 6k-deficient viruses show reduced virus 
budding (Liljeström et al., 1991). Its role may be to maintain the correct folding of 
glycoproteins required for budding (Yao et al., 1996). 
The viroporin activity of 6k was first shown by an E. coli permeabilisation assay (Sanz 
et al., 1994). Bacterially expressed protein in planar lipid bilayers was shown to have 
a preference for the conductance of monovalent cations, with a lower conductance of 
divalent cations (Melton et al., 2002). There is a lack of detailed structural analysis, 
but mutation of a region hypothesised to map to a ring structure inside the channel 
reduces the cation selectivity of the channel (Melton et al., 2002). 
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1.4 Molecular biology of HCV 
1.4.1 Taxonomy 
HCV is an enveloped, positive stranded RNA virus classified as part of the family 
flaviridae, in the genus hepacivirus. The flaviridae family has two further genera, 
flaviviruses and pestiviruses. Flaviruses are vector-borne and include Dengue virus 
and Yellow Fever virus. Pestiviruses include bovine viral diarrhoea virus and classical 
swine fever virus (Lindenbach & Rice, 2001). A further genus within this family, 
pegivirus, has been proposed for the GB viruses A, C and D (Stapleton et al., 2011). 
A close relative of HCV was recently identified among dogs in two animal shelters in 
the USA, which showed a 66% sequence homology of the 5’ UTR and is estimated to 
have diverged from HCV between 500-1000 years ago (Kapoor et al., 2011). Given 
the preliminary name of canine hepacivirus, recent work has also found the virus to be 
present in horses (Burbelo et al., 2012).  
1.4.2 Genotype variation 
The six major HCV genotypes and more than 50 subtypes are defined by their genetic 
variance from one another (Simmonds, 2004; Simmonds et al., 1993). One subtype of 
a seventh genotype has also been identified (Murphy et al., 2007). A simplified 
evolutionary tree in Fig. 1.4 illustrates the divergence between the 7 HCV genotypes 
(Mandell et al., 2009). While there is a high selection pressure to maintain functional 
regions of the genome, some areas of viral genomes, particularly those coding for the 
hypervariable regions of the envelope glycoproteins, are very tolerant to mutations. 
Mutations in one protein under selection pressure from the immune response can 
result in compensatory mutations in other viral proteins, and over time can lead to the 
evolution of separate genotypes whose proteins are incompatible in chimeric viruses. 
Within a subtype, isolated sequences can differ by between 5-15% of nucleotides, 
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between subtypes within a genotype 10-30% and between genotypes by as much as 
30-50% (Hoofnagle, 2002). 
HCV also has a high mutation rate within patients, leading to the formation of viral 
quasispecies. The quasispecies variation ranges between 1-5% of the virus genome 
(Hoofnagle, 2002).  
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Figure 1.4 Evolutionary divergence of the HCV genotypes 
Radial format evolutionary tree showing the genetic relationship between HCV 
genotypes, evolving from a distant common ancestor. Subtypes are indicated by 
branches within each genotype group, with limited subtypes shown for simplicity. 
Scale shown is that of the distance representing nucleotide substitutions per site. 
Taken from Mandell et al. 2009. 
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1.4.3 Lifecycle 
1.4.3.1 Virus entry 
The HCV virion binds to a number of cellular receptors that mediate cell entry via the 
E1-E2 heterodimer. The initial binding of the virion to the cell is to glycosaminoglycans 
(GAGs), including heparan sulphate. Treatment of cells with heparin inhibits the initial 
binding of the virion (Morikawa et al., 2007), but does not inhibit entry once the initial 
binding has occurred (Koutsoudakis et al., 2006).  
A number of cellular cofactors have been shown to bind to the virion after initial 
attachment and mediate cell entry. The first to be identified was cluster of 
differentiation 81 (CD81), a tetraspanin expressed on a number of cell types (Pileri et 
al., 1998). CD81 binding was shown to occur after initial attachment of the virion 
(Cormier et al., 2004). Scavenger receptor class B type 1 (SRBI) is a high density 
lipoprotein (HDL) internalisation molecule that binds soluble E2. E2 shows a high 
specificity for SRBI, with the closely related CD36 and mouse SRBI unable to bind E2 
(Scarselli et al., 2002). SRBI was shown to bind E2 and HCVpp in a manner indicative 
of a co-receptor (Bartosch et al., 2003c). Claudin1 (CLDN1) is a tight junction 
component that is highly expressed in the liver and is able to render some non-hepatic 
cell lines susceptible to HCV infection when ectopically expressed. The kinetics of 
binding inhibition also indicate that CLDN1 acts at a late stage of virus entry, following 
CD81 interaction (Evans et al., 2007). Occludin is another tight junction complex 
protein that is expressed highly in hepatocytes compared with other cells, and ectopic 
expression in other cell lines results in increased uptake of HCVpp (Ploss et al., 
2009). It also shows species specificity, with murine cells rendered infectable by its 
expression. The low density lipoprotein receptor (LDL-R) has also been shown to be 
involved in HCV entry, and the internalisation of LDL via clathrin mediated 
endocytosis to early endosomes is the same predicted path as HCV entry (Thorley et 
al., 2010). The epidermal growth factor receptor (EGFR) has also been shown to be a 
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host cell cofactor for HCV entry, by mediating association between CD81 and CLDN-1 
(Lupberger et al., 2011). Expression of the HCV-entry cofactors is on the basolateral 
side of the hepatocytes, with tight-junction involvement. However, this cell polarisation 
is not required for HCV entry as shown by entry into Huh7 cells, a non-polarised 
hepatoma cell line.  
Once the virion has bound the required co-receptors, it is internalised by clathrin 
mediated endocytosis and trafficked to early endosomes, where acidification mediates 
membrane fusion and uncoating of the virus (Hsu et al., 2003). 
E2 can also bind to the C-type lectins L-SIGN and DC-SIGN, but binding to these 
does not cause the virion to enter the cells (Lozach et al., 2004). Instead, these 
receptors may allow ‘capture’ of the virions, where the presence of L-SIGN on the liver 
sinusoidal epithelial cells allows binding of the virion which can then pass from the 
epithelium to nearby hepatocytes. 
A summary of the known receptor proteins involved in the entry pathway is shown in 
Fig. 1.5. 
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Figure 1.5 HCV Entry 
Diagram summarising the known receptors and processes involved in HCV entry into 
hepatocytes. SRBI is referred to as SCARB1. HCV associates with very-low-density 
and low-density lipoproteins (LPs) in the bloodstream. It binds the basolateral surface 
of hepatocytes through glycosaminoglycans (GAGs) and the low-density lipoprotein 
receptor (LDLR). Engagement by the virus of SCARB1, the tetraspanin CD81 and the 
tight junction proteins claudin-1 and occludin leads to the clathrin mediated 
endocytosis of virions. HCV fuses with acidified endosomes and releases its genome 
into the cytosol. EGFR activation promotes CD81–claudin-1 interactions and 
membrane fusion, thereby enhancing productive HCV uptake. Taken from (Gerold & 
Rice, 2011).  
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1.4.3.2 Viral replication 
Once the virus has been uncoated after entry, the genome is thought to undergo 
several rounds of translation to produce viral proteins that inhibit the cellular immune 
response and allow the formation of the membranous web replication complexes 
(Gosert et al., 2003; Egger et al., 2002). The HCV genome is translated to a 3000 
amino acid polyprotein that is cleaved by host and viral proteases to produce the ten 
mature virus proteins, plus an additional ‘F’ protein translated from a +1 frameshift (Xu 
et al., 2001; Grakoui et al., 1993). A summary of the translation and cleavage of the 
polyprotein is shown in Fig. 1.6. 
Once viral proteins induce the formation of replication complexes, the RNA-dependent 
RNA polymerase (RdRp) NS5B can replicate the viral genome via a negative-sense 
intermediate. The presence of dsRNA in the replication complex could trigger the 
cellular antiviral response via the RIG-I pathway, but this is blocked by NS3/4a 
cleavage of MAVS/Cardif, a component of this pathway. Also, HCV has an RNA 
secondary structure that prevents the binding of host RNAs as an additional means of 
blocking the activation of dsRNA response pathways (Davis et al., 2008). Analysis of 
isolated replication complexes found that each contains one negative-sense copy of 
the genome, with between 2 and 10 positive strands and a high proportion of non-
structural proteins NS3-5b with hundreds present per replication complex (Quinkert et 
al., 2005). The transcribed RNA is then either translated into more viral proteins or 
packaged into virions.  
  
 
 
31 
 
 
Figure 1.6 Genome organisation and polyprotein processing of HCV 
The 9.6kb genome has conserved secondary structure at the 5’ and 3’ UTRs, with the 
5’ UTR containing the IRES and the 3’ UTR the transcription initiation site required on 
the negative strand for positive strand synthesis. The genome is translated to a 3000 
amino acid polyprotein. The polyprotein is cleaved by signal peptide peptidase (grey 
triangle), signal peptidase (black triangle), NS2-3 autoprotease cleavage (green 
triangle) and NS3/4a protease activity (red triangle) to produce 10 mature virus 
proteins. The cleaved proteins fold into the structures shown, where these structures 
are known. Genome and protein structures are taken from Moradpour et al. 2007. 
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1.4.3.3 Virus assembly and egress 
The process of HCV assembly and egress is not yet fully understood. For the 
infectious virions to be assembled, HCV genomes from the replication complexes 
have to associate with Core protein to form virus capsids. Core has been shown to 
associate with lipid droplets as a crucial step in the production of infectious virus 
(Boulant et al., 2006) but it is not known if this is the site at which the virus is 
packaged. The viral proteins E2, NS2, NS3 and NS5A have been shown to colocalise 
at lipid droplets at 72 hrs after infection (Jirasko et al., 2010). NS2 and p7 have been 
shown to be required at an early stage of virus assembly, with the role of p7 at this 
point not requiring its viroporin function (Jones et al., 2007). The hypothesised role for 
NS2 and p7 at this stage is to mediate the association of structural proteins with the 
replication complexes in order to mediate viral assembly (Stapleton et al., 2011; Ma et 
al., 2011; Jirasko et al., 2010). The envelope glycoproteins remain associated with the 
ER and adjacent ER-derived membranes, and also interact with NS2. 
HCV virions are trafficked through the cis-golgi and the endosomal pathway, mediated 
by ESCRT proteins (Corless et al., 2010). p7 prevents the acidification of the 
endosomes in order to maintain the integrity of the envelope glycoproteins (Wozniak 
et al., 2010).  
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Figure 1.7 Secondary structure of 5’ and 3’ UTRs 
Panel (a) 5’ UTR secondary structure, including the IRES and start codon. The 4 
stem-loop domains and start codon are labelled. Taken from (Honda et al., 1999). 
Panel (b) 3’ UTR secondary structure, with the variable domain, PolyU(U/C) domain 
and X-tail with 3 stem-loop structures labelled. Taken from (Kolykhalov et al., 1996). 
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1.4.4 RNA genome/ Untranslated regions (UTRs) 
The genome of HCV is a single-stranded, positive-sense RNA that can be directly 
translated into the polyprotein, which is cleaved to form the individual HCV proteins. 
The polyprotein coding sequence is flanked by untranslated regions at the 5’ and 3’ 
ends that contain elements important for the replication of the virus. 
1.4.4.1 5’ UTR 
The 5’ untranslated region (UTR) of the HCV genome, shown in Fig. 1.7 (a), is a 
region of 341 nucleotides. It is conserved between HCV genotypes, and has regions 
of sequence homology with pestiviruses (Han et al., 1991). The 5’ UTR shows specific 
regions of high sequence conservation interspersed with variable regions (Bukh et al., 
1992). The 5’ UTR is involved in the initiation of both translation of the polyprotein and 
in genome replication initiation.  
Much of the 5’ UTR forms the internal ribosome entry site (IRES) of the virus, which 
initiates protein translation without the need of a 5’ cap that cellular mRNAs require for 
translation initiation. Deletion analysis of the 5’ UTR has found that nucleotides 40-
370 are required for efficient IRES function, with the initiation codon for protein 
translation at position 342 (Reynolds et al., 1995). The efficiency of IRES initiation is 
improved by the presence of the first section of the coding region for Core protein 
(Reynolds et al., 1995). Deletion of the first 40 nucleotides of the 5’ UTR has only a 
minimal effect on translation (Friebe et al., 2001). The functioning of the IRES has 
been found to be dependent on a number of structural elements, with mutational 
analysis showing that preservation of the stem-loop structures is more important than 
the nucleotide sequence.  
The IRES interacts with a number of cellular proteins to facilitate ribosome binding 
and translation initiation. The translation initiation of HCV differs from the canonical 
eukaryotic process, needing just two cellular factors, eIF2 and eIF3 to form the pre-
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initiation complex (Ji et al., 2004; Pestova et al., 1998). The La antigen, a non-
canonical initiation factor, has been shown to bind to the HCV IRES (Costa-Mattioli et 
al., 2004). A liver-specific micro-RNA, mir122, has been found to greatly enhance 
virus translation/replication, possibly playing a role in the tissue-distribution of HCV 
(Jopling et al., 2005). Exogenous expression of mir-122 in the replication non-
permissive cell line HepG2 was found to render the cells permissive for HCV 
replication (Narbus et al., 2011) 
The 5’ UTR must also interact with viral replication complexes in order to replicate the 
HCV genome. The first 125 nucleotides of the coding region are sufficient for the 
initiation of genome replication, but replication is greatly enhanced by the presence of 
elements within the 5’ UTR. In the replicon system, it was found that domains I and II 
were absolutely required for genome replication and further 5’ deletions abolished 
replication entirely. The addition of domain III increased the colony-forming efficiency 
100-fold (Kim et al., 2002). 
1.4.4.2 3’ UTR 
Like the 5’ UTR, the 3’ UTR is also highly conserved among HCV genotypes 
(Kolykhalov et al., 1996). The 3’ UTR is composed of 3 regions: a short, 40nt variable 
region immediately after the coding sequence, a polypyrimidine (poly U(U/C)) tract 
and a 98nt region, known as the X-tail, which forms 3 stem-loop structures, shown in 
Fig 1.7 (b). The variable region is not absolutely required for genome replication, but 
its deletion reduces the efficiency of genome replication in the replicon system. 
Replicons lacking a poly (U(U/C)) tract could only be made viable when this was 
replaced by a homouridine stretch. No replicons with deletions to any of the stem loop 
structures of the X-tail were viable (Friebe & Bartenschlager, 2002). Further 
mutational analysis of the stem-loop structures in the X-tail found that both the 
nucleotide sequence and the stem-loop structures were required 
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The 3’ UTR has been found to affect protein translation from the IRES, and thus part 
of its role may be to interact with the 5’ UTR. Binding of the cellular protein 
polypyrimidine tract-binding protein (PTB) to the 3’ UTR has been shown to enhance 
translation of the polyprotein (Ito & Lai, 1997). The 3’ UTR is presumed to act to 
initiate replication from the minus strand of the HCV replication complex, but this part 
of the virus lifecycle is, as yet, poorly understood.  
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1.4.5 Structural proteins 
1.4.5.1 Core 
Core is the first of the viral structural proteins to be translated, and forms the bulk of 
the virion. There are two major forms; an immature p23 cleaved from the polyprotein, 
and a mature p21 form that is cleaved further in the ER by signal peptide peptidase 
(Targett-Adams et al., 2008; Santolini et al., 1994). A further form, p16, has been 
observed in GT1 and is the dominant product when the HCV genome is truncated, but 
it is only observed at much lower levels in longer HCV constructs and is not thought to 
play a major role in the production of infectious virus (Lo et al., 1994). Core isolated 
from infected patient sera is exclusively p21, and thus the processed form of the 
protein is the one that forms the virus capsid (Yasui et al., 1998).  
Core is divided into three domains. Domain 1 contains many basic residues and has 
been shown to be involved in RNA binding and protein-protein interactions. Domain 2 
has fewer basic residues and has two amphipathic α-helices linked by a hydrophobic 
loop. Domain 3 is highly hydrophobic, and has been shown to act as a signal peptide 
for the correct localisation of the E1 glycoprotein (McLauchlan, 2000).  
Core protein forms the virus capsid. Purified Core protein expressed from E. coli was 
found to homo-oligomerise into micelle-like aggregates in aqueous solution in the 
absence of detergent. Detergent addition led to Core forming stable dimers (Boulant 
et al., 2005). Deletion studies found that the correct folding of domain 1 was 
dependent on the presence of the hydrophobic domain 2.  
Core has been found to localise to the ER, to punctate structures close to lipid 
droplets and coating lipid droplets within the cell, with some of the protein localising to 
the nucleus (Boulant et al., 2008) and to the mitochondria (Schwer et al., 2004). The 
relocation of Core to the lipid droplets is dependent on the second amphipathic helix 
of domain 2 (Boulant et al., 2006). Core trafficking is also affected by p7 and NS2 in a 
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strain-specific manner, with p7-NS2 of the high-titre Jc1 chimera showing a large 
degree of localisation to the ER, and reduced LD distribution compared with JFH1 
(Boson et al., 2011). 
NS5A protein has also been found to interact and colocalise with Core at the surface 
of lipid droplets, and it is hypothesised that its role here may be to associate HCV 
genomic RNA with the Core protein in order to facilitate virion assembly (Shi et al., 
2002). 
A fraction of the Core protein is phosphorylated, and a mutant possessing an extra 
phosphorylation site showed increased trafficking to the nucleus, indicating that 
phosphorylation of Core protein may cause its nuclear distribution (Lu & Ou, 2002). 
Core has been found to suppress transcription from the p53 promoter and reduce p53 
expression in mammalian cell transfection studies, possibly contributing to the 
reported transforming capability in mouse studies (Ray et al., 1997), and may thus 
contribute to the risk of HCV infection resulting in HCC. 
In mouse studies using chimeric vaccinnia viruses, it was found that the presence of 
Core was sufficient to impair the immune response, leading to reduced function of 
cytotoxic T-leukocytes (CTLs), and reduced production of IFN-γ and interleukin 2 (IL2) 
(Large et al., 1999). A transgenic mouse line expressing Core in T-cells using the CL2 
promoter found that there was increased T-lymphocyte cell death and a reduced 
immune response in the mice and, surprisingly, also found high levels of liver 
pathology with infiltration of apoptotic T-lymphocytes into the liver tissue.  
1.4.5.2 F protein 
The frameshift (F) protein was discovered in 2001 (Xu et al., 2001; Walewski et al., 
2001). It is formed by a ribosomal shift during the translation of Core protein. 
Antibodies to F protein are found in advanced cases of chronic HCV (Komurian-
Pradel et al., 2004), and acute cases (Morice et al., 2009). Initially it was thought to 
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have a role in the virus lifecycle, and it is known to be expressed in vivo as antibodies 
have been detected in patient sera. The protein has been shown to be unstable 
(Roussel et al., 2003) and it is not yet known if it is necessary for virus infection in cell 
culture. High levels of antibodies against F protein have been found in patients with 
HCC however, which may indicate a role for F protein in pathogenesis (Dalagiorgou et 
al., 2011) 
1.4.5.3 E1 and E2 
E1 and E2 are the Type 1 envelope glycoproteins that are incorporated into the virion 
and mediate virus entry. Following cleavage from the viral polyprotein, they associate 
in the ER to form heterodimers (Deleersnyder et al., 1997), and this association is 
dependent on the C-terminal transmembrane domains (TMDs) of both proteins (De 
Beeck et al., 2000). E1 requires the presence of E2 in order to fold correctly, but E2 
folding is independent of E1 (Boo et al., 2012; Michalak et al., 1997). A number of ER 
chaperones including calnexin, calreticulin and BiP also bind to E1 and E2 
heterodimers, but only calnexin has been found to be involved in correct protein 
folding (Choukhi et al., 1998). Both E1 and E2 possess-terminal signal sequences that 
are required for their correct membrane association (Cocquerel et al., 2002; Michalak 
et al., 1997). 
Heterodimerisation of E1 and E2 is a crucial step for virus infectivity. Within the ER, 
dimerisation occurs through non-covalent bonds. During virus assembly, a number of 
cysteine residues present in each protein are able to form disulphide bridges, linking 
the proteins covalently. These cysteine residues are highly conserved across all 
genotypes in both glycoproteins (Wahid et al., 2013). 
E2 is the primary glycoprotein involved in virus entry. It has been found to bind to 
CD81, SRBI, claudin and occludin. Recently E1 has been identified as binding to 
ApoE and ApoB lipoprotein receptors (Mazumdar et al., 2011). 
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E2 possesses hypervariable regions (HVR), where the majority of quasispecies 
variation within patients is concentrated. These regions map to areas of the proteins 
that are accessible to antibody binding, suggesting there is a high selection pressure 
on these regions during chronic infection. The HVR1 of E2 is involved in virus 
attachment and entry, and antibody-neutralisation of this region with patient or 
chimpanzee sera renders the virus unable to infect cells (Owsianka et al., 2005; 
Bartosch et al., 2003a). 
1.4.6 p7  
p7 is discussed in detail in section 1.5. 
1.4.7 Non-structural proteins 
1.4.7.1 NS2 
NS2 is a 217 residue membrane-anchored protein (Santolini et al., 1995), with at least 
one transmembrane domain and a cytosolic C-terminal domain. The cytosolic domain 
is a protease which, in conjunction with the first section of NS3, displays autoprotease 
activity in a zinc dependent manner. This is required for correct protein folding 
(Pallaoro et al., 2001; Pieroni et al., 1997). The N-terminal transmembrane region of 
NS2 is dispensable for protease activity, as shown by expression of minimal NS2/3 
constructs in E. coli (Thibeault et al., 2001). NS2 contains the catalytic domain for 
NS2-3 autocleavage, with the Zn2+ binding domain of NS3 acting as a cofactor 
(Schregel et al., 2009). The structure of the catalytic domain of NS2 has been shown 
to be a dimer with two active sites acting in tandem (Lorenz et al., 2006). The HCV 
subgenomic replicon shows that NS2 is not required for replication of the HCV 
genome (Lohmann et al., 1999). However, it is absolutely required for virus assembly. 
NS2 has been shown to interact with E2, p7, NS3 and NS5A (Popescu et al., 2011). 
Mutations in Core, E1, E2, p7 and NS5A reported to abolish viral assembly also 
changed the subcellular localisation of NS2 (Popescu et al., 2011). Based on its direct 
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interactions with these viral proteins, NS2 is thought to act as a linker between the 
structural and non-structural proteins, linking the replication complexes to viral 
assembly (Popescu et al., 2011). 
Alterations in the p7 sequence preceding NS2 cause significant disruption to NS2 
localisation and function. The NS2-NS5A interaction was disrupted by both deletion of 
p7, or alanine mutations of the two basic loop residues of p7 (Tedbury et al., 2011). 
Mutations in the protease active site of NS2 have been shown to affect RNA 
replication, but this is likely due to the inhibition of NS2/3 cleavage (Dentzer et al., 
2009). NS2 is phosphorylated at Serine 168 (S168) which targets NS2 for 
proteasomal degradation (Franck et al., 2005). Mutation of this site significantly 
impairs the production of infectious virus (Yi et al., 2009). The S168A mutation did not 
affect the localisation of Core, NS3 or NS5A, and intracellular particles with a buoyant 
density similar to infectious virus were produced, indicating that S168 of NS2 is 
required at a post-assembly state of virus maturation (Yi et al., 2009). NS2 has also 
been shown to inhibit IFNβ promoter activity independently of other HCV proteins, via 
an as-yet unknown mechanism (Kaukinen et al., 2006). 
1.4.7.2 NS3 
NS3 is a 72 kDa, 483-residue protein that non-covalently associates with NS4A as a 
cofactor. It has an N-terminal half that is a chymotrypsin-like serine protease (Hahm et 
al., 1995; Eckart et al., 1993), which cleaves the downstream viral proteins NS4A, 
NS4B, NS5A and NS5B from the polyprotein (Bartenschlager et al., 1994; Tomei et 
al., 1993). The C-terminal half of the protein acts as an RNA helicase during 
replication of the viral genome (Gwack et al., 1996; Kim et al., 1995). 
The crystal structure of NS3 shows two 6-stranded β-barrels with a trypsin-like fold 
and a tetrahedrally coordinated zinc binding site, with the catalytic triad of the enzyme 
lying between the two β-barrel domains (Love et al., 1996). Addition of a minimal 
 
 
42 
 
NS4A cofactor peptide shows that it is incorporated into a β-sheet of the enzyme core 
(Kim et al., 1996). 
NS3 is cleaved from NS2 by an autoprotease activity dependent on the catalytic 
domain of NS2 and the Zn2+ binding domain of NS3 (Schregel et al., 2009). No 
uncleaved NS2/3 can be detected without the use of protease inhibitors or inhibitory 
mutations.  
NS3/4a also inhibits several pathways of the cellular immune response (Breiman et 
al., 2005). NS3/4A cleaves TRIF, an adapter protein in the TLR3 pathway that can 
activate both IRF3 and NFκB transcription factors (Li et al., 2005); and Cardif/MAVS, 
an adapter downstream of the RIG-I signalling pathway (Horner et al., 2012; Kaukinen 
et al., 2006). By cleaving these two proteins, the virus is able to significantly reduce 
the cellular antiviral response and prevent extracellular signalling to the immune 
system via IFN-β (Kaukinen et al., 2006).  
The RNA helicase function of NS3 is dependent on the C-terminal 466 residues and 
remains when the protease domain is truncated (Kim et al., 1995). Helicase activity is 
dependent on the presence of ATP and Mg2+ ions (Frick et al., 2007; Kim et al., 1995), 
and has been shown to proceed in an ‘inchworm’ like fashion, unwinding a stretch of 
nucleotides before pausing (Dumont et al., 2006; Serebrov & Pyle, 2004). The crystal 
structure of the helicase domain shows a 3 domain-structure with an oligonucleotide 
binding-groove between domains 2 and 3 (Kim et al., 1998). While NS4A is not 
required for the RNA helicase function of NS3, its presence has been shown to 
increase RNA binding and ATP hydrolysis efficiency (Beran et al., 2009). 
NS3 has also been found to interact with DNA repair pathways including ATM (ataxia-
telangiectasia mutated), reducing the DNA repair response after cell irradiation. This 
reduction in repair mechanisms may contribute to the risk of development of HCC (Lai 
et al., 2008).  
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1.4.7.3 NS4A 
NS4A is a 54-residue membrane protein that acts as a cofactor for the NS3 viral 
serine protease. Truncation analysis has shown that the functional domain required 
for NS3 binding is a central portion comprising residues 21-32, which is sufficient for 
NS3/4a protease function in cell-free systems (Tomei et al., 1996; Lin et al., 1995). In 
addition to its crucial role as a cofactor for NS3 protease function, NS4A has also 
been found to promote ATP hydrolysis in the NS3 helicase domain. Residues in the 
C-terminal acidic domain of NS4A mediate this cofactor activity, shown by mutational 
studies that drastically reduce ATP-coupled RNA binding and duplex unwinding 
(Beran et al., 2009). The N-terminal 21-residue transmembrane α-helix of NS4A has 
been shown to be involved in intramembrane protein-protein interactions during the 
assembly of functional replication complexes (Brass et al., 2008). 
The C-terminal 19 residues contain acidic residues that allow pH-dependent folding 
into an α-helix. Mutation of these residues reduces the hyperphosphorylation of NS5A 
and reduces the efficiency of the NS5B replicase. These residues have been 
postulated to act as a regulatory electrostatic switch that regulates the 
hyperphosphorylation of NS5A and viral replication (Lindenbach et al., 2007). 
NS4A has also been shown to accumulate on mitochondria and render cells prone to 
mitochondria-mediated apoptosis (Nomura-Takigawa et al., 2006). Whilst this effect 
may be balanced by the anti-apoptotic effects of other HCV proteins, NS4A may be 
partially responsible for the increased cytopathic effect observed in HCV infected cells 
in culture.  
1.4.7.4 NS4B 
NS4B is a 27 kDa highly hydrophobic integral membrane protein (Hügle et al., 2001), 
predicted to comprise an N-terminal amphipathic domain, a central 4-span 
transmembrane region and an amphipathic helical C terminal domain (Gouttenoire et 
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al., 2010a). The N and C termini were thought to be oriented towards the cytoplasm 
due to their availability for NS3/4A proteolytic cleavage, but a fraction of NS4B shows 
post-translational translocation of the N-terminal amphipathic domain into the ER 
lumen (Lundin et al., 2003). This fraction is reduced when coexpressed with NS5A 
which may modulate this translocation by a direct or indirect association (Lundin et al., 
2006). NS4B shows some oligomerisation, thought to be mediated by the amphipathic 
α-helix AH2, which becomes a transmembrane domain following N-terminal 
translocation to the cytosol, (Gouttenoire et al., 2010b). The central hydrophobic 
domain, comprising the hypothesised 4 α-helical transmembrane spans, can act as 
both a membrane anchor and an ER-targeting domain (Gouttenoire et al., 2009).  
NS4B has been show to localise to the ER where it colocalises with the other non-
structural proteins (Hügle et al., 2001). It induces membrane rearrangements to form 
the membranous web, a membrane-bound matrix of vesicles on which HCV 
replication complexes form (Gosert et al., 2003; Egger et al., 2002). Mutations which 
abolish this rearrangement, such as those to the N-terminal amphipathic domain, 
have been shown to abolish virus replication (Lundin et al., 2006). 
1.4.7.5 NS5A 
NS5A is a multifunctional protein that is involved in both virus replication and 
assembly. NS5A also acts to modify the cell environment to make it more conducive 
to viral replication. It is a phosphoprotein that can exist in a basally phosphorylated 
p56 or a hyperphosphorylated p58 form, and localises to the virus replication 
complexes, directly binding to NS5B and co-localising with other non-structural 
proteins in the replication complexes (Macdonald & Harris, 2004). NS5A has 3 
domains separated by low complexity sequences. The first domain is an amphipathic 
α-helix, which mediates membrane association of the protein. Mutation of the 
amphipathic domain has been shown to impair HCV replication (Elazar et al., 2003; 
Brass et al., 2002). It also contains a zinc-binding domain that is required for the 
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functioning of the protein (Tellinghuisen et al., 2004). Domain I also mediates NS5A 
dimer formation, for which two differing structures have been determined (Love et al., 
2009; Tellinghuisen et al., 2005). The second and third domains are natively 
unstructured (Hanoulle & Verdegem, 2009; Liang et al., 2007), although domain III 
has a slight propensity to partially fold into an α-helix (Verdegem et al., 2011).  
NS5A has been shown to interact with the viral polymerase NS5B to enhance viral 
replication (Macdonald & Harris, 2004). All 3 domains are involved to some extent in 
RNA binding (Foster et al., 2010), preferentially binding the polypyrimidine tract of the 
3’ UTR, as well as the 3’ region of the negative strand (Huang et al., 2005). Domain III 
enhances RNA replication but is not required for it (Hughes et al., 2009). It is, 
however, absolutely required for virus assembly (Tellinghuisen et al., 2008).  
NS5A is involved in the modulation of cell signalling pathways to block the cellular 
antiviral response and enhance virus replication. NS5A has been shown to suppress 
the induction of IFN within the cell (Aizaki et al., 2000). Mutations in NS5A have been 
shown in some studies to correlate with an increased response to IFN-treatment 
(Enomoto et al., 1995, 1996), but this has been disputed (Brillet et al., 2007). It has 
also been shown to block the action of a pro-apoptotic K+ channel (Mankouri et al., 
2009) maintaining the survival of infected cells in response to oxidant stress, inhibit 
p38 and Ras-ERK signalling and activate PI3 kinase-AKT signalling (Macdonald et al., 
2005). The majority of NS5A protein interactions are mediated by a conserved 
polyproline motif (Macdonald & Harris, 2004) that interacts with SH3 domain-
containing host cell proteins. 
1.4.7.6 NS5B 
NS5B is a 65 kDa RNA-dependent RNA-polymerase (RDRP) that replicates the viral 
genome. It is anchored to cell membranes by a C-terminal 21-residue transmembrane 
domain (Ivashkina et al., 2002), truncation of which does not affect the in vitro activity 
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of the RDRP domain, but does result in the protein being soluble and monodispersed 
(Ferrari et al., 1999). NS5B is localised to the ER and ER-associated membranes 
modified by NS4B, and the transmembrane anchor is both necessary and sufficient 
for this localisation (Schmidt-Mende et al., 2001).  
The RDRP structure has been determined, with an active site showing a number of 
conserved motifs found in other viral RDRPs, such as the GDD domain (Lesburg et 
al., 1999; Yamashita et al., 1998). Mutation of the GDD residues renders the virus 
unable to replicate. The active site shows a high specificity for the X-tail of the 3’UTR 
(Zhong et al., 2000b, 2000a), and this specificity is mediated by a conserved ‘thumb’ 
like domain, deletion of which allows nonspecific dsRNA to bind to the active site 
(Hong et al., 2001).  
NS5B has been shown to associate with a number of other proteins, both viral and 
cellular, in order to form the RNA replication complex, including the cellular RNA 
helicases elF4A and p68 (Goh et al., 2004; Kyono et al., 2002). The viral helicase 
NS3 is able to associate with NS5B, and NS4B has also been shown to associate with 
both of these proteins in a possibly inhibitory role (Piccininni et al., 2002). NS5A 
modulates the activity of NS5B, and mutations that abolish their association also 
impair RNA replication (Shimakami et al., 2004). NS5B has no proofreading ability, 
and comparative sequencing of HCV in patients and inoculated chimpanzees 
estimated an error rate of between 1.44x10-3-1.92x10-3 per base per year 
(Bartenschlager & Lohmann, 2000). This high error rate is responsible for the 
observed quasispecies variation found in HCV patients. 
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1.4.8 Experimental systems for HCV 
1.4.8.1 Animal models 
Animal models for HCV are limited: the only primate species susceptible to HCV 
infection are chimpanzees (Pan troglodytes). Early work, prior to the identification of 
HCV, found that sera from patients with non A, non B post transfusion hepatitis was 
able to infect chimpanzees and cause elevated ALTs and hepatitis-associated liver 
histology changes (Shimizu et al., 1979; Alter et al., 1978; Tabor et al., 1978). As well 
as exposure to infectious patient sera, chimpanzees can also be infected by injection 
of HCV RNA directly into the liver, allowing assessment of the in vivo replication ability 
of specific HCV mutations (Sakai et al., 2003). However, while there are a number of 
uses for chimpanzees in HCV research, there are a number of important clinical 
differences when compared with the disease in humans. In humans it is estimated 
that 85% of those exposed to HCV will develop a chronic infection; in chimpanzees 
this figure is estimated to be between 30-40% (Lanford et al., 2001). They are also 
long lived and, with the higher clearance rate, few chimpanzees will sustain a chronic 
infection for sufficient number of years for the potential development of cirrhosis and 
hepatocellular carcinoma.  
Chimpanzees are a protected species and their use as a HCV model system is 
therefore extremely limited, with only a very small number of individual animals used. 
Thus, experiments using chimpanzees may be highly prone to differing effects based 
on the genetic variation between the hosts.  
GB virus B (GBV-B) is another member of the flavivirus family and has a similar 
genome organisation to HCV. It is able to cause an acute, self-limiting infection in 
tamarins (Schlauder et al., 1995; Karayiannis et al., 1989) and has thus been used as 
a model for HCV. The lack of chronic infection limits its uses as a model for HCV, but 
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examination of the differences between the viruses may shed light on what causes the 
differences between acute and chronic infections.  
The development of mouse models for HCV has produced some promising results. 
Transplantation of human hepatocytes into immune deficient mice renders them 
vulnerable to infection, but the immune deficiency results in no liver damage 
occurring, thus limiting their use as a model for HCV infection (Bissig et al., 2010; 
Mercer et al., 2001). Engineering the expression of human receptors CD81 and 
occludin into murine cells (Ploss et al., 2009) and mice (Dorner et al., 2011) rendered 
them permissive to HCV entry, but viral protein expression could not be detected 
indicating that murine cellular factors may be blocking HCV replication. The most 
physiologically-relevant mouse model so far produced is one transplanted with both 
human hepatocytes and immune cells, which shows signs of hepatitis and fibrosis 
following HCV infection (Washburn et al., 2011). 
1.4.8.2 HCV pseudoparticles 
Before the development of an infectious virus clone, the expression of HCV 
pseudoparticles (HCVpp) was the only means of studying the entry mechanism of the 
virus. These particles are a hybrid of the lentivirus murine leukaemia virus with the 
envelope glycoproteins E1 and E2 of HCV, generated by co-transfection of expression 
constructs for the constituents into a producer cell line (Bartosch et al., 2003b). The 
virus pseudoparticles generated can then enter permissive cells.  
Virus-like particles (VLPs) can also be generated using a baculovirus expression 
system, which found that Core, E1 and E2 are sufficient to generate VLPs that can 
enter permissive cells (Baumert et al., 1998) 
The pseudoparticle systems were used to identify cell receptors that interact with E1 
and E2, such as CD81, SRBI, Claudin and Occludin (Ploss et al., 2009; Evans et al., 
2007; Cormier et al., 2004; Scarselli et al., 2002). 
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1.4.8.3 Subgenomic replicon 
The subgenomic replicon contains the minimal viral RNA sequence required for 
replication of the genome. The bicistronic construct was made using the GT1B 
consensus sequence (Con1), with the HCV IRES driving translation of neomycin 
phosphotransferase to allow colony selection, followed by an EMCV IRES driving 
expression of the NS3-5B region of the HCV genome (Lohmann et al., 1999), a 
schematic of which is shown in Fig 1.8 (a). Following transfection of the construct into 
the Human hepatoma 7 (Huh7) cell line, cells harbouring the replicon were selected 
using geneticin. Inclusion of NS2 was found to reduce RNA replication (Lohmann et 
al., 1999). Sequencing of the replicon following serial passage found a number of 
culture-adaptive mutations that increased replication; two in NS3, one in NS4B and 
four in NS5A (Krieger et al., 2001). This culture-adapted replicon was given the name 
FK5.1. However, when these culture adaptations were engineered into RNA used to 
infect chimpanzees, it was found that the RNA was no longer able to establish an 
infection. Thus, mutations that improve RNA replication may be harmful to the virus if 
the assembly of infectious virions becomes impaired (Bukh et al., 2002). 
Further adaptations to the replicon, such as creating a chimeric 5’ UTR with poliovirus 
also increased replication efficiency (Friebe et al., 2001). An Huh7-derived cell line, 
Huh7.5, created by serial passage of FK5.1 harbouring cells which were cured with 
interferon, were found to be more permissive for replicon RNA replication due to a 
defect in the dsRNA-detecting RIG-I signalling pathway (Blight et al., 2002). This cell 
line was also found to be permissive for replication of GT1A replicons (Blight et al., 
2003), where previous attempts in Huh7 cells had not been successful (Blight et al., 
2000). Further modifications to the replicon included replacement of the neomycin 
phosphotransferase gene with firefly luciferase, allowing RNA replication after 
transfection to be measured (Krieger et al., 2001). 
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Creation of a GT2A replicon using JFH1 produced a replicon capable of forming 
colonies at 60X the rate of FK5.1, and the replicon was also found to have efficient 
replication without culture adaptations (Kato et al., 2003). A JFH1 luciferase replicon 
for transient replication assays had a replication rate 200X greater than FK5.1 
(Targett-Adams & McLauchlan, 2005). The advantage of these systems is that, 
without culture adaptations that can impair the infectivity of the virus, the replication 
observed is more likely to be physiologically relevant to HCV virus replication. 
1.4.8.4 JFH1 infectious clone 
The infectious cell culture system for HCV was developed using a genotype 2a isolate 
from a patient with fulminant hepatitis, Japanese Fulminant Hepatitis (JFH1), cultured 
in the replication-permissive cell line Huh7 (Lindenbach et al., 2005; Wakita et al., 
2005; Zhong et al., 2005). This system is able to produce virus at an infectivity of 104 
focus forming units per ml (FFU/ml) (Zhong et al., 2005), and was able to infect 
chimpanzees, although the resulting infection was shorter in duration and had lower 
pathogenicity than that caused by the original JFH1 patient sera (Kato et al., 2008; 
Zhong et al., 2005).  
A number of JFH1 chimeras have been developed in order to investigate how 
genotype variation affects viral replication. In order to replicate, most of these 
chimeras require the replicative machinery (NS3-5B) of JFH1 but will tolerate the 
Core-NS2 region of other HCV isolates. One such chimera, Jc1, has the Core-NS2 
region of GT2A J6, and can produce titres as high as 105 FFU/ml, the highest thus far 
observed with HCV in culture (Pietschmann et al., 2006). A full-length GT1A, H77S, 
was found to be able to replicate in cells and to produce a limited amount of virus, but 
production of infectious virus was at very low levels when compared with JFH1 (Yi et 
al., 2006). A chimera of this isolate with JFH1 produced higher levels of infectious 
virus, showing some adaptive mutations that enhanced particle production (Yi et al., 
2007). These chimeras allow the effect of changes in the structural proteins on virus 
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infectivity to be investigated, and provide a much more relevant model of viral entry 
than the previously used pseudoparticle systems. a simplified diagram of full-length 
JFH1 and its chimeras H77 and Jc1 is shown in Fig. 1.8.   
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Figure 1.8 Genome structure of HCV replicon and virus constructs 
Organisation of HCV constructs used to investigate the virus lifecycle.(a) Subgenomic 
replicon, containing the HCV IRES followed by the neomycin phosphotransferase 
gene (Neo), the encephalomyocarditis virus IRES (EMCV IRES), and the non-
structural proteins NS3-5B of the HCV sequence. (b) Full-length JFH1 sequence. (c) 
Chimeric construct containing the Core-NS2 region from the GT1A H77 isolate. (d) 
Chimeric construct Jc1 containing the Core-NS2 region from GT2A J6. 
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1.5 p7 
1.5.1 Discovery 
p7 was the last HCV protein to be identified. The other nine proteins were 
characterised by the use of expression constructs and in vitro translation, and it was 
noted that cleavage of the E2-NS2 region was slower than for other linkages in the 
polyprotein. E2 also undergoes glycosylation during processing which increases its 
molecular weight (Grakoui et al., 1993), and in combination with the presence of 
uncleaved E2-p7 may have indicated multiple forms of E2 rather than the existence of 
an additional viral protein. Further analysis of the E2-NS2 linker region found a 
second cleavage site, but at the time this was ascribed to generating two different 
forms of E2 (Mizushima et al., 1994). Further investigations into the E2-NS2 region 
using a series of c-myc tagged C-terminal truncations identified a 7 kDa protein, p7, 
after immunoprecipitation (Lin et al., 1994). A high proportion of uncleaved E2-p7 was 
also observed, indicating lower cleavage efficiency than found for other HCV proteins. 
1.5.1.1 Cleavage from the HCV polyprotein  
As with the preceding structural proteins in the polyprotein, cleavage of p7 from E2 
and NS2 was shown to be mediated by host signal peptidase (SP), as the presence of 
microsomal membranes was sufficient for protein cleavage. The SP cleavage of the 
p7 junctions in the ER is slower than for the preceding structural proteins, leading to 
the presence of uncleaved E2-p7-NS2, E2-p7 and p7-NS2. Mutations upstream of p7 
in E2 have been found to increase the rate of cleavage and so the limited cleavage 
rate may well be a viral mechanism to limit the availability of the fully cleaved proteins 
(Isherwood & Patel, 2005). However, work in the JFH1 virus system has confirmed 
that none of these uncleaved p7 products are required for virus replication, as 
insertion of an additional IRES at either end of p7 does not significantly affect the 
production of infectious virus particles (Jones et al., 2007). 
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1.5.1.2 Topology and localisation 
Early sequence analysis identified two possible transmembrane domains (TMDs), with 
a predicted topology of the N and C termini of the protein being oriented towards the 
lumen of the channel, with two basic residues present in the cytosolic loop (Carrère-
Kremer et al., 2002). This topology was confirmed by overexpression of N or C termini 
myc-tagged constructs that reached the plasma membrane, with the myc tag 
detectable by immunofluorescence without permeabilisation of the cell (Carrère-
Kremer et al., 2002).  
Initial overexpression studies to determine the localisation of p7 found that it localised 
to the ER, the mitochondria and the plasma membrane (Carrère-Kremer et al., 2002). 
However, in more physiologically relevant systems, trafficking to the plasma 
membrane is not observed, and the apparent mitochondrial localisation was in fact ER 
positive sites surrounding the mitochondria (Griffin et al., 2005). JFH1 p7, when 
tagged with eGFP or HA epitopes, showed no localisation to mitochondria or the 
plasma membrane (Haqshenas et al., 2007b). The ER is the primary localisation of 
p7, with no association found with the Golgi by immunofluorescence (Vieyres et al., 
2013). IAV M2, the prototype viroporin which forms a proton conductive channel, 
localises to the trans-Golgi to prevent acidification that can lead to conformational 
changes in the envelope glycoproteins (Ciampor et al., 1992). The presence of p7 in 
endosomes, while not detectable by immunofluorescence, can be seen indirectly by 
its effect on raising endosomal pH, which is blocked by the p7 inhibitor rimantadine 
(Wozniak et al., 2010). 
1.5.1.3 p7 as a viroporin 
The viroporin activity of p7 was identified by ion channel recordings performed using 
GST-tagged bacterially expressed protein in the black lipid membrane (BLM) system. 
Channel activity could be blocked by the M2 inhibitor amantadine (Griffin et al., 2003). 
Chemically synthesised p7 also displayed channel activity in this system (Pavlović et 
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al., 2003). High throughput assays of p7 function were then developed using a 
liposome based dye-release assay, using the self-quenching fluorescent dye 
carboxyfluorescein, that could be used to measure activity levels of the protein in vitro 
under a variety of conditions (StGelais et al., 2007).   
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Figure 1.9 J4 p7 monomer structure 
Cartoon NMR structure of the GT1B J4 p7 monomer in solution in methanol, including 
the N-terminal FLAG tag and 4 additional residues on the C terminus, with the 
sequence shown below. The extra residues at the N and C terminus are coloured 
yellow in the structure cartoon and in the sequence, and annotated residues in the 
structure cartoon are highlighted in blue in the sequence below. Three copies are 
shown in vertical rotation, and proline residues P49, P58 and P59 are highlighted. 
TMD 1 shows a straight helix containing the lumenal residues H17, S31 and F25, 
followed by a short loop domain containing the two conserved basic residues K33 and 
R35, and TMD2 with a slight kink at P49 before a sharp turn at the C-terminus caused 
by P58 and P59. Top image taken from Foster et al, 2014. 
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1.5.2 Structure 
1.5.2.1 Structural analysis 
p7 is a 63 amino-acid protein with a high proportion of hydrophobic residues. In silico 
analysis of the p7 sequence predicted a mostly alpha-helical secondary structure 
(Patargias et al., 2006) with helical wheel plots of both transmembrane domains 
predicting that the helices were amphipathic (Clarke et al., 2006). The overall 
structure of the monomer was predicted to be a helix-loop-helix structure (Carrère-
Kremer et al., 2002). A number of solution and solid state NMR studies have been 
performed to establish the structure of p7. While none of these studies have, at this 
time of writing, produced a complete atomic structure of full length p7, they have 
shown details of the α-helical secondary structure and inter-helix interactions. Other 
structural analysis techniques, such as circular dichroism (CD) spectroscopy and 
electron microscopy, have also provided details of the protein architecture. 
Biochemical analysis confirmed the topology of p7 as an integral membrane protein 
with both N and C termini present on the same side of the membrane, providing 
evidence for a hairpin protein structure (Carrère-Kremer et al., 2002). 
The helix-loop-helix structure has been confirmed by NMR in GT1B J4 (Fig 1.9). A 
slight kink in TMD1 occurred at H17, showing a possible constriction point in the 
channel (Cook & Opella, 2011). A further, hydrophobic constriction point in the 
channel at F25 was hypothesised to play a role in maintaining the closed position of 
the channel and possibly contribute to its cation selectivity (Montserret et al., 2010). 
This hypothesis may be supported by biochemical data, as mutations of phenylalanine 
residues in TMD1 of GT1B J4 p7; F22, 25 and 26 to alanine, and the point mutation 
F25A, all produce highly active channels (Foster et al., 2011; StGelais et al., 2009).  
It had previously been hypothesised from in silico modelling that TMD2 would have 
some degree of tilt relative to TMD1 (Patargias et al., 2006). NMR data showed that in 
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GT1B J4 p7 both of the TMDs are tilted in the membrane, with TMD1 and 2 showing 
tilt angles of 10° and 25° respectively from the bilayer normal (Cook & Opella, 2010). 
It was found that in vitro synthesised GT1B p7, with a C27A mutation to prevent 
disulphide bond formation, in a variety of membrane mimetic conditions showed a 
mostly alpha-helical structure by CD spectra in all tested conditions, and solution 
NMR in 50% trifluoroethanol/water confirmed the presence of these helices. As well 
as those TMD alpha helices already predicted, a further helix was found in the N-
terminal domain of the protein (Montserret et al., 2010). However, no inter-helix 
interaction by long-range NOE was detected under these conditions indicating that the 
protein did not fold into full tertiary structure. A recent study of the GT1B J4 p7 
monomer structure in methanol (Foster et al., 2014) has modified the previously 
generated in silico structures, shifting the position of the cytosolic loop and showing 
interactions between the TMDs, confirming the hairpin structure (Fig 1.9). 
Early theoretical analysis hypothesised that p7 required at least 5 subunits to form a 
functioning channel (Pavlović et al., 2003). Evidence for oligomerisation of the protein 
came from chemical crosslinking studies. These studies showed that HepG2 cells 
transfected with a p7 expressing plasmid produced a p7 antibody-reactive band on 
western blot of a size consistent with a hexamer (Griffin et al., 2003). Crosslinking was 
also used to show channel structures by electron microscopy, with crosslinking of 
bacterially expressed GST-p7/GST-His-p7 fusion proteins in microsomal membranes 
showing possible hexamer or heptamer channel structures (Griffin et al., 2003). Later 
work by the same group found both hexamers and heptamers were formed in 
liposome membranes (Clarke et al., 2006), although other studies under different 
experimental conditions using chemically synthesised protein and different lipids 
found that only hexamers were present (Luik et al., 2009). These hexamers, 
consisting of GT2A p7 in micelles of the detergent DHPC, showed a flower-petal like 
channel structure at a resolution of 16 Å, where the wide ‘petals’ were formed by the 
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N and C terminal tails of the protein, confirmed by gold-particle immunolabelling (Luik 
et al., 2009). It is possible that both heptamers and hexamers may coexist under in 
vivo conditions as functional channels. Consistent with this, in silico analysis of both 
possible oligomer structures indicates that both hexamers and heptamers are capable 
of forming functional channels (Chandler et al., 2012).  
Recent work has indicated that the composition of the membrane environment also 
has a strong effect on p7 structure (Whitfield et al., 2011). This could have potentially 
high significance. While the majority of p7 within a cell accumulates within the ER, the 
functioning of the protein may well change as it is trafficked through different cellular 
compartments. It is possible that p7 may not function as an ion channel until it is 
required during the latter stages of viral assembly or egress.  
1.5.2.2 N and C terminal tails 
The N and C termini show a high degree of conservation with the first and last 3 
residues absolutely conserved between HCV genotypes. These residues adjacent to 
the cleavage site are absolutely required for signal peptidase cleavage. While these 
regions do not play a direct role in the viroporin activity of p7, they may act to stabilise 
the oligomer. 
The N and C terminal tails of the protein are thought to act as signal sequences for p7 
cleavage. They may also be responsible for genotype-specific interactions with other 
HCV proteins, as chimeras between GT1A H77 and GT2A J6 p7 found that the 
transmembrane domains could be exchanged between genotypes and still produce 
infectious virus in chimpanzees, but not the terminal tails of the protein (Sakai et al., 
2003). This genotype specificity could indicate that these regions are responsible for 
interactions with other viral proteins, unrelated to the viroporin activity of the channel.  
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1.5.2.3 Basic loop 
The cytosolic basic loop between the two TMDs at positions 33-35, consisting of two 
positively charged residues of arginine or lysine separated by a single glycine, has 
been shown to be crucial to the functioning of the protein and for infectivity of the virus 
(Griffin et al., 2004). These residues are highly conserved, with only arginine or lysine 
ever present at these positions. Initial mutations generated in HCV RNA injected into 
chimpanzees found that these residues were required for infectivity in vivo (Sakai et 
al., 2003). In vitro, mutation of both residues to alanine, K33A R35A, in J4 p7 
abrogates p7 function and it was found to no longer form an integral membrane 
protein, as the mutant p7 could be dissociated from liposome membranes when 
washed with sodium bicarbonate (StGelais et al., 2009).  
The equivalent mutation in the JFH1 system, R33A R35A, was found to abolish the 
infectivity of the virus and cause a significant reduction in Core release, with no 
significant effects on genome replication. The double loop mutant did show a small 
recovery of virus infectivity when the infected cells were treated with the vATPase 
inhibitor Bafilomycin A, which raises endosomal pH and may partially compensate for 
the loss of p7 viroporin function (Wozniak et al., 2010). The less-severe mutation 
R33Q R35Q also caused complete abrogation of both Core release and infectivity, 
and single mutations of each arginine residue displayed a significant drop of 1 log10 in 
the production of infectious virus (Jones et al., 2007). However, mutation of the basic 
loop has also been shown to disrupt the processing of the downstream NS2 protein, 
indicating that the loss of viral infectivity as a result of these mutations may be due to 
the disruption of correct polyprotein processing, rather than a specific ion channel 
defect (Tedbury et al., 2011). 
1.5.2.4 Channel lumen 
The nature of the p7 channel lumen dictates ion conductance, and specificity. Work in 
BLMs found that p7 has a high specificity for cations, with a relative conductance rate 
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11 times higher for cations than for anions (Montserret et al., 2010). Analysis of the 
channel pore identified a number of luminal residues affecting channel characteristics. 
The passage of cations through this pore is dependent on this local environment, with 
some residues possessing side-chains that protrude into the channel, restricting the 
flow of ions. Other residues, whether polar or hydrophobic in character, will affect the 
hydrophilicity of the pore and thus aid or hamper the passage of ions.  
In vitro studies of the GT1B J4 p7 have included alanine mutations to all the residues 
thought to line the lumen of the pore. Of these mutations, S21A and C27A had only a 
minimal effect on channel activity, whereas mutation of H17 to alanine showed a 
significant drop in activity (StGelais et al., 2009). It is worth noting, however, that 
GT1A H77 p7 does not show a loss in activity with the H17A mutation in the BLM 
system (Chew et al., 2009).  
The presence of H17 in the lumen of the channel has been demonstrated 
biochemically in the H77 isolate, through the use of copper ions to chelate the 
histidine residue and block ion flux through p7 in a BLM system (Chew et al., 2009). 
Structural modelling in silico of p7 of other genotypes has also shown orientation of 
H17 to the channel lumen (Foster et al., 2011; StGelais et al., 2009). J4 p7 has been 
shown in vitro to have an increased level of activity in response to reduced pH 
(StGelais et al., 2007).  
While hydrophilic residues in the channel lumen are required for the conductance of 
aqueous ions, a number of hydrophobic residues are also present. Structural data 
from NMR experiments predict a constriction point at F25, where the large, 
hydrophobic side chain may form a barrier to the passage of ions forming part of a 
gating mechanism. This hypothesis is supported by mutational analysis of p7 where 
mutations F22, 25 and 26 to alanine, and the single F25A mutation, were shown to 
produce p7 channels with enhanced activity in liposome dye release assays (Foster et 
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al., 2011; StGelais et al., 2009). The F25A mutant was later also found to confer 
resistance to iminosugar inhibitors (Foster et al., 2011) 
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Figure 1.10 Inter-genotype sequence variation in p7 
p7 amino acid sequence for 6 isolates from commonly used laboratory HCV strains; 
H77 from GT1A, Con1 and J4 from GT1B, JFH1 and J6 from GT2A and 452 from 
GT3A. Residues with hydrophobic side chains are shown in green, residues with polar 
side chains in orange, residues with charged acidic residues shown in red, and 
residues with charged basic side chains shown in blue. Black arrows indicate the 
frequent histidine at position 17, and the conserved basic residues arginine and lysine 
at positions 33 and 35.  
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1.5.2.5 Genotype variation 
The primary sequence of p7 across HCV genotypes identifies a number of highly 
conserved residues (Fig 1.10). The N and C termini show a high degree of 
conservation, owing to the need to maintain the recognition sequence for signal 
peptidase cleavage of p7 from E2 and NS2. In many cases, the variations between 
genotypes show synonymous mutations, most commonly where hydrophobic residues 
are replaced with other hydrophobic residues. The two basic residues in the loop 
domain at positions 33 and 35 are interchangeable between arginine and lysine. 
However, substitution of the hydrophobic residues, while not changing the overall 
hydrophobicity of the protein, may have other consequences. It has been shown that 
in genotype 1b HCV, the L20F mutation observed in clinical trials of the p7 inhibitor 
amantadine (Mihm et al., 2006) was confirmed in vitro to confer resistance to 
adamantanes (Foster et al., 2011). Similarly, an F25A mutation in GT1B J4 p7 and 
GT2A JFH1 p7 confers resistance to iminosugar inhibitors (Foster et al., 2011). Thus, 
while synonymous mutations within and between genotypes may not significantly alter 
the biophysical properties of the protein, they can have significant effects on p7 drug 
sensitivity, representing sites of resistance mutations during drug treatment.  
Other residues display notable differences between genotypes. Of particular interest 
are the residues hypothesised to play a role in p7 gating with particular focus on H17. 
This histidine residue may act as a pH sensor within the lumen of the channel, with its 
protonation state determining the open or closed state. While H17 is conserved 
between many HCV genotypes, it is not universal, with J6 p7 possessing an 
asparagine at this position. In vitro J6 p7 is less active than GT1B J4 p7, but when the 
structural proteins of J6 are substituted into the JFH1 virus system, the chimera 
shows the highest production of infectious virus of any HCV viral construct. Whilst 
sequence variation between J6 and JFH1 in other viral proteins exists, it is interesting 
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that the mutation of a conserved p7 residue does not significantly impact the infectivity 
of the virus. 
1.5.2.6 Hypothesised gating mechanism 
The gating mechanism for influenza A M2 viroporin has been well established, with a 
substantial amount of structural data available (Manor et al., 2009; Huang et al., 2008; 
Tang et al., 2002). In brief, H37 of IAV M2 acts as a proton sensor, as histidine is 
unprotonated at neutral pH but becomes protonated at acidic pH, with a pKa of 6.5. 
Once protonated, the change in electrostatic potential of the channel results in a shift 
in the gating residue W41, this opens the channel to allow proton flux.  
There are clearly a number of differences between M2 and p7. p7 is formed of 6 or 7 
subunits with a second TMD to stabilise the oligomer, compared to M2 which has only 
4 subunits with a single TMD span across the membrane. However, the increased 
activity of p7 in response to low pH (StGelais et al., 2007) would indicate that some 
form of pH activation is taking place. 
A similar motif to IAV M2, HXXX(W/Y) can be found in some HCV isolates. In IAV M2 
these helix-adjacent residues act as the gating mechanism, with the protonation of 
H37 under acidic conditions causing a change in the electrostatic potential that 
causes a shift in the position of the gate residue W41 that opens the channel (Kass & 
Arkin, 2005). However, this motif is not universally conserved in HCV with many 
isolates having serine at position 21 (Meshkat et al., 2009). (Fig. 1.10, Fig. 3.1). 
1.5.2.7 Non-lumenal TMD residues 
Mutagenesis of a number of other residues has also identified other important 
structural elements of p7. A conserved proline in TMD2, P49, introduces a kink in the 
helix. Mutation of this residue to alanine shows a slight reduction in channel activity at 
5 μM compared with wild-type J4 p7, but when assayed at higher concentration 
shows much higher activity than WT J4 p7 (StGelais et al., 2009).  
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A glycine, G39, near the start of TMD2, has also been mutated to alanine. This was 
found to cause a 60% reduction in channel activity (StGelais et al., 2009). However, it 
is worth noting that this residue is only conserved within genotype 1, with other 
genotypes possessing a leucine at this position.  
Alanine mutations targeting a series of leucines in TMD2, L50-55, also hypothesised 
to be involved in oligomerisation, caused only a slight reduction in channel activity, 
and conferred increased resistance to amantadine (StGelais et al., 2009). This region 
shows some sequence divergence between J4 p7, with L50-55, and JFH1 p7, with 
FCLLLM, and so this poly-leucine motif may be required for amantadine binding.  
1.5.3 Role of p7 in the virus lifecycle 
1.5.3.1 Prevention of endosomal acidification during virus assembly and egress 
The prototype viroporin, IAV M2, has two roles within the virus life cycle: it prevents 
acidification of cellular compartments during the maturation and assembly of the 
envelope glycoproteins HA and NA, and is incorporated into the virion where, on entry 
into a cell, it allows the influx of protons, a trigger allowing the virus to uncoat and 
release its genome to initiate replication. However, other viroporins have been shown 
to play differing roles in the virus lifecycle; viroporin 2B of poliovirus acts to destabilise 
the plasma membrane and thus aid the release of the unenveloped virion (Agirre et 
al., 2002).  
p7 has been shown to have a higher level of activity in vitro in response to reduced 
pH, but has also been shown to conduct other cations (Premkumar et al., 2004). 
There was some doubt on the importance of p7 in the prevention of endosomal 
acidification in the HCV lifecycle as the mature virions, unlike IAV, are not inactivated 
by exposure to low pH. However, it has since been shown that nascent, intracellular 
HCV virions are sensitive to reduced pH. It was also shown that p7 is highly effective 
in preventing the acidification of endosomal compartments, and this effect could be 
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inhibited by the addition of p7 inhibitors. A p7 mutant deficient in virus production 
could be partially rescued by the addition of the endosomal vATPase inhibitor 
bafilomycin (Wozniak et al., 2010). 
The prototype viroporin IAV M2 is incorporated into virions, but many other viroporins 
are not. Studies using HCV pseudoparticles have shown that p7 is dispensable for 
HCV entry (Hsu et al., 2003; Bartosch et al., 2003b). 
1.5.3.2 Non-viroporin activity 
While the primary role of p7 in the virus lifecycle is likely to be the prevention of 
compartmental acidification during virus assembly and egress, it is known to interact 
with a number of other viral proteins independently of its viroporin activity. NS2, in 
particular, has been shown to be affected by alterations in p7, with its absence or 
mutation of the basic loop residues to alanine altering NS2 localisation. In GT1B, the 
culture adapted replicon FK5.1 was given the additional sequence of NS2, or p7-NS2 
with the preceding signal peptide sequence from E2. In the absence of p7, the NS2 
protein did not show the usual reticular staining pattern and was fully soluble in 
detergent, indicating decreased membrane association. NS2 also no longer interacted 
or localised with NS5A (Tedbury et al., 2011). 
p7 was also shown to strongly affect the localisation pattern of NS2 in different virus 
isolates. Interestingly, the change in NS2 localisation differed between wild-type JFH1 
and the GT2A chimera Jc1 (Boson et al., 2011).  
Other viral proteins shown to interact with p7, primarily by co-immunoprecipitation, 
include Core, E2, NS3 and NS5A (Popescu et al., 2011). Thus, while p7 has been 
shown to not be required for replication, it may play a role in the switch between 
replication and assembly. As the majority of p7 distributes to the endoplasmic 
reticulum, where acidification of the compartment is not yet likely to have a significant 
impact on the infectivity of the resulting virions, its role early in the life cycle may be 
 
 
68 
 
the correct conformation and localisation of other viral proteins. The changes in lipid 
composition between different cellular compartments may also play a role in this 
functional switching between the activities of the protein (Whitfield et al., 2011), 
although, as yet, any viroporin activity of p7 in the ER has not been demonstrated.  
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Figure 1.11 p7 inhibitor structures 
Structures of the adamantanes amantadine and rimantadine, the iminosugars N-nonyl 
deoxynojirimycin (NNDNJ) and N-nonyl deoxygalactonojirimycin (NNDGJ), and the 
amilorides hexamethylene amiloride (HMA) and BIT225.  
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1.5.4 Inhibitors of p7 
1.5.4.1 Adamantanes 
The adamantanes, amantadine and rimantadine, are the oldest antiviral drugs and 
were originally developed against influenza virus (Wingfield et al., 1969). The 
structures are shown in Fig. 1.11. A method was established to express tagged p7 in 
bacteria and purify it by reverse-phase high performance liquid chromatography 
(HPLC), allowing the initial studies of the function of p7 to be performed. The BLM 
studies showed that amantadine, an inhibitor of the prototype viroporin IAV M2, also 
inhibited p7 ion channel activity (Griffin et al., 2003). Later studies found that another 
drug from the same family, rimantadine, was also effective (StGelais et al., 2007). 
The efficacy of the adamantanes varies between genotypes, both in vitro and in 
chimeras of the JFH1 virus. GT1b J4 p7 showed sensitivity to both amantadine and 
rimantadine, while JFH1 showed resistance to amantadine but was still sensitive to 
rimantadine. GT1A H77 p7 showed lower sensitivity to both adamantanes (Griffin et 
al., 2008). 
Clinical trials using these drugs observed few anti-viral effects. This may be due to a 
number of factors: amantadine was the most commonly used adamantane in trials but 
has been shown in vitro to be less effective against GT2A p7, and the use of a single 
virus-specific drug in combination with IFN/Rib treatment is likely to result in rapid 
escape mutations as observed with HIV monotherapy, prior to the advent of highly 
active antiretroviral drug therapy (HAART). A possible escape mutation, L20F, in 
GT1B was identified during one such clinical trial with amantadine (Mihm et al., 2006). 
In silico modelling identified a putative adamantane binding site in the pore of p7 
(Patargias et al., 2006), similar to a previously identified site in IAV M2 (Cady et al., 
2010). Later work from more detailed oligomer computer models based on the known 
monomer structure identified a second site with a higher predicted binding affinity, this 
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time in the membrane side of the channel, comprising a leucine-rich binding pocket. 
When the L20F mutation was modelled into this pocket, a reduction in the predicted 
binding efficiency of adamantine was observed. Subsequent analysis using bacterially 
expressed protein in NMR experiments to measure changes in rimantadine binding 
found that the L20F mutant showed no shift that would indicate drug binding, and so it 
is likely that this mutation blocks rimantadine binding (Foster et al., 2011). Recent 
work developing compounds to bind to this leucine-rich pocket has identified a 
number of potential leads that can possibly overcome the L20F escape mutation 
(Foster et al., 2011). 
1.5.4.2 Iminosugars 
Chemically synthesised GT1A H77 p7 in the BLM system was used to identify a new 
family of p7 inhibitors, the iminosugars n-nonyl deoxynojirimycin (NNDNJ) and n-nonyl 
deoxygalactonojirimycin (NNDGJ) (Pavlović et al., 2003). The structure of the 
iminosugars includes a long alkyl-chain that is thought to intercalate between 
monomers and prevent the formation of a functioning channel, shown in Fig. 1.11. 
NNDNJ has been shown to prevent oligomerisation of GT1B p7 in DHPC (Foster et 
al., 2011).  
Iminosugars also display different levels of activity against different genotypes, with 
genotype 3A showing the least sensitivity to the drug (Griffin et al., 2008). A 
comparison of the sequence variation between the genotypes identified a possible 
resistance polymorphism at position 25, where genotype 3a had an alanine instead of 
phenylalanine. Further investigation of this polymorphism through introducing the 
F25A mutation into JFH1 found that this mutation was sufficient to confer iminosugar 
resistance, with only a minimal effect on the production of infectious virus observed 
(Foster et al., 2011).  
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1.5.4.3 Amilorides 
Hexamethylene amiloride (HMA) has been shown to block p7 activity in vitro in BLMs 
(Premkumar et al., 2004) and in the liposome system. However, at concentrations 
inhibitory to p7 function, HMA showed cytotoxic effects meaning its effects on JFH1 
could not be assessed (S. Griffin, unpublished observations). 
The amiloride analogue BIT225 was identified from a pool of antiviral compounds 
using a bacterial survival assay, where p7 expression is induced in bacteria in the 
presence of potential inhibitors. As p7 expression in bacterial cells results in cell lysis, 
inhibitors can be identified by an increase in cell survival times. BIT225 was then 
tested for p7 inhibition in planar lipid bilayers, and was found to efficiently inhibit ion 
channel activity. It also displayed good antiviral activity against the HCV-related BVDV 
(Luscombe et al., 2010). The structures of both amiloride compounds are shown in 
Fig. 1.11. 
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1.6 Aims of this project 
 
Genotype variations have been shown to affect the activity and inhibitor sensitivity of 
p7. This project sought to answer the question of how patient-derived, naturally 
occurring p7 polymorphisms within a single genotype affected p7 activity, drug 
resistance and the production of infectious virus. A number of methods were used to 
answer this question: previously characterised in vitro liposome based dye release 
assays, cloning of the p7 sequences into a chimeric virus to investigate the effects on 
the production of infectious virus, and the development of cell-based assays to study 
the effect of p7 on cellular endosomal pH. 
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 Chapter 2: Materials and methods 
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2.1  Antibodies: 
Primary 
Antibody 
Supplier Monoclonal/ 
polyclonal 
Species Experimental 
Dilution 
1055 terminal 
bleed serum 
Custom, Glaxo-
Smith-Kline 
Polyclonal Rabbit 1:7000 
2716 In-house Polyclonal Rabbit 1:1000 
FLAG Sigma-Aldrich Monoclonal Mouse 1:20,000 
GST Serotec Monoclonal Mouse 1:1000 
NS5A In house Polyclonal Sheep 1:5000 
Core In house Polyclonal Sheep 1:5000 
NS2 Dr. G Haqshenas, 
Monash University 
Polyclonal Rabbit 1:5000 
AP33 (E2) Dr. A. Patel, 
University of 
Glasgow 
Monoclonal Mouse 1:2000 
AB8245 
(GAPDH) 
Abcam Monoclonal Mouse 1:30,000 
Table 2.1 Primary antibodies 
 
Secondary 
antibody 
Supplier Monoclonal/ 
polyclonal 
Species Experimental 
Dilution 
Anti-mouse 
HRP linked 
Sigma-Aldrich Polyclonal Goat 1:10,000 
Anti-rabbit HRP 
linked 
Sigma-Aldrich Polyclonal Goat 1:10,000 
Anti-sheep 
HRP linked 
Sigma-Aldrich Polyclonal Donkey 1:10,000 
Alexa-Fluor 
594 anti-sheep 
Invitrogen Polyclonal Donkey 1:500 
Table 2.2 Secondary antibodies 
 
2.2 Bacterial culture methods 
2.2.1 Bacterial strains 
Escherichia coli DH5α Genotype: F-, Φ80dlacZΔM15, endA1, recA, hsdA1, (rk
-, mk
+), 
supE44, thi1, deoR, gyrA96, relA1, (ΔlacZYA-argF), U169, λ-, were purchased from 
Life Technologies Inc. Escherichia coli BL21-(DE3) Genotype: F-, ompT, hsdSB, (r-, 
mB-), gal, dcm, (DE3), were purchased from Novagen Ltd. 
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All bacterial cultures were grown in Luria-Bertani (LB) broth (10 g/L NaCl, 5 g/L yeast 
extract, 10 g/L tryptone, pH 7.5), supplemented with 100 μg/ml ampicillin or 50 μg/ml 
kanamycin where appropriate. For bacterial colony production, agar was 
supplemented with the appropriate selection antibiotic, poured onto single-vented 
plates and stored at 4 °C until required. Bacteria were plated out or streaked onto the 
agar and incubated overnight at 37 °C unless otherwise stated. 
2.2.2 Plasmids 
pGEX-6P-1 (GE Healthcare) was used for the expression of GST-FLAG-p7 fusion 
proteins in BL21 DE3 cells, and carries an ampicillin resistance marker. pET24a 
containing histidine-tagged human rhinovirus serotype 14 3C protease was supplied 
by Arie Geerlof, University of Oxford, and carries a kanamycin resistance marker. 
The JFH1 full length virus construct was supplied by Dr Takaji Wakita, National 
Institute of Infectious Diseases, Tokyo, Japan, (Wakita et al., 2005) and carries an 
ampicillin resistance marker. The H77/JFH1 chimera HJ3-5 was supplied by Prof. 
Stanley Lemon, University of North Carolina, USA, (Yi et al., 2007) and carries an 
ampicillin resistance marker. 
pCDNA3.1+ (Invitrogen) carries an ampicillin resistance marker. 
pLXV-IRES-mCherry (Clontech) containing IAV M2 and IAV M2 (A30P) were supplied 
by Ann Wozniak, University of Kansas, USA (Wozniak et al., 2010) and carry an 
ampicillin resistance marker. 
VAMP-pHluorin was originally constructed by Prof. Gero Miesenbock (Miesenbock et 
al., 1998), University of Oxford, and was supplied by Dr Jonathan Lippiat, University of 
Leeds. 
The subgenomic replicon FK5.1 was originally supplied by Prof. Ralf Bartenschlager, 
University of Heidelberg, and cloning of NS2 and SPp7-NS2 into this replicon was 
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performed by Dr. Phillip Tedbury, University of Leeds. Cloning of the JFH1 replicons 
was also performed by Dr. Tedbury. All contain an ampicillin resistance marker. 
pBF+ is an amphibian expression vector containing the 5’ and 3’ UTRs of the 
Xenopus β-globin gene flanking the multiple cloning site. It was supplied by Dr 
Jonathan Lippiat, University of Leeds, and carries an ampicillin resistance marker.  
2.2.3 Preparation of competent bacterial cells 
Cells were prepared according to the Inoe method (Sambrook et al., 1989). Bacterial 
cultures (250 ml) were grown overnight at 18 °C. Once the cells reached an optical 
density of 0.55 at OD600nm they were harvested at 6000 xg and resuspended in 80 ml 
of ice-cold Inoe transformation buffer (55 mM MnCl2, 15 mM CaCl2, 250 mM KCl, 
10 mM PIPES (pH 6.7)). The bacteria were pelleted again by centrifugation and 
resuspended by swirling in 20 ml of ice-cold Inoe transformation buffer. DMSO (1.5 ml) 
was added and the culture aliquoted and snap-frozen in liquid nitrogen. Competent 
bacteria were stored at -80 °C. 
2.2.4 Transformation of bacterial cultures 
For each transformation, 100 μl of competent cells were thawed on ice, added to 10–
50 ng of DNA and gently mixed and incubated on ice for 30 minutes. The cells were 
transferred to a 42 ˚C water bath for 45 seconds (heat shocked) and placed on ice for 
a further 1 minute. LB medium (100 μl) was then added to the cells and they were 
placed in a 37 ˚C shaking incubator for 1 hour. The cells were plated onto pre-warmed 
2YT-agar plates (containing appropriate selection antibiotics) with a sterile glass 
spreader. The inoculated plates were placed in a 37 ˚C incubator and grown overnight.  
2.2.5 Preparation of bacterial cultures for protein expression: 
A single colony was picked from freshly transformed BL21 cells and a 5 ml culture 
grown overnight in LB broth containing the appropriate antibiotic (100 μg/ml ampicillin 
or 50 μg/ml kanamycin). Overnight cultures were diluted 1:100 into 400 ml LB broth 
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and grown at 30 °C in a shaking incubator at 180 rpm until the OD600 reached 0.6, at 
which point a 1 ml pre-induction sample was taken for reference. IPTG was then 
added to the bacterial culture to a final concentration of 1 mM and cells incubated for 
a further 4 hrs. A second, post induction sample was taken prior to harvesting at 4 hrs 
and the OD normalised to that of the pre-induction sample. Cells were pelleted at 
6000 xg for 15 minutes and the supernatant removed. Bacterial pellets were either 
immediately progressed to the lysis and inclusion body prep or resuspended in 5 ml 
PBS and frozen at -20 °C for later use. The pre and post induction reference samples 
were run on SDS-PAGE gels and coomassie-stained to visualise protein expression. 
2.3 DNA methods 
2.3.1 Polymerase chain reaction (PCR) 
2.3.1.1 Primers 
Oligonucleotide primers were designed with a minimum of 15 complementary bases 
to the sequence to be amplified. Any additional desired sequence (FLAG-tag, 
restriction endonuclease cleavage sites etc.) were added to the design. Primers were 
ordered from either MWG or Sigma-Aldrich and dissolved in dH2O to a concentration 
of 100 pmol/μl and stored at -20 °C. 
2.3.1.2 Cloning PCR 
Polymerase chain reaction (PCR) was performed using Pfu Turbo (Stratagene) 
according to the manufacturer’s instructions. Reactions were assembled in thin-walled 
0.1 ml PCR tubes with the following: 5 μl 10x Pfu buffer (200 mM Tris-HCl (pH 8.8), 
20 mM MgSO4, 100 mM KCl, 100 mM (NH4)2SO4, 1% Triton X-100, 1 mg/ml 
nuclease-free BSA), 0.5 μl of a dNTP mix (25 mM 2’-deoxyadenosine 5’-triphosphate, 
25 mM 2’-deoxycytidine 5’-triphosphate, 25 mM 2’-deoxyguanosine 5’-triphosphate, 
25 mM 2’-deoxythymidine 5’-triphosphate), 10-20 ng template DNA, 50 pmol of each 
primer (see primer sequences in Appendix 1), 1.25 units of Pfu Turbo polymerase, 
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and an appropriate volume of dH2O to give a total volume of 50 μl. Thermocycling 
reactions were set for 2 minutes of denaturation at 90 °C, followed by 10 cycles of 
denaturation (90 °C, 1 minute), annealing (45 °C, 1 minute) and elongation (70 °C, 1 
minute per kb), followed by another 20 cycles with the annealing temperature raised 
to 55 °C, and a final elongation step of 72 °C for 1 minute. The PCR product was 
assessed by gel electrophoresis and purified by phenol-chloroform extraction. 
2.3.1.3 Overlap PCR 
Overlap PCR was used during virus cloning to extend beyond the p7 sequence to a 
suitable restriction endonuclease site. Chimeric primers incorporating the terminal 
sequence of p7 and the start of the H77 NS2 sequence were used to generate PCR 
products, which were purified and combined in a 1:1 molar ratio for the second round 
of PCR, with 5’ and 3’ primers added. The full length product for virus cloning was 
then analysed by gel electrophoresis to verify the desired length, before continuation 
of the cloning. 
2.3.1.4 Colony screening PCR 
Colony screening PCR was performed to screen for bacterial colonies following 
transformation. A reaction mixture of 10X ThermoPol buffer (20 mM Tris-HCl (pH 8.8), 
10 mM (NH4)2SO4, 10 mM KCl, 2 mM MgSO4, 0.1% TritonX100) (NEB), 50 pmol of 
each primer, dNTPs to the same concentration as the cloning-PCR reactions, 1.25 
units of Taq polymerase (NEB) and dH2O was made up to 50 μl in thin-walled 0.1 ml 
PCR tubes. Single colonies were picked and inoculated onto agar plates containing 
suitable antibiotic and then pipetted up and down in the PCR reaction mixture. 
Thermocycler reactions were set up with an initial denaturation step (90 °C, 1 minute), 
followed by 30 cycles of denaturation (90 °C, 45 seconds), annealing (45 °C, 45 
seconds) and elongation (72 °C, 0.5 minute per kb), with a final elongation step (72 °C, 
1 minute). Products were analysed by gel electrophoresis. 
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2.3.2 Phenol-chloroform extraction of DNA 
This method was used for removal of protein contamination from DNA samples, which 
can potentially interfere with DNA modification or transfection experiments. PCR 
products were made up to a volume of 200 μl and then thoroughly mixed with an 
equal volume of phenol-chloroform isoamyl alcohol 25:24:1 (v/v) (Sigma Aldrich) pH 
8.0. This was centrifuged (16,000 xg, 10 minutes) and the upper, aqueous layer 
carefully transferred to a fresh tube avoiding the protein interface. An equal volume of 
chloroform was added, and centrifuged as above. The aqueous layer was then 
transferred to a fresh tube and 0.1 volumes of 3M sodium acetate (pH 5.2) and 2.5 
volumes absolute ethanol added. The mixture was then incubated at -80 ˚C for 30 
minutes, and the DNA pelleted by centrifugation, washed with ice-cold 70% ethanol 
and dried. The DNA pellet was then dissolved in dH2O and the DNA quality examined 
by agarose gel electrophoresis. 
2.3.3 Determination of DNA concentrations 
DNA concentration was determined by absorbance at 260 nm on a Nanodrop 
(Thermo-Scientific), with absorbance at 280 nm also measured to detect any protein 
impurities in the DNA preparation. 
2.3.4 Restriction endonuclease digestion 
Restriction digests were carried out using NEB restriction endonucleases with the 
exception of MauBI (Fermentas). Reactions were set up according to the 
manufacturer’s instructions, with a minimum of 1 unit of enzyme per 1 μg of DNA. 
Screening digests were performed for 1 hr at 37 °C, and digests for cloning ligations 
for 16 hr. 
2.3.5 TAE Agarose gel electrophoresis 
Agarose powder was diluted into 1 X TAE buffer (40 mM Tris, 40 mM glacial acetic 
acid, 1 mM EDTA, pH 8) at 0.5% (w/v) for large plasmids, or 2% (w/v) for small PCR 
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or restriction digest fragments. The agarose mixture was heated until dissolved, and 
allowed to cool before the addition of 0.5 μg/ml ethidium bromide. The gels were 
poured into the casting mould (Biorad); well combs inserted and allowed to set. The 
gel was placed in the running tank (Biorad) and immersed in 1 X TAE buffer. DNA 
samples were mixed with Orange-G loading buffer (5% glycerol (v/v), 1 mM EDTA, 
0.01% Orange G, 1 X TAE) and loaded into the wells. Electrophoresis was performed 
at 8 V/cm until the Orange G dye-front migrated to the end of the gel. Hyperladder I 
(Bioline) size markers were used to estimate the size of DNA fragments. DNA was 
imaged on a UV-transilluminator (Syngene). 
2.3.6 Gel-extraction of DNA fragments 
DNA bands were excised from agarose gels and placed in a 1.5 ml microcentrifuge 
tube. The DNA was extracted by freeze thawing and mashing the gel slice using a 
sterile pipette tip. An equal w/v of phenol (pH 8) (Sigma-Aldrich) was added and the 
sample vortexed for 1 min. The samples were then frozen at -80 °C for 20 minutes 
then thawed at 37 °C for 1 min, then centrifuged at 16,000 xg for 20 minutes. The top 
aqueous phase was then transferred to a fresh microcentrifuge tube and ethanol 
precipitated as described in section 2.3.2. 
2.3.7 Ligation 
T4 DNA Ligase (Invitrogen) was used for all DNA ligations. Estimations of the quantity 
of vector and insert DNAs were made from the intensity of bands upon agarose gel 
electrophoresis by comparison with standard DNA markers. Typical ligation reactions 
comprised a 3:1 molar ratio of vector: insert DNA in 1X T4 ligase buffer with 1 unit of 
ligase. The reaction was performed overnight at 14 °C. The ligation mix was then 
transformed into DH5α E. coli, plated on agar plates containing appropriate selective 
antibiotic and resulting colonies screened for the presence of insert by either colony 
PCR or restriction endonuclease digestion of the purified plasmid. 
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2.3.8 Small-scale preparation of plasmid DNA 
DNA for screening analysis was prepared using the alkaline lysis method (Sambrook 
et al., 1989). Single colonies were picked and grown in 5 ml of LB broth, containing 
the appropriate antibiotic overnight at 37 °C. Cultures were pelleted at 4000 xg and 
the supernatant removed. 
Bacterial pellets were resuspended in 100 μl of solution 1 (50 mM Tris HCl (pH 8.0), 
50 mM glucose, 10 mM EDTA), then lysed with 100 μl of solution 2 (0.2 M sodium 
hydroxide, 1% (w/v) SDS) and incubated for 5 min. The lysis reaction was terminated 
and cellular debris precipitated by the addition of solution 3 (3 M potassium acetate 
(pH 5.2)), and the sample centrifuged at 16,000 xg for 5 minutes to remove the 
precipitate. The aqueous solution was then transferred to a fresh tube and the DNA 
ethanol-precipitated, air-dried and resuspended in an appropriate volume of dH2O. 
DNA for sequencing was prepared using the Qiagen Spin Miniprep kit according to 
the manufacturer’s protocol. Bacterial pellets were resuspended in 250 μl of buffer P1, 
lysed with 250 μl of buffer P2 and neutralised in 350 μl of buffer N3. The reactions 
were centrifuged at 16,000 xg for 10 minutes to pellet the precipitates and the 
supernatants loaded onto Qiagen spin columns. The DNA was then washed with 
buffers PB and PE before elution with dH2O. The isolated DNA was diluted to a 
concentration of 50 ng/μl and sequenced by GATC Biotech. 
2.3.9 Large-scale preparation of plasmid DNA 
Larger quantities of DNA were prepared using Qiagen Midi- or Maxi-prep kits 
according to the manufacturer’s instructions. For midipreps, 50 ml of LB broth 
containing the appropriate antibiotic were inoculated with a single colony and 
incubated overnight at 37 °C in a rotary shaker. For maxipreps, 250 ml cultures were 
inoculated with a 5 ml overnight starter culture picked from a single colony and grown 
for 10 hours. Bacteria were pelleted at 6000 xg. The bacterial pellets were 
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resuspended in an appropriate volume of buffer P1, and lysed in buffer P2 at room 
temperature for 5 min. Chilled buffer P3 was then added to neutralise the reaction, 
and the plasmid preps incubated on ice for 15-20 min. The precipitate was pelleted by 
centrifugation at 21,000 xg for 30 min, and transferred to a fresh tube and centrifuged 
as above. Qiagen-tips were equilibrated with buffer QBT and the lysates loaded. The 
column-bound DNA was then washed twice with buffer QC before elution with buffer 
QF. An appropriate volume of isopropanol was added and precipitated DNA was 
pelleted by centrifugation at 4000 xg for 1hr at 4°C. The pellet was washed with 70% 
ethanol, air-dried, and dissolved in dH2O. 
2.4 Protein purification 
2.4.1 Preparation of 3C protease: 
pET24a containing His-tagged 3C protease from rhinovirus was a kind gift from Arie 
Geerlof (University of Oxford). Bacteria were transformed and a 5 ml overnight culture 
inoculated (1:100) into a 400 ml culture in a shaking incubator at 37 °C until an OD600 
of 0.6 was achieved. Protein expression was induced with 1 mM IPTG for 4 hours and 
cells harvested by centrifugation at 6000 xg. Bacterial pellets were resuspended in 
lysis buffer (PBS supplemented with protease inhibitors Aprotinin, Leupeptin, 
Pepstatin A and AESBF (Pefabloc)) and sonicated on ice for 20 seconds with 20 
seconds rest, for 10 cycles. The lysates were cleared by centrifugation at 21,000 xg 
and the supernatant filtered through a 0.45 micron filter (Millipore). A HiTrap column 
(GE Healthcare Lifesciences) was charged with nickel and equilibrated with Buffer A 
(20 mM Na3PO4 (pH 8), 0.5 M NaCl, 10 mM imidazole) prior to loading the protein. 
The filtered supernatant was loaded onto the column and washed with buffer A, with 
all flow through from the column stored for analysis. The protein was then eluted in 
Buffer B (20 mM Na3PO4, 0.5 M NaCl) with increasing concentrations of imidazole 
(0.1 M- 0.5 M) and 1 ml stored at each step. Samples from each flow-through, wash 
 
 
84 
 
and elution step were analysed by SDS-PAGE followed by coomassie staining. 
Elution fractions containing the desired protein band were pooled and dialysed into 
4 L of storage solution (50 mM Tris-Cl (pH 8), 150 mM NaCl, 10mM EDTA, 1 mM 
DTT, 20% glycerol) at 4 °C. The dialysis solution was changed once and left at 4 °C 
overnight. The dialysed protein was then aliquoted and frozen at -80 °C until use. 
2.4.2 Expression of GST-fusion constructs 
GST-FLAG-p7 plasmids were transformed into BL21 E. coli and a single colony grown 
in a 5 ml overnight starter culture. This starter culture was diluted (1:100) into 400 ml 
of LB and incubated in a shaking incubator at 30 °C until an OD600 of 0.6 was 
achieved. A 1 ml sample of the uninduced bacterial culture was taken for analysis. 
Protein expression was induced by the addition of 1 mM IPTG and the culture 
incubated with shaking at 30 °C for a further 4 hrs. A further 1 ml sample of the 
bacterial culture was taken and the concentration by OD600 normalised to that of the 
pre-induction sample. The bacterial culture was harvested by centrifugation at 6000 
xg for 15 min, the supernatant removed and the bacterial pellet either stored at -20 °C 
until use or directly progressed to French Press lysis and inclusion body preparation. 
2.4.3 French Pressure Cell lysis of bacterial cells: 
Bacterial pellets were resuspended in a total volume of 30 ml lysis buffer (PBS 
supplemented with protease inhibitors: leupeptin 1 μg/ml, pepstatin A 1 μg/ml, 
aprotinin 2 μg/ml, 0.2 mM AEBSF (Pefabloc), 1 mM EDTA). The French Pressure Cell 
(Thermo-Fisher Scientific) was chilled at 4 °C and the bacterial solution placed in the 
chamber. The lysate was subjected to a piston pressure of 1000 psi, equivalent to an 
internal shear pressure around the valve of 40,000 psi. The lysate was passed 
through the French Press twice and stored on ice after lysis. A 50 μl sample of the 
lysate was taken for SDS-PAGE analysis. 
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2.4.4 Inclusion body preparation and cleavage 
The inclusion bodies were pelleted at 3300 xg for 45 min, and the supernatant 
decanted and stored. The pellet was then resuspended in 100 mM ammonium acetate, 
and the inclusion bodies pelleted at 3300 xg for 15 minutes and a sample of the 
supernatant stored. The inclusion body pellets were then washed in Tris-NaCl (50 mM 
Tris, 150 mM NaCl, pH 7) and pelleted as above. The inclusion bodies were 
resuspended in cleavage buffer (50 mM Tris, 150 mM NaCl, 1 mM DTT, 1 mM EDTA, 
pH 7) and a pre-cleavage sample stored for analysis. 3C protease was then added 
(volume added dependent on the activity of the batch of 3C protease) and the 
cleavage reaction incubated on a rotating disc overnight at 4 °C. The following 
morning, a sample of the cleavage reaction was stored and the inclusion bodies 
pelleted again for 15 minutes at 3300 xg. A sample of the supernatant was also taken 
at this stage. The pellets were resuspended in Tris-NaCl (50 mM Tris, 150 mM NaCl, 
pH 7) to a small total volume (typically 4 ml) and solubilised by the addition of 10% 
solution N-lauroylsarcosine (Aldrich) in Tris-NaCl (50 mM Tris, 150 mM NaCl, pH 7) to 
a final concentration of 0.5%. The solubilised protein was cleared of any remaining 
insoluble matter by centrifugation at 16,000 xg. The supernatant was then transferred 
to a High Performance Liquid Chromatography (HPLC) loading vial and stored at 4 °C. 
Reference samples taken throughout the bacterial lysis, inclusion body preparation 
and cleavage steps were analysed by SDS-PAGE to ensure that the protein had been 
purified and cleaved as expected. 
2.4.5 High Performance Liquid Chromatography (HPLC) 
Reverse-phase HPLC was carried out on a Dionex HPLC system incorporating a 
PDA-100 photodiode array detection unit, an ASI-100 automated sample injector, a 
P680 HPLC pump and an automated fraction collector. Reverse phase buffers were 
made up as follows: Buffer A 95% H2O, 5% acetonitrile, 0.1% trifluoroacetic acid 
(TFA); Buffer B 20% H2O, 80% acetonitrile, 0.1% TFA. The buffers were filtered 
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through a 0.1 micron Nalgene filter prior to loading onto the HPLC system. The HPLC 
columns used, either a Phenomenex Jupiter C4 300 Å 10 mm x 250 mm or 30 mm x 
250 mm, were equilibrated into Buffer A. The solubilised protein was placed in the 
autosampler. Gradients were run by increasing the percentage of Buffer B from 0-55% 
over the first 3 minutes, then from 55-80% from minutes 3-30, then 80-100% for 
minutes 30-31, staying at 100% for minutes 31-35, returning back to 0% buffer B for 
minutes 35-40 and running at 0% buffer B for minutes 40-45 in order to re-equilibrate 
the column in preparation for the next run. If particular proteins showed poor peak 
separation with this programme, the programme was altered to extend the gradient 
during the peak separation stages. Spectroscopy for the column eluents was read at 
wavelengths of 215 nm and 280 nm, to detect peptide bonds and side chain 
absorbance respectively. Each protein peak detected in the HPLC eluent was 
collected during the first run, after which only the region in which the p7 peak eluted 
was collected. 100 μl samples were taken from the peak fractions and dried in a 
Genvac rotary evaporator overnight. The samples were run on SDS-PAGE and 
assessed by western blot analysis to ensure separation of the peak fractions. 
2.4.6 Determination of purified FLAG-p7 concentration by A280 
absorption in methanol 
Purified FLAG-p7 was dissolved in methanol and the absorbance (A280) measured in a 
spectrophotomer using quartz cuvettes. The concentration was determined using the 
Beer-Lambert equation, where: 
 A = ε c l 
The absorbance A, at A280, is the product of the extinction coefficient ε, the 
concentration in moles per litre, c, and the length of the path through which the light 
travelled (the width of the cuvette, 1 cm), l. The extinction coefficient was calculated 
for each p7 protein purified using the ProtParam tool on the ExPASy Bioinformatics 
 
 
87 
 
Resource Portal, provided by the Swiss Institute for Bioinformatics (www.expasy.com). 
The coefficients are shown in Table 3.2. 
2.4.7 Tris-Glycine Polyacrylamide Gel Electrophoresis: 
All SDS-PAGE work was carried out using the BioRad Mini-Protean II system. 30% 
acrylamide was purchased from VWR International. Tris-glycine gels were prepared to 
the following recipes: 12-15% (v/v) acrylamide, 0.35M Tris-Cl pH 8.8, 0.5% (w/v) SDS, 
0.1% (w/v) APS, 0.2% (v/v) TEMED. The plates were assembled and gels poured to 
three quarters of the height of the front plate and a layer of water saturated butanol 
added to ensure that the surface of the resolving gel was level. Once the resolving gel 
had polymerised, the butanol was removed and the surface washed with distilled 
water. The stacking gel was made to the following recipe: 5% acrylamide (v/v), 0.175 
M Tris pH 6.8, 0.2% (w/v) SDS, 0.7% (w/v) APS, 0.36% (v/v) TEMED. The stacking 
gel was poured into the top of the plates and combs (10 or 15 wells) inserted. Protein 
samples were denatured in 2X Laemmli buffer (100 mM Tris-Cl pH 6.8, 4% (w/v) SDS, 
15% (v/v) glycerol, 10 mM DTT, 0.01% (w/v) Bromophenol blue) and heated for 5 
minutes at 95 °C. 
2.4.8 Tris-Tricine Polyacrylamide Gel Electrophoresis: 
Tris-tricine gels were made to the following concentrations: Resolving gel 10% 
acrylamide, 1 M Tris pH 8.45, 10.5% glycerol, 0.1% SDS (w/v), 0.06% APS, 0.13% 
(v/v) TEMED. Stacking gel: 4% acrylamide, 0.75 M Tris-Cl pH 8.45, 0.75% SDS (w/v), 
0.6% APS (w/v), 0.3% TEMED (v/v). Cathode buffer (0.1 M tricine, 0.1 M Tris, 0.1% 
SDS) was poured into the top tank, and anode buffer (0.2 M Tris-Cl, pH 8.9) added to 
the bottom tank. Samples were denatured as above and gels were run at 100 V for 
100 minutes until the dye front reached the bottom of the gel. 
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2.4.9 Coomassie staining of SDS-PAGE gels: 
SDS-PAGE gels were soaked in Coomassie stain (0.1% (w/v) Coomassie Brilliant 
Blue, 10% (v/v) acetic acid, 45% (v/v) methanol, 45% (v/v) H2O) for a minimum of 1 hr. 
Excess stain was removed by soaking in destain solution (10% (v/v) acetic acid, 45% 
(v/v) methanol, 45% (v/v) H2O) for a minimum of one hour until protein bands were 
visible. 
2.4.10 Western Blotting: 
Proteins from SDS-PAGE gels were transferred to Polyvinylidene fluoride (PVDF) 
membranes using a semi-dry transfer unit. PVDF was activated by soaking in 
methanol, and blotting paper was soaked in transfer buffer (25 mM Tris, 192 mM 
glycine, 20% methanol (v/v)) and rolled to remove residual trapped air. PVDF was 
placed on top of one sheet of blotting paper and each gel placed on the PVDF, 
making sure no air was trapped between the layers. The second layer of blotting 
paper was placed on top and the sandwich pressed to remove trapped air. The 
transfer rig was set at 15 V for one hour, with a maximal current of 500 mA. PVDF 
membranes were then removed and blocked in 10% dried skimmed milk (w/v) in TBS-
T (Tris-buffered saline, 0.1% Tween-20) for one hour on a rotary shaker at room 
temperature. The blots were then placed in 5% skimmed milk in TBS-T with the 
appropriate primary antibody (see section 2.1) and labelled overnight at 4 °C on a 
rotary shaker. Membranes were then washed for 5-10 minutes in TBS-T three times 
and labelled with the appropriate HRP conjugated secondary antibody in 5% skimmed 
milk in TBS-T for one hour at room temperature. The membranes were washed four 
times in TBS-T. ECL solution was prepared by mixing equal volumes of ECL 1 
(100 mM Tris-Cl pH 8.5, 0.3 mM p-coumaric acid and 25 mM luminol) and ECL 2 
(100 mM Tris-Cl pH 8.5 and 0.01% H2O2). 1 ml of ECL solution was added to each 
membrane. When blots showed weak staining with standard ECL solutions, ECL Plus 
(GE Healthcare) was used as per the manufacturer’s instructions. Excess ECL was 
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removed by rinsing in dH2O and the membranes sealed in clear plastic. Membranes 
were exposed to photographic film under darkroom conditions and developed using a 
Konica SR0101 processor. 
 
2.5 In vitro liposome assays 
2.5.1 Liposome preparation 
Liposomes were prepared as described previously (StGelais et al., 2007). 
Carboxyfluorescein buffer (50 mM 5(6)-carboxyfluorescein, 10 mM HEPES, 10 mM 
NaCl, 134 mM NaOH), while stated to be pH 7.4 in the original buffer recipe (Rex & 
Schwarz, 1998), when tested was found to be pH 7.0. Phosphatidic acid (PA, 
10 mg/ml), phosphatidylcholine (PC, 10 mg/ml) and rhodamine-labelled 
phosphatidylethanolamine (rPE, 1 mg/ml) in chloroform solution were purchased from 
Avanti Polar Lipids and stored at -20 °C. Lipids were pipetted into a glass test tube 
using glass syringes (Hamilton Ltd.) with 1:1 ratio of PA: PC to a total of 1 mg of lipid 
with 5 μg of rPE as a label. The lipids were dried into a film on the bottom of the test 
tube and further dried under vacuum for 2 hrs. The lipids were then resuspended in 
carboxyfluorescein buffer, the tube filled with argon, sealed with parafilm, and 
resuspended by vigorous shaking at room temperature overnight. 
The lipid suspension was extruded using an Avanti Polar Lipids extrusion kit, using 
0.4 μm pore size filters. The extruder was warmed to 37 °C and the extrusion 
performed at this temperature. A 5 μl sample of the lipid suspension was taken and 
stored for later comparison. The lipid suspension was passed through the filter a 
minimum of 15 times. The liposome mixture was added to a 2 ml ultracentrifuge tube 
and the liposomes pelleted at 100,000 xg for 15 minutes. The supernatant was then 
removed and the pellet resuspended in assay buffer (107 mM NaCl, 10 mM HEPES, 
pH 7.4), and centrifuged as above. The wash step was repeated a further 2 times to 
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remove any unincorporated carboxyfluorescein. After the final spin, the liposome 
pellet was resuspended in 0.5 ml of assay buffer and the rhodamine absorbance 
compared with the pre-extrusion sample. The concentration of the liposomes was 
calculated as a proportion of the total lipid remaining after extrusion. Liposomes were 
stored at 4 °C. 
2.5.2 Real-time dye-release assay 
The liposomes were diluted in assay buffer in a 96-well black fluorescence plate 
(Greiner Bio One) to a final concentration of 50 μM. Purified p7 protein was 
resuspended in methanol and added to wells to no greater than 5% methanol (v/v). 
The pore-forming bee-venom peptide melittin was included as a positive control, and 
total dye release induced with the addition of 0.5% Triton X100 (v/v). The release of 
carboxyfluorescein was measured using a FluoStar platereader with excitation and 
emission wavelengths of 485 nm and 520 nm respectively. Fluorescence values were 
measured every 30 seconds over a period of 30 minutes. Initial dye release rates 
were calculated from the curve gradient over the first 5 minutes. 
2.5.3 Liposome pH assay 
The liposome pH assay was adapted from previously described methods (StGelais et 
al., 2007). As the liposomes displayed high background dye release in the previously-
used citrate-phosphate buffers, an alternative protocol was developed using liposome 
assay buffers titrated to different pH points. The liposomes were pelleted at 100,000 
xg for 15 minutes and resuspended in liposome assay buffer at pH 7.4, 6.7 and 6.2. 
200 μl reactions were prepared including methanol and triton X100 controls, and 
FLAG-p7 incubated with the liposomes for 15 minutes. The reactions were then 
transferred into 0.2 ml ultracentrifuge tubes and spun at 160,000 xg for 20 min. At the 
end of each spin, 100 μl of supernatant was removed and placed in a 96-well 
fluorescence plate. The Triton-X100 controls were measured and the pH 6.7 and 6.2 
samples restored to full fluorescence by the addition of 1 M Tris-Cl (pH 8). Equal 
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volumes of 1 M Tris-Cl were added to each of the other samples at each pH, and the 
fluorescence of each well measured on the platereader. 
 
2.6 RNA synthesis 
2.6.1 Preparation of DEPC-treated solutions 
Water and phosphate-buffered saline (PBS) used for RNA experiments was treated 
with diethylpyrocarbonate (DEPC) to a final concentration of 0.1% (v/v) to remove 
RNase activity. The solutions were then placed overnight in a 37 °C shaker and 
autoclaved to sterilise the solutions. 
2.6.2 Preparation of DNA template 
RNA templates were linearised by restriction endonuclease digest with either ScaI or 
XbaI (New England Biolabs), and if necessary, DNA overhangs were removed by 
treatment with Mung Bean Nuclease (New England Biolabs). The linearised DNA was 
purified by phenol-chloroform extraction and resuspended in DEPC-treated water. 
2.6.3 RNA synthesis and clean-up 
Surfaces and equipment were treated with RNase-Zap (Ambion) prior to RNA 
preparation. RNA was synthesised using the Promega T7 RiboMax Express Large 
Scale RNA Production System. The reactions were assembled according to the 
manufacturer’s instructions and incubated for 30 minutes at 37 °C, after which DNAse 
was added to digest the template. The reactions were then purified by phenol-
chloroform extraction as detailed in section 2.3.2, using acidic phenol-chloroform 
isoamyl-alcohol (pH 4) (Sigma-Aldrich). 
Xenopus mRNA transcripts were generated using the SP6 mMachine mMessage 
system (Ambion) according to the manufacturer’s instructions and purified as above. 
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2.6.4 RNA agarose gel electrophoresis 
RNA transcripts were analysed for purity and degradation by denaturing 3-(N-
morpholino) propanesulfonic acid (MOPS) formaldehyde gel electrophoresis. 1% (w/v) 
agarose was heated in 1 X MOPS buffer (0.04 M MOPS, 0.01 M sodium acetate, 
1 mM EDTA in DEPC-treated H2O) until dissolved, and allowed to cool before the 
addition of 6.5% (v/v) formaldehyde. The gel was poured into the casting mould; a 
well-comb inserted, allowed to set and immersed in 1 X MOPS buffer in a gel tank. 
RNA samples were prepared by the addition of 10 μl RNA loading buffer (56% (v/v) 
formamide, 10% v/v formaldehyde, 6% glycerol, 0.025% (w/v) bromophenol blue and 
10 g/ml ethidium bromide in MOPS buffer) to 1 μl of RNA transcript or RNA ladder 
(Ambion) and heated at 65 °C for 10 minutes. Gels were run at 80 V for 1 hr, and the 
RNA imaged on a UV transilluminator (Syngene). 
2.6.5 RNA quantification 
RNA was quantified by measurement of the absorbance at 260 nm on a NanoDrop 
(Thermo Scientific). The 260:280 nm ratio was measured to assess RNA purity. 
 
2.7 Cell culture 
2.7.1 Routine cell passage 
Huh-7 cell lines were cultured in DMEM supplemented with 10% FCS, 1% non-
essential amino acids, 2 mM L-glutamine, 100 IU/ml penicillin, and 100 μg/ml 
streptomycin at 37 °C in a humidified 5% CO2 incubator. Media for virus work was 
supplemented with 25 mM HEPES (GIBCO, pH 7.4, sterile) for additional buffering 
against acidic metabolites. Huh7 and Huh7.5 cells were maintained at sub-confluent 
levels for up to 20 passages. Subgenomic replicon-harbouring cell lines were 
maintained in DMEM supplemented with 250 μg/ml G418. 
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2.1.1 Transfection of cell lines 
Cells were plated out onto 6 well plates for protein analysis at a density of 2 x 105 per 
well, and onto 8-well microscopy slides (Ibidi) for live cell imaging at a density of 1 x 
104 per well. One day prior to transfection, Huh-7 cells were seeded (2 × 105) into six-
well plates. Cells were transfected using 5 μl polyethylenimine (PEI) (Polysciences 
Inc.) with 1 μg DNA per well of a 6-well plate in 0.5 ml Opti-Mem (Gibco). For 8-well 
microscopy slides, the transfection reagents were mixed in the same proportions and 
100 μl were added to each well. Cells were incubated for a minimum of 16 hrs before 
detection of protein expression. Where 6-well plates were harvested for protein 
analysis, cells were washed twice in PBS, lysed in 200 μl of GLB and removed from 
the 6-well plate using a cell scraper. 
 
2.8 Virus work 
2.8.1 Electroporation of Huh7 cells 
Huh7 cells were pelleted at 1000 xg and washed by resuspension in DEPC-PBS 3 
times prior to resuspension in DEPC-PBS at a concentration of 1.5x107 cells per ml. 
6x106 cells were transferred into an electroporation cuvette and 10 μg of RNA added. 
The cells were electroporated at 950 μF, 270 V. Following electroporation, the cells 
were diluted into warm media and pipetted to preventing clumping of cells. All 
equipment was sterilised in 5% virkon after use (w/v). The electroporated cells were 
moved into the CL3 facility, and media changed 4 hours post-electroporation. 
2.8.2 Harvesting of extracellular and intracellular virions 
Extracellular virus was harvested from the media of virus electroporated cells and 
stored at 4 °C. Virus supernatants were clarified by centrifugation at 1000 xg for 5 
minutes to remove cell debris. To assess intracellular virus infectivity, cells were 
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harvested using the following protocol. Cells were washed 3 times in PBS, and 
resuspended in 1 ml of PBS using a cell scraper. The cells were then pelleted at 1500 
xg and resuspended in an appropriate volume of PBS. A sample of the infected cells 
was pelleted and lysed in Glasgow lysis buffer (GLB) (10 mM PIPES (pH 7.2), 
120 mM KCl, 30 mM NaCl, 5 mM MgCl2, 1 Triton X-100, 20% glycerol, leupeptin 
1 g/ml, pepstatin A 1 g/ml, aprotinin 2 g/ml, 0.2 mM AEBSF (Pefabloc), 1 mM EDTA, 
5 mM NaF, 2 mM Na3VO4, 5 mM Na4P2O7) for western blot analysis. The cells were 
then subjected to 5 rounds of freeze-thaw lysis using a 37 °C water bath and a dry-
ice/ethanol mixture. Lysed cells were centrifuged at 1000 xg to remove cell debris. 
2.8.3 Measurement of infectious viral titres 
8x103 Huh7 cells were seeded into each well of a 96-well flat bottom clear plate and 
allowed to grow overnight. These plates were then taken into the CL3 facility. For the 
assessment of extracellular virus infectivity, the media was removed and replaced 
with virus supernatants harvested from electroporated cells. Virus supernatants were 
diluted 10-fold and serially diluted into subsequent wells in triplicate. For intracellular 
virus infectivity assays, 50 μl of PBS containing harvested intracellular virus was 
added to the first well, and serially diluted into subsequent wells. Following 48 hrs of 
infection, cells were washed twice in PBS and fixed in 4% PFA (4% (w/v) 
paraformaldehyde in PBS) for 20 minutes, after which the plates were removed from 
the CL3 facility. Cells were then washed in filtered PBS, and permeabilised with 0.1% 
Triton in PBS (v/v). Cell were blocked in 10% FBS in PBS (blocking media) for 30 
minutes and labelled with sheep anti-NS5A antibodies diluted in blocking medium for 
1hr. Cells were stained with AlexaFluor594 Donkey α-Sheep secondary antibodies, 
with 3 PBS washes between each stage. Cells were viewed on a Nikon eclipse T5100 
fluorescence microscope at 20X magnification and focus forming units (FFU) counted. 
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2.8.4 Virus infectivity time course 
For the assessment of the time course of virus infection, Huh7 cells were 
electroporated, and each electroporation divided into 3 T25 vented flasks (Sarstedt). 
The media of each flask was then replaced at 4 hours post-electroporation. Virus 
supernatants were harvested at 24, 48 and 72 hours post electroporation and virus 
infectivity of the supernatants assayed as above. 
2.8.5 pH sensitivity assay 
The following methods were adapted from (Wozniak et al., 2010). HEPES/MES buffer 
(20 mM HEPES, 20 mM MES, 133.5 mM NaCl, 2 mM CaCl2, 4 mM KCl, 1.2 mM 
MgSO4, 11 mM glucose) was prepared to pH 3.3, pH 3.9, pH 6.0 and pH 7.4, so that 
when mixed 1:1 (v/v) with PBS at a later stage of the experiment it would generate a 
pH gradient of 4.0, 5.2, 6.2 and 7.4. Extracellular virus was collected and 
concentrated by centrifugation through a sucrose cushion pellet at 150,000 xg using 
an AH650 rotor in a Sorvall ultracentrifuge and resuspended in PBS. Intracellular virus 
was prepared by freeze-thaw lysis of harvested cells into a suitable volume of PBS, 
followed by removal of cell debris by centrifugation at 1000 xg for 5 minutes. Virus 
samples, both extracellular and intracellular, were then mixed 1:1 with the 
HEPES/MES buffers to generate the pH gradient, and incubated at 37 °C in a 
waterbath for 10 minutes. On removal from the waterbath, those at acidic pH were 
neutralised by the addition of 1 M NaOH to a final pH of 7.4. The infectivity of the virus 
was then titred. 
2.8.6 Temperature sensitivity assays 
Previous studies have demonstrated that that secreted JFH1 HCV virions are steadily 
inactivated at 54 °C over a period of 40 minutes (Song et al., 2010). To determine the 
temperature sensitivity of collected virus supernatants, media from electroporated 
cells was collected 48 hr post-electroporation and stored at 4 °C until required. This 
media was then aliquoted to the appropriate volume and placed in a waterbath at 
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54 °C. At each 5 minute timepoint, the supernatants were removed from the 
waterbath and placed immediately on ice to reduce the temperature. The 
supernatants were then titred to measure the reduction of infectivity over time in 
response to high temperature. 
 
2.9 Microscopy 
2.9.1 Fluorescence microscopy 
Whole-cell fluorescence microscopy was carried out on an Axiovert 135 microscope 
with a monochromatic excitation unit controlled by Openlab software. Cell media was 
removed and replaced with HEPES cell buffer (10 mM HEPES, 133.5 mM NaCl, 
2 mM CaCl2, 4 mM KCl, 1.2 mM MgSO4, 1.2 mM NaH2PO4, 11 mM glucose, pH 7.4) 
prior to imaging. For Lysosensor Yellow/Blue DND-160 (Invitrogen) staining, cells 
were incubated in 5 μM Lysosensor in cell imaging buffer for 30 minutes and washed 
3 times in HEPES cell buffer before imaging. Alkalinising chemicals were added to the 
cells in cell media for 2 hrs prior to imaging, and were present in all subsequent wash 
and stain solutions. Where p7 inhibitor compounds were used, they were diluted in 
cell imaging buffer, added after the final wash step and incubated for 5 minutes prior 
to imaging. 
For confocal microscopy, labelled cells were viewed on an inverted Zeiss 510-META 
laser scanning confocal microscope under an x40 objective lens (numerical aperture = 
1.40). pHluorin was excited using an argon laser fitted with 488 nm filters, and 
emission read at 530 nm. 
Images were analysed using ImageJ software, where appropriate using macros to 
identify regions of interest (ROI). The macro used is detailed in Appendix 2. 
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Fluorescence intensity in the ROIs was measured using ImageJ, and data were then 
analysed using Microsoft Excel.  
2.10 Electrophysiological methods 
All electrophysiological procedures were carried out by Dr Jonathan Lippiat. 
2.10.1 Removal and preparation of Xenopus laevis oocytes 
Female Xenopus laevis frogs were anaesthetized by immersion in 2% 3-
aminobenzoic acid (pH 7.2 with Tris and HCl) for 45 minutes. The frogs were then 
killed by cervical dislocation and pithing, in full accordance with Home-office Schedule 
1 guidelines. Ovarian lobes were then removed via a mid-line incision (Stuhmer & 
Parekh, 1995). The ovarian lobes were broken into small fragments with forceps and 
separated into single cells via two 60 minute incubations in 1 mg ml-1 collagenase 
dissolved in OR-Mg solution (NaCl 82 mM, MgCl2 2 mM, HEPES 0.5 mM, KCl 0.2 mM; 
pH 7.4). The cells were washed between collagenase incubations five times with OR-
Mg solution (first wash) and 8 times (second wash) prior to transferring the now single 
cells into ND-96 solution (NaCl 9.6 mM, MgCl2 0.1 mM, HEPES 0.5 mM, CaCl2 
0.18 mM, KCl 0.2 mM; pH 7.4). Dumont stage V and VI oocytes were then selected 
for injection. 
2.10.2 cRNA microinjection of Xenopus laevis oocytes 
Prior to injection, glass capillaries were sterilised by baking at 200 ºC for at least 4 
hours. Sterile glass capillaries were pulled into very fine tipped pipettes and then 
broken to the desired length and diameter with a pair of flame-sterilized forceps. 50 nl 
of cRNA was then injected into the light hemisphere of each oocyte using a 
Pneumatic Pico-Pump pressure injection system (WPI). Successfully injected and 
healthy oocytes were incubated at 18 ºC for 24 hrs in ND-96 solution. 
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2.10.3 Electrophysiological recordings from Xenopus laevis oocytes 
The Gene Clamp 500 amplifier (Axon Instruments) was used for electrophysiological 
recordings. Both current and voltage outputs from the voltage-clamp amplifier were 
displayed on a Takronix 5113 dual beam storage oscilloscope (using D.C. coupled 
5A22N and 5A21N amplifiers). The signals were fed via a CED 1401 analogue 
interface to a computer running the CED on-line analysis software (version 6). The 
current signal was low-pass filtered at 1 kHz by the amplifier and sampled at 4 kHz. 
The oocyte was placed into the chamber perfused with high potassium Ringer solution 
(90 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 mM HEPES (pH 7.4)) at a rate of ~ 2 ml 
min-1. The perfusion was maintained through the chamber via removal of excess 
solution via a suction tube connected to a peristaltic pump. The electrode holders 
containing the current and voltage electrodes were filled with 3 M KCl and mounted 
onto head stages either side of the oocyte chamber and the bath electrode 
submerged in the bath solution. The electrode resistances were adjusted between 0.3 
and 1 MΩ for the current electrode and between 0.3 and 2 MΩ for the voltage 
electrode via gentle tapping of the tips with tissue paper. To minimize the interference 
the current and voltage electrodes were separated with a copper shield once the 
oocyte had been impaled and the whole apparatus was assembled inside a Faraday 
cabinet placed on an air-table, both of which were earthed to the circuit ground. Both 
electrodes were offset to 0 mV and gently inserted into the oocyte. The oocyte was 
then left 10 minutes to allow the membrane potential to stabilise with healthy oocytes 
displaying membrane potentials of ~ -30 to -70 mV. The amplifier was then set to 
clamp and the gain and stability on the amplifier adjusted to maximize the square 
wave of the voltage trace with small capacitance for the current trace.  
Results were processed using Origin Pro software (Origin Lab). 
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 Chapter 3: In vitro functional 
analysis of naturally-occurring 
variations in p7. 
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3.1 Introduction: How do naturally occurring p7 
polymorphisms in a patient cohort affect protein function? 
p7 is essential for HCV infectivity in culture (Jones et al., 2007; Steinmann et al., 
2007) and for virus replication in chimpanzees (Sakai et al., 2003). While some 
residues are highly conserved, there are regions of sequence variability across HCV 
genotypes. Fig. 3.1 (a) shows a consensus sequence derived from analysis of all 
genotypes and subtypes, with variants at each position listed below in order of 
decreasing frequency (Steinmann et al., 2007). Experimental infection of 
chimpanzees with inter-genotypic chimeric viruses indicated that the N and C termini 
of the protein show genotype specificity, possibly linked to interactions with other HCV 
proteins (Sakai et al., 2003). Other variations are less significant; homologous 
substitutions where residues are replaced by those with similar properties, such as 
substitution of hydrophobic residues within the TMDs and the interchangeability of 
arginine and lysine at positions 33 and 35 in the basic loop domain are common 
variants between HCV isolates.  
A major role of p7 in the virus life cycle is to prevent endosomal acidification during 
virion secretion/production, in order to preserve the infectivity of nascent virions 
(Wozniak et al., 2010). The prototype viroporin IAV M2 has a well characterised 
structure and gating mechanism, with the protein forming tetramers with high 
specificity for directional proton conductance, where the channel only opens in 
response to reduced external pH (Pinto & Lamb, 2006). The gating mechanism 
responsible involves two key residues, His37 and Trp41, which are adjacent in the 
channel lumen. Protonation of the His37 residues in the channel lumen results in σ-π 
interactions with the Trp41 side chain that cause a conformational change that opens 
the channel. This conformational change is blocked by amantadine (Okada et al., 
2001).  
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Previous work in this laboratory has developed methods to study the activity of p7 
using in vitro methods (StGelais et al., 2007; Clarke et al., 2006). In brief, to avoid the 
toxicity of native p7 expression in bacterial cells, it is expressed as a GST-fusion 
protein that forms inclusion bodies. These inclusion bodies are purified and the 
GST-tag cleaved using rhinovirus 3C protease. The protein can then be solubilised 
with detergent and purified by reverse-phase HPLC. After this purification, the HPLC 
solvents are evaporated, and the desiccated protein stored until required. The protein 
is soluble in methanol and folds into a monomeric conformation, with channel activity 
measurable in vitro using a liposome dye-release assay (Foster et al., 2011; StGelais 
et al., 2007). The liposomes contain carboxyfluorescein (CF) at a self-quenching 
concentration; on the addition of a pore-forming peptide such as bee venom peptide 
melittin (Rex & Schwarz, 1998) or membrane-disrupting detergent such as Triton X-
100, the dye is released and diluted into the surrounding media, allowing it to 
fluoresce. The addition of p7 to liposomes causes a rapid initial release of CF which 
gradually tails off at a point below the maximum level of dye release as measured by 
Triton X-100 liposome lysis, as liposomes are present in excess. This activity is 
titratable, with higher concentrations of p7 resulting in faster initial rates of dye release 
and higher endpoint levels. CF is also quenched when the pH is reduced below pH 
7.4, and so using liposomes to investigate p7 activity requires the use of an endpoint 
assay where the dye release is allowed to occur at reduced pH, and the pH restored 
to 7.4 prior to fluorescence readings. It was determined that GT1B J4 p7 shows a 
2-fold increase in activity when the pH is reduced to pH 6.2 (StGelais et al., 2007). 
These methods were used to assess differences in p7 activity and drug response 
between a number of different genotypes (Griffin et al., 2008), as well as the effect of 
targeted mutagenesis on the activity of J4 p7 (StGelais et al., 2009).  
p7 from different HCV genotypes also showed distinctive responses to drug treatment, 
with GT1B J4 p7 showing sensitivity to two adamantane drugs, amantadine and 
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rimantadine, GT1A H77 p7 showing low sensitivity to both adamantanes, and GT2A 
JFH1 p7 only showing sensitivity to rimantadine. Given the effect of amantadine on 
IAV M2 to ‘lock’ the channel into the closed conformation (see section 1.3.2), 
differences in the adamantane sensitivity between HCV genotypes may indicate 
possible changes in channel gating. Previous mutagenic analysis of GT1B J4 p7 
identified a number of residues important for p7 function, including a histidine residue 
at position 17 that may have a role in gating the channel, analogous to the His37 
proton-sensor of IAV M2 (Wang et al., 1995).  
Targeted mutagenesis and the variation between genotypes have revealed many 
variants in p7 activity, but p7 alterations also exist within individual patients as a result 
of virus quasispecies. It is possible therefore that the high mutation rate inherent to 
HCV will result in changes in the p7 amino acid sequence with both functional and 
structural consequences, tolerated within the evolutionary constraints of maintaining 
viral fitness. Our collaborators at the University of Washington, Seattle, have worked 
with HCV patients with a particular focus on measuring quasispecies mutation rates 
and natural, functional variants of HCV that arise in response to selection pressure 
from variation between hosts (Li et al., 2011). Our collaboration focused on one 
particular study assessing changes in p7 sequences in 27 newly-diagnosed patients 
infected with a single HCV GT (1A). These patients had varying disease profiles; 
some had mild disease with little or no liver fibrosis (Ishak fibrosis score 0-1), and 
others had severe disease and more advanced liver fibrosis (2-3). A number of the 
patients were also co-infected with HIV. The frequency of mutations within p7 in the 
patient quasispecies was determined prior to treatment, and from each patient serum 
sample 12 p7 clones were amplified by RT-PCR. The genetic diversity of these 
sequences was analysed, with specific residues showing a high degree of 
conservation and others showing greater mutability. Those who were co-infected with 
HIV showed a lower degree of sequence variability.  
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Six isolates were identified with a number of non-synonymous mutations (Li et al., 
2012a). Fig 3.1 (b) shows an alignment of the much-studied GT1B J4 p7 with the 
GT1A prototype H77, and the deviations of the Seattle patient isolates from H77 p7 
shown below. Two of the isolates came from patients with mild disease (M) with low 
levels of liver fibrosis, whilst the remaining 4 isolates were derived from 3 patients with 
more severe disease (S), showing advanced liver fibrosis. The majority of mutations 
were synonymous with respect to amino acid composition, including substitutions of 
the hydrophobic residues leucine, isoleucine and valine at position 7 and the 
replacement of arginine with lysine at position 35 in Seattle isolates M1 and M2. Table 
3.1 summarises the patient data for these isolates and highlights the non-synonymous 
mutations.  
Variant ID Short name 
Amino acid 
change 
Host characteristics 
Fibrosis stage HIV status 
M220_4 M1 
S21P, P38S, 
A40T 
1 Negative 
M234_1 M2 H17R 0 Positive 
S235_1 S1 Y31H 3 Negative 
S056_167 S2 H17N, F44C 3 Negative 
S630_175 S3-1 T16A 3 Negative 
S630_180 S3-2 
T16A, R35G, 
V41T 
3 Negative 
 
Table 3.1 Details of Seattle patient isolates 
The original identification numbers for each isolate with their abbreviations, significant 
mutations, fibrosis stage by Ishak score and HIV status. The isolates are referred to 
by their abbreviated names throughout.  
 
 
A number of notable non-synonymous mutations were found in each isolate, including 
several within trans-membrane domain (TMD) 1 that we predicted may change the 
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character of the channel lumen, based both on previous functional data (StGelais et 
al., 2009) as well as our recently solved monomeric 1b NMR structure (Fig. 1.9).  
M1 has a mutation of a highly conserved lumenal serine, S21P. Previous work 
showed that a J4 p7 S21A mutation did not significantly impair channel activity in vitro 
(StGelais et al., 2009), making it possible that this amino acid position may not be 
functionally significant. However, changing the serine to a proline may introduce a 
kink in TMD1 that could affect the activity of the protein. Proline is also more 
hydrophobic than the polar serine, and thus may also change the balance between 
hydrophobicity and hydrophilicity within the channel lumen.  
The hypothesised pH-sensor residue, H17, is altered in two of the isolates; the H17N 
polymorphism in S2 also occurs in some GT2A p7 sequences, including the J6 
infectious clone, but the H17R mutation in M2 is a much less common variant at this 
position (Steinmann et al., 2007). H17N removes a ionisable residue from the 
channel, with the potential to alter the hydrophilicity of the channel lumen and thus 
affect the activity of the protein; as a polar molecule, asparagine is more hydrophilic 
than unprotonated histidine as calculated by hydropathy analysis (Kyte & Doolittle, 
1982). The H17R mutation substitutes a larger residue which, unlike histidine, is 
protonated at neutral pH. The addition of this larger, charged residue to the lumen of 
the channel might be expected to cause a significant change in p7 activity. It is of note 
that the H17A mutation in the JFH1 virus system, which has an additional histidine at 
position 31, only reduces infectivity by 1 log10, and a H17E mutation shows no 
impairment in infectivity (Meshkat et al., 2009). 
S1 has an Y31H mutation, introducing a second histidine. This polymorphism is also 
present in JFH1 p7, and while it is not in the lumen of the channel, the NMR structure 
shows that it is likely to reside close to the entrance of the pore, potentially allowing it 
to exert influence as a second pH sensor. Mutation of the H31 residue in the JFH1 
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virus system to Y, F or L only showed a 0.5 log10 drop in infectivity for the H31F 
mutant, and no significant reductions for H31Y or H31L (Steinmann et al., 2007). 
The T16A change in both S3-1 and S3-2 does not occur at a luminal residue, but it is 
adjacent to the His17 residue and alanine is also present in GT1b p7 sequences, 
including J4. Other variants found at this position include serine, cysteine, glutamine 
and asparagine (Steinmann et al., 2007). 
S3-2 has an R35G mutation of one of the two basic loop residues; mutation of both 
these residues to alanine loses all p7 activity in vitro (StGelais et al., 2009). The loop 
domain has been shown to be crucial to infectivity (Sakai et al., 2003), and short 
peptide analysis found that this region was highly membranotropic with the basic 
residues at positions 33 and 35 possibly interacting with the heads of negatively-
charged phospholipids (Pérez-Berná et al., 2008). Mutations of these residues in the 
JFH1 virus system also have a major impact on the production of infectious virus. 
Single mutations of either residue to the non-charged but polar residue glutamine 
causes a greater than 1 log10 drop in infectivity, and mutation of both residues to 
either glutamine or alanine results in a complete loss of virus infectivity (Steinmann et 
al., 2007). However, in the J6/JFH1 chimera Jc1 the R33Q R35Q mutant is reduced 
by 2 log10 compared with a 3 log10 drop for the R33A R35A mutant. The mutation of 
only one of these residues may still allow the remaining residue to fulfil the function of 
the basic loop domain, hypothesised to be required for correct orientation of the 
channel. A double alanine mutation in J4 p7 in the in vitro liposome assay results in 
the protein associating with, but not fully integrating into membranes, as it can be 
washed off with a high pH bicarbonate solution (StGelais et al., 2009).  
In this chapter, the consequences of the sequence variations in the patient isolate p7s 
were investigated using the previously-developed in vitro liposome assays to measure 
the activity of these isolates. Previous work had also shown that J4 p7 showed 
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increased activity at reduced pH (StGelais et al., 2007), as does the prototype 
viroporin IAV M2 and, given that the hypothesised pH sensor residue His17 was 
altered in two of the Seattle isolate p7s, the activity in response to reduced pH should 
also be investigated. As the isolates came from patients with both mild and severe 
disease, as rated by fibrosis level, it is also of interest to see if there is any correlation 
between p7 activity in vitro and with the severity of disease.  
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Figure 3.1 Sequence variation of p7 across genotypes, and patient isolate 
sequences  
Panel (a): Consensus sequence from 26 p7 sequences from all major HCV genotypes 
and subtypes, adapted from Steinmann et al 2007. Variants from this consensus 
sequence at each position are listed in decreasing order of frequency. Panel (b): J4 
and H77 prototype p7 sequences with 6 GT1A Seattle patient isolates below, with 
sequence variants from H77 shown. Conserved residues between H77 and the 
Seattle patient sequences are represented by dashes. 
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3.2 Results 
3.2.1 Cloning of Seattle patient isolate sequences into pGEX-6p1 for 
bacterial expression 
The patient isolate sequences were sent from Seattle as cDNA. These segments 
were then amplified by PCR, using primers that incorporated EcoRI and NotI 
restriction sites and an N-terminal FLAG tag. The primers used are listed in Appendix 
1. Fig. 3.2 is a map of the pGEX-6p-1 vector, showing the 3C protease cleavage site 
and the restriction sites used for cloning. 
The PCR products and vector were digested and ligated, the ligation reaction 
transformed into bacteria, and plasmids from resulting colonies screened by restriction 
digest. Successful cloning was confirmed by dsDNA sequencing. Successful 
constructs were transformed into BL21 E. coli and protein expression induced and 
purified as previously described (see methods sections 2.2.5 and 2.4) (StGelais et al., 
2009).  
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Figure 3.2 Schematic of the pGEX-6p-1 plasmid  
Plasmid map of the pGEX-6p-1 plasmid showing the 3C protease cleavage site and 
the multiple cloning site, with restriction endonuclease cleavage sites EcoRI and NotI 
highlighted. Image copyright: GE Healthcare 
 
 
 
 
 
Figure 3.3 Coomassie stain showing bacterial expression of H77 GST-FLAG-p7 
and GST-FLAG-p7 constructs of all 6 patient isolate p7 sequences 
Bacterial culture samples were taken before induction and 4hrs after induction of 
expression with 1mM IPTG. Post induction samples were normalised to the optical 
density of the pre-induction samples, the bacteria harvested by centrifugation and 
resuspended in Laemmli buffer. Samples were run on SDS-PAGE gels and stained 
with Coomassie Brilliant Blue. Samples are shown in the following order: 1. H77, 2. 
M1, 3. M2, 4. S1, 5. S2, 6. S3-1, 7. S3-2, with both the uninduced and induced 
samples shown. Induced expression of GST-FLAG-p7 proteins appears at 36 kDa, 
with a smaller band appearing below, matching the size of GST alone.   
 
 
110 
 
3.2.2 Expression and purification of HCV genotype 1a FLAG-p7 proteins 
3.2.2.1 Protein expression 
Cloned plasmids were transformed into BL21 E. coli and bacterial cultures grown. 
Protein expression was induced using the galactose analogue IPTG, and the cultures 
grown for a further 4 hours before the bacteria were harvested by centrifugation. 
Samples were taken before induction and before harvesting, with the latter normalised 
to the optical density at OD600 of the pre-induction samples. These samples were then 
run on SDS PAGE and stained with Coomassie Blue to show protein expression, 
shown in Fig. 3.3. GST-FLAG-p7 proteins can be seen at 36 kDa in the induced lane 
for each construct, with a smaller band at ~28 kDa corresponding to GST alone.  
3.2.2.2 Purification of prototype genotype 1a FLAG-p7 from the H77 isolate. 
The GT1A prototype H77 was expressed and purified as described previously (Griffin 
et al., 2008; Clarke et al., 2006). Bacterial cultures expressing the protein were 
harvested and the cells lysed by pressure lysis using a French Press. The insoluble 
inclusion bodies were then purified by centrifugation and resuspension in various 
wash buffers to remove cell debris and unwanted protein. The purified protein was 
then cleaved overnight using His-tagged rhinovirus 3C protease, which results in 
approximately 50% cleavage efficiency of inclusion body resident protein (Fig. 3.4). 
The cleaved protein was then solubilised in N-lauroylsarcosine and purified by 
reverse-phase HPLC. The chromatogram shown in Fig. 3.4 shows the peak 
separation of the solubilised proteins, with FLAG-p7 the last peak to be eluted from 
the column. The purity of the peak fractions was tested by western blot, and p7 peak 
fractions from multiple HPLC runs pooled and desiccated under vacuum.  
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Figure 3.4 Purification of H77 FLAG-p7 by inclusion body preparation and 
reverse-phase HPLC 
Panel (a) shows the inclusion body protein cleavage by 3C protease and solubilised 
protein, with samples from each stage run on 15% Tris-Glycine SDS-PAGE gels and 
either stained with Coomassie or assessed by western blot analysis with GST and 
FLAG antibodies. Panel (b) shows the HPLC elution peaks as measured by the 
absorbance at wavelength 215 nm, with the peaks shown generated by Dionex 
Chromeleon Software. Regions shaded green represent the fraction collection of 
peaks for the specific run shown, and the blue dashed line shows the percentage of 
Buffer B used to generate the reverse-phase gradient. Protein elution peaks for GST, 
GST-FLAG-p7 and FLAG-p7 are shown by the red arrows. Panel (c) shows the 
analysis of eluted peaks by 15% Tris-glycine SDS-PAGE followed by western blot with 
GST and FLAG antibodies, with GST, GST-FLAG-p7 and FLAG-p7 bands shown by 
red arrows.  
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3.2.2.3 Patient isolate p7 sequences exhibit altered retention times during HPLC 
purification 
The patient isolate p7 sequences were expressed and purified in the same manner as 
H77 p7. However, some differences were seen in the column retention times for the 
p7 peaks of the Seattle FLAG-p7s, shown in Table 3.2. In reverse-phase HPLC, a 
reduction in retention time would indicate a reduction in hydrophobicity of the protein, 
as a less hydrophobic mixture of HPLC solvents is required to elute the protein from 
the column. Mutations that cause non-synonymous changes in residues in a protein 
as small as p7 are likely to result in changes to the physical properties of the protein. 
These changes can be predicted using the ProtParam tool on the ExPASy website, 
which analyses the amino acid sequence and predicts many physical properties of the 
protein, such as the molecular weight, the grand average of hydropathy (GRAVY) 
score and the extinction coefficient for absorbance at 280 nm. The values calculated 
for H77 FLAG-p7 and the Seattle p7s are listed in Table 3.2. The GRAVY score for 
each protein, where the higher the number the more hydrophobic the protein is, was 
used to estimate if any of the sequence variations would cause a change in column 
retention likely to require a change in the HPLC program parameters.  
While these predicted values may explain some of the shifts in HPLC retention times 
for the different proteins, they do not explain all observations. H77 and M1 are 
predicted to have similar scores for both molecular weight and hydrophobicity, yet 
there is a 4-minute reduction in retention time for M1 (Table 3.2). Two isolates that 
show a lower GRAVY score than H77, M2 and S1, vary in their retention times; M2 
has reduction of 2 minutes, while S1 has a 10 minute reduction in retention time that 
required a reduction in the gradient in the HPLC programme to ensure adequate peak 
separation, with an extension of the time taken for the gradient between the 55-80% 
buffer B phase of the program (See materials and methods section 2.4.5). S2 has a 
slightly higher GRAVY score than H77, which would be predicted to extend the 
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column retention, but in fact the retention time showed a reduction by 4.5 minutes. 
S3-1 had a higher GRAVY score than H77 but the retention time was similar with a 
difference of only 0.5 min, while S3-2 with the highest GRAVY score showed a slight 
increase in the retention time by 1.5 minutes. 
FLAG-p7 
protein 
MW (Da) Grand average of  
hydropathicity (GRAVY) 
Extinction  
coefficient 
(M-1 cm-1) 
HPLC retention 
time (minutes) 
JFH1 8509 0.548 17210 N/A 
J4 8203.6 0.732 18450 N/A 
H77 8444.9 0.63 23950 34.5 
M1 8398.8 0.629 23950 31.5 
M2 8407.8 0.589 23950 32.5 
S1 8342.7 0.583 22460 24.5 
S2 8296.7 0.645 18450 30 
S3-1 8352.8 0.654 23950 34 
S3-2 8283.7 0.675 23950 36 
Table 3.2 Physical properties of the FLAG-p7 proteins calculated by ProtParam, 
and HPLC retention times  
Theoretical values for the physical and chemical properties of the FLAG-p7 proteins 
were calculated by inputting each amino acid sequence into the ProtParam tool of the 
ExPASy Bioinformatics Resource Portal. HPLC retention times were taken from the 
first run for each FLAG-p7 protein using the standard program, before any changes 
were made to the HPLC gradients to ensure peak separation.  
 
3.2.2.4 Purified proteins show changes in electrophoretic mobility 
After the removal of the HPLC solvent, the concentrations of each of the purified 
proteins were checked by resuspension in methanol and measurement of the 
absorbance at 280 nm (A280). The ProtParam tool was used to calculate the predicted 
extinction coefficient for each of the isolate proteins and the concentration determined 
using the Beer-Lambert law (see Materials and Methods, section 2.4.6).  
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Once the concentration of each of the proteins was established, 5 μg of each protein 
per gel was run on SDS-PAGE gels, which were either stained with Coomassie 
brilliant blue stain or transferred to PVDF membrane for western blot, with results 
shown in Fig 3.5. The FLAG blot (Fig. 3.6 (c)) shows very strong antibody binding 
making correct identification of the FLAG-p7 proteins difficult, but the GST blot (Fig. 
3.5 (b)) shows minimal contamination of the S2, S3-1 and S3-2 purified proteins by 
uncleaved fusion protein, and no fusion protein in the other purifications. The 
Coomassie stain (Fig 3.5 (a)) clearly shows the monomeric purified proteins, but there 
are some slight size variations. This has been seen before with targeted mutagenesis 
of GT1B p7 (StGelais et al., 2009), and is hypothesised to be due to the minor 
changes in protein size and hydrophobicity caused by the sequence variations.  
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Figure 3.5 Coomassie stain and western blots of purified FLAG-p7 proteins 
following desiccation. 
Protein samples were resuspended in Laemmli buffer, heated at 95 °C and 5 μg of 
each protein run on 15% Tris-glycine SDS-PAGE gels. The gels were then either 
stained with Coomassie Brilliant Blue or transferred to PVDF membrane and probed 
by western blot for FLAG and GST proteins. For all panels, the lanes are: 1. H77 
FLAG-p7, 2. M1 FLAG-p7, 3. M2 FLAG-p7, 4. S2 FLAG-p7, 5. S1 FLAG-p7, 6. S3-1 
FLAG-p7, 7. S3-2 FLAG-p7. Panel (a) shows the Coomassie stain, panel (b) shows 
the α-GST western blot, and panel (c) shows the α-FLAG western blot. 
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3.2.3 Patient derived FLAG-p7 proteins show wide variation in activity 
levels compared to prototype sequences  
To investigate how the naturally-occurring patient variations affected the activity of p7, 
the FLAG-p7 proteins were tested in the liposome dye release assays (StGelais et al., 
2007). On addition of a pore-forming protein, CF is released from the liposomes, 
where it is present at self-quenching concentration, to the surrounding media allowing 
it to fluoresce. Each protein was tested in duplicate. The p7 proteins were added last, 
and the plate immediately measured. The rate of fluorescence increase as the dye 
was released from the liposomes was measured every 30 seconds over a period of 30 
minutes. The rate of dye release over the first 5 minutes was also calculated. The 
results are shown in Fig 3.6.  
J4 FLAG-p7 was included as a control, but the principle relevant comparison for 
patient isolate sequences was with the genotype 1a prototype H77 FLAG-p7. The 
result that initially stands out is the S2 isolate, which shows a very high reaction rate 
and endpoint, with an initial reaction rate three times that of H77 and an endpoint 
twice as high, with a p-value on the initial rate of less than 0.05. M2 and S3-2 show 
similar rates to H77 and do not have p-values below 0.05. M1, S1 and S3-1 all show 
initial reaction rates that are lower than H77 and have p-values less than 0.01. S1 also 
shows a reaction rate only moderately higher than the background control of the 
protein-carrier methanol alone. 
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Figure 3.6 Liposome assay showing total fluorescence over time and initial 
reaction rates for J4, H77 and Seattle patient isolate FLAG-p7s 
FLAG-p7 proteins were resuspended in methanol and mixed with 50 μM liposomes 
prepared as described in section 2.5.1. Carboxyfluorescein release was measured by 
fluorimetry at excitation and emission wavelengths of 485 nm and 520 nm 
respectively, at 37 °C for 30 min. Panel (a): Carboxyfluorescein release over time. 
Panel (b): Initial rates calculated from the first 5 minutes of the curves shown in panel 
(a). Results were performed in duplicate and error bars represent standard deviation 
between the duplicates. 
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3.2.4 Do prototype and patient genotype 1a p7 proteins exhibit 
differential pH responsiveness? 
3.2.4.1 J4 FLAG-p7 displays increased activity at reduced pHext in a liposome 
based assay. 
In addition to the liposome activity assay, an endpoint assay to measure changes in 
p7 activity in response to changes in external buffer pH (pHext) was also developed 
(StGelais et al., 2007). Briefly, liposomes were pelleted and then resuspended in 
citrate-phosphate buffers at different pH values. These liposomes were then 
incubated with p7 protein, followed by removal of the remaining liposomes by 
ultracentrifugation, and the fluorescence of the released carboxyfluorescein restored 
by the addition of Tris-Cl (1M, pH 8.0) buffer to restore neutral pH. This showed that 
J4 p7 showed increased activity in response to reduced pHext in this system, as does 
the prototype viroporin IAV M2 (Stephen Griffin, unpublished observations). 
Previous work with J4 p7 showed a 2-fold increase p7 activity when the pHext was 
reduced from 7.4 to 6.2 (StGelais et al., 2007). With the modified pH assay, the 
results shown in Fig 3.7 indicate that activity at pH 6.7 shows a 15% increase 
compared with the activity at pH 7.4, and the activity at pH 6.2 is 175% higher, an 
increase of almost 3-fold in activity.  
3.2.4.2 H77 displays a different pH-activity profile to prototype controls from 
other HCV genotypes. 
Two other HCV genotype prototypes, JFH1 and H77 p7 were then also investigated 
for their response to low pH. H77 is the prototype GT1A sequence, and thus makes 
the closest comparison for the patient isolate sequences. JFH1 is the GT2A isolate 
that is able to replicate in cell culture, and thus is the best-characterised isolate to 
have been studied with full rounds of virus replication. Like the S1 patient isolate 
sequence, JFH1 has a second histidine at position 31, which may lie just outside the 
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entrance to the channel pore, and so the effect of this additional histidine residue in 
proximity to the pore in both p7 proteins was also worthy of investigation.  
The results are shown in Fig 3.7. JFH1 showed a similar profile to J4 p7, but with a 
much higher increase in activity. At pH 6.7, the activity increases by 43% compared 
with the activity at pH 7.4, and at pH 6.2 the activity increases by 700%, 8-fold higher 
activity than at pH 7.4.  
However, H77 showed a different activation profile. At pH 7.4, H77 activity was 54% 
higher than the J4 p7 control at the same pH. At pH 6.7, the activity dropped 60% to 
just below the activity of J4 p7 at pH 7.4, then at pH 6.2 the activity rebounded to 48% 
higher than the activity of J4 p7 at pH 7.4. This pattern formed a V-shaped activity 
profile.  
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Figure 3.7 Liposome pH assay for prototype FLAG-p7 proteins 
Liposomes were pelleted by ultracentrifugation and resuspended in liposome assay 
buffer at pH 6.2, 6.7 and 7.4. Liposomes at 50 μM were incubated with 10 μg FLAG-
p7 protein in methanol for 15 minutes then ultracentrifuged to pellet the remaining 
liposomes. Controls with methanol alone for background and 0.5% (v/v) triton-X100 
for complete dye release were also included. Supernatants were removed to a 
fluorescence plate and the fluorescence of the triton-X100 controls at pH 6.2 and 6.7 
restored by the addition of 1 M Tris-Cl pH 8. The same volume of Tris-Cl pH 8 was 
then added to the methanol controls and FLAG-p7 wells to restore their full 
fluorescence. Panel (a) shows the results for J4-FLAG-p7, with the methanol 
backgrounds subtracted from the fluorescence released by FLAG-J4-p7. Results were 
normalised to the fluorescence release at pH 7.4. Panel (b) shows the results for H77-
FLAG-p7, with the methanol only controls subtracted and J4-FLAG-p7 at pH 7.4 
controls included allowing normalisation to this value. Panel (c) shows the pH assay 
for JFH1-FLAG-p7, with the methanol-only controls subtracted. As no J4-FLAG-p7 
control was used in this experiment, JFH1-FLAG-p7 is normalised to its dye release at 
pH 7.4. 
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3.2.4.3 Activity profiles of the Seattle isolate p7s in response to reduced pH  
The pH activity of the Seattle patient isolates was then investigated, to see how the 
sequence variations might affect the pH activity profiles of p7. Of particular interest 
were the M2 and S2 with alterations from His17, and S1 with a second histidine 
residue at position 31.  
Two of the Seattle patient isolate sequences, M1 with an S21P variation and S1 with 
an Y31H mutation displayed a switch in the channel gating to the low-pH activated 
phenotype. Shown in Fig 3.8, M1 activity at pH 7.4 was 65% that of the J4 p7 control, 
with a slight increase at pH 6.7 to 68%, then at pH 6.2 the activity increased to 154% 
that of the J4 p7 control at pH 7.4. S1 showed the lowest activity at pH 7.4 at 36% that 
of the J4 p7 control, which increased to 42% at pH 6.7 and 125% at pH 6.2. 
The isolates M2, S2, S3-1 and S3-2 all showed a similar V-shaped pH activation 
profile to H77 p7, with the lowest activity at pH 6.7 and higher activities at pH 7.4 and 
6.2, shown in Fig 3.9. M2 showed an activity of 165% that of the J4 p7 control at pH 
7.4, then dropped to 120% at pH 6.7 and increased again to 141% at pH 6.2. S2 
showed the highest activity rate, starting at 199% of the J4 p7 control at pH 7.4, then 
dropping to 144% at pH 6.7 and increasing to 188% at pH 6.2. S3-1 started at 135% 
of the J4 p7 control at pH 7.4, dropping to 110% at pH 6.7 and increasing to 154% at 
pH 6.2. S3-2 showed similar activity to J4 p7 at pH 7.4, only 4% higher than the J4 p7 
control, dropping to 82% at pH 6.7 and increasing to 90% at pH 6.2. 
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Figure 3.8 Seattle FLAG-p7 proteins M1 and S1 show low-pH activation 
Panel (a) shows the pH activity profile for M1, with its S21P polymorphism, and Panel 
(b) shows the pH activity profile for S1, with its Y31H polymorphism. Activity profiles 
for J4-FLAG-p7 and H77-FLAG-p7 are shown in pale grey (J4 FLAG-p7) and dark 
grey (H77 FLAG-p7). 
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Figure 3.9 Seattle FLAG-p7 proteins displaying a V-shaped pH response profile, 
but at varying activity levels 
pH activity assays for the remaining Seattle FLAG-p7s M2, S2, S3-1 and S3-2. 
Activity profiles for J4-FLAG-p7 and H77-FLAG-p7 are shown in pale grey (J4 FLAG-
p7) and dark grey (H77 FLAG-p7). Panel (a) shows M2 (H17R), panel (b) shows S2 
(H17N), panel (c) shows S3-1 (T16A) and panel (d) shows S3-2 (T16A, R35G) 
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3.3 Discussion 
The functional variants of HCV p7 derived from patients allow the investigation of how 
far the p7 sequence can change, and what effect these changes may have on p7 
activity. This initial work focused on using the previously developed bacterial 
expression system and in vitro liposome dye release assay to investigate the activity 
(StGelais et al., 2007). The real-time dye release assay had been previously used to 
measure variation in p7 activity levels and drug responses between different 
genotypes (Griffin et al., 2008), and the effect of targeted mutagenesis on J4 p7 
(StGelais et al., 2009). 
3.3.1 Predicted changes in protein hydropathy cannot wholly explain 
changes in HPLC column retention times 
The changes in column retention times for the Seattle patient isolates cannot wholly 
be explained by the changes in protein hydrophobicity as calculated using the 
ProtParam tool. S1, predicted to be the most hydrophilic, does show a major 10 
minute reduction in retention time when compared with H77, but M2 with a predicted 
hydropathy score almost as low only showed a 2 minute reduction in retention time. 
Of the 3 isolates predicted to be more hydrophobic than H77, S2 showed a 4.5 minute 
reduction in retention time, S3-1 showed a 0.5 minute reduction and S3-2 showed a 
1.5 minute increase. There are two possible reasons for this mismatch between 
predictions and results. Firstly, the GRAVY score is calculated using a cumulative 
score of all the amino acids present, and whether or not they are hydrophobic or 
hydrophilic, without reference to whatever residues are adjacent. Also, these numbers 
are based on the amino acid properties at neutral pH, and so the physical properties 
of the protein may have been changed by the low pH conditions of the HPLC buffers 
which contain 0.1% TFA, a strong acid used as an ion pairing agent in HPLC solvents. 
Secondly, it has previously been observed for N-lauroylsarcosine when comparing its 
retention times between two different sized columns that its retention time was 
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dependent on the number of column volumes of buffer that had passed through the 
column, rather than the specific hydrophobicity of the buffer concentrations at the 
elution point (T. Foster, unpublished observations). Such shifts in elution times 
between different columns have not however been observed for any of the protein 
peaks. 
3.3.2 Seattle p7 variations result in very different activity levels in a real-
time dye release assay at pH 7.4 
Of the two mutants with His17 substitutions, M2 with an H17R mutation and S2 with 
an H17N mutation; only S2 showed a significantly higher activity than H77 p7 activity 
at pH 7.4. The H17R mutation, adding a residue to the channel that is permanently 
protonated at neutral pH, could be predicted to result in a more open channel 
conformation. However, the H17N mutation results in a 3-fold increase in channel 
activity under standard conditions, whilst the H17R mutant does not show activity that 
is significantly different from that of H77 p7. The same variant in the genotype 2a J6 
p7 was previously found to result in a slightly higher endpoint than the GT2A JFH1 p7 
in the same in vitro system, with initial dye release rates at ~100 FU/min for both 
(StGelais, 2008). However, in virus studies the Jc1 chimera containing the structural 
proteins of J6 with the non-structural proteins of JFH1 produces a higher number of 
infectious virus particles (Pietschmann et al., 2006), although differences in the other 
structural proteins may also play an important role in the increase in viral titres. 
Substitution of J6 p7 alone into JFH1 was also found to increase production of 
infectious virus, but not to the same extent as seen with the Jc1 chimera (Steinmann 
et al., 2007). 
Three of the isolates showed significant reductions in activity compared with H77 
under standard conditions. Of these, two isolates showed several mutations from the 
H77 sequence. S1 showed the greatest reduction in activity and possessed an Y31H 
mutation. This severe reduction in activity is surprising as the Y31H mutation is 
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relatively common across HCV genotypes, and thus would not be expected to cause 
such a significant drop in p7 activity. Based on the J4 p7 NMR structure model the 
residue at position 31 does not map to the lumen of the channel, and so would not 
necessarily be predicted to block the channel directly. However, it is close enough to 
the cytosolic entrance to the channel lumen that it is feasible that it could be acting as 
a second sensor, restricting the channel further than the single histidine at position 17 
is able to do.  
S3-1, with an A16T mutation, may have affected the position of the adjacent His17 in 
the channel lumen and thus have changed the ability of p7 to allow the movement of 
molecules through the channel.  
The relatively high activity of S3-2 with its R35G mutation is unexpected, given that 
loop mutations have previously been shown to significantly decrease virus infectivity if 
the mutation is to anything other than a basic residue (Steinmann et al., 2007). The 
low levels of bacterial expression could also indicate a degree of malfunction in the 
protein, as previously observed with the K33A R35A mutation (StGelais et al., 2009). 
This double-alanine loop mutation was also found to be unable to fully insert into 
membranes. However, as R35G is a single polymorphism, of one of two basic loop 
residues, the single arginine at position 35 may maintain the structural requirements 
for the basic loop. 
3.3.3 Naturally occurring patient variants result in a switch in p7 gating 
phenotype 
The pH of the carboxyfluorescein buffer inside the liposomes (pHint) was pH 7, while 
the assay buffer external to the liposomes (pHext) was pH 7.4; pH 6.7 is the closest of 
the 3 external pH points measured. As the pH gradient is increased in either direction 
from this midpoint then H77 p7 activity increases. The pH changes of p7 activity 
between the different genotypes in response to pH was unexpected – there are 12 
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amino acid differences between the GT1A H77 p7 and GT1B J4 p7, compared with 26 
differences between J4 p7 and the GT2A JFH1 p7 and 29 between H77 and JFH1. 
The role of His17 in H77 p7 may also not be as clear as for J4 p7; in J4 p7 the H17A 
mutation results in a severe reduction in p7 activity in the liposome assay, while in 
H77 p7 the same mutation in black lipid membranes, an alternative in vitro system, 
does not result in any loss of protein activity (Chew et al., 2009). Thus, while His17 in 
H77 p7 has been shown to be present in the lumen of the channel using copper-
chelation in the BLM system that blocks channel activity (Chew et al., 2009), it may 
well not be acting as a pH sensor and/or gate. H77 p7 may already have a wider 
channel lumen, meaning any restriction caused by the lumenal histidine residue is 
insignificant to p7 function. 
It is likely that low-pH activation of the p7 channel requires a histidine residue in or 
close to the lumen of the channel, so the phenotypic switch to low-pH activation 
cannot occur in the two isolates with no histidine residues. The remaining two isolates, 
S3-1 and S3-2 that do have His17 may just be too similar to H77 p7 to have a 
different phenotype. 
Very few mutations were required for this switch in phenotype to pH-gated activity: the 
non-synonymous change for M1 was S21P and for S1, Y31H. Both isolates are far 
closer in overall sequence to H77 than they are to either J4 or JFH1. The S21P 
mutation may cause a change in the structure of transmembrane domain 1, 
introducing a kink in the alpha-helix that may constrict the channel to the point where 
the protonation-state of His17 can change the activity of the channel. Proline is also 
more hydrophobic than the polar serine, and thus may also change the characteristics 
of the channel pore lumen 
The introduction of a second histidine through the Y31H mutation in the S1 isolate 
introduces a second possible sensor or gating residue; it may well be the case that for 
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this isolate the protonation-state of His17 is insignificant for channel opening but 
His31 is significant. It is notable that the increase in activity is more similar to that of 
J4 p7 than of JFH1: JFH1 also has a histidine at position 31 but shows a much higher 
proportionate increase in activity. With JFH1 p7 it is possible that both histidine 
residues are acting to gate the channel and thus the proportionate activity change on 
reduction of pH is considerably higher.  
3.4 Conclusions  
Naturally occurring variants in the p7 sequence cause changes in activity levels 
observed in vitro. There is no correlation between p7 activity and disease severity 
seen in the patients with the few samples tested. There is, however, a change in the 
channel gating phenotype observed in M1 and S1, with the non-synonymous 
variations S21P and Y31H respectively being sufficient to alter the pH-activation 
profile to that found in other genotypes. 
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 Chapter 4: The effect of naturally-
occurring variations in p7 on the 
production of infectious virus. 
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4.1 Introduction 
The genotype 2a JFH1 infectious virus system was developed in 2005 (Wakita et al., 
2005). Until recently JFH1 and its chimeras were the only HCV constructs to efficiently 
produce infectious virions, and so other genotypes have been studied by the use of 
chimeric constructs with structural proteins substituted into the JFH1 system. The 
GT1A chimera HJ3-5, which contains the Core-NS2 sequence of H77 and NS3-5B of 
JFH1 shows the highest production of infectious virus of any GT1A chimera yet 
created (Yi et al., 2007). HJ3-5 is referred to throughout this chapter as the H77 
chimera or H77 for simplicity. A replication-null mutant JFH1-GND, henceforth 
referred to as GND, has a GDD-GND mutation in the viral RNA dependent RNA 
polymerase NS5B that renders it unable to replicate its genome, and is used as a 
control. 
Previous studies have identified genotype-specific effects of p7, with the lumenal tails 
of the protein mediating non-viroporin activity (Sakai et al., 2003). Substitution of p7 
from the high-titre Jc1 (J6/JFH1) chimera into JFH1 has been shown to increase 
infectious virus titres (Steinmann et al., 2007), while substitution of GT1B p7 into JFH1 
resulted in delayed virus release (Haqshenas et al., 2007a).  
Following the initial characterisation of the Seattle isolate p7 activity in vitro, the p7 
sequences were substituted into the H77 chimera. While variations in other viral 
proteins are likely to have occurred in the original patient isolate viruses, the 
substitution of p7 alone allows any changes in the production of infectious virus to be 
directly ascribed to the variations in the p7 sequence. It is possible that some changes 
may result in changes to p7 protein processing, particularly in the case of S3-2 where 
the R35G variant may impair p7-NS2 processing, as shown in the GT1B SPp7 
replicon with the K33A R35A loop mutation (Tedbury et al., 2011) and with the 
equivalent mutation in the JFH1 virus (Steinmann et al., 2007). Thus, viral protein 
expression was also analysed by western blot analysis.  
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The change in gating phenotype observed in vitro may affect the production of 
infectious virus. Previous work found that nascent JFH1 virions displayed reduced 
infectivity when transiently exposed to reduced pH, while secreted virions had 
undergone a maturation process that rendered them insensitive to the same 
conditions (Wozniak et al., 2010). The difference in gating phenotype between JFH1 
and H77 may lead to changes in virion pH sensitivity and the maturation process. 
Thus, the Seattle p7 viruses that displayed a low-pH activation gating phenotype may 
also show changes in virion pH sensitivity. 
Substantial variations in p7 inhibitor sensitivity have previously been observed 
between p7 from different genotypes (Griffin et al., 2008), and some resistance 
mutations to inhibitors identified. These include the L20F mutation that renders GT1B 
less sensitive to amantadine (Foster et al., 2011; Mihm et al., 2006), and F25A that 
confers resistance to NNDNJ (Foster et al., 2011; StGelais et al., 2009). Changes in 
gating phenotypes shown in vitro may also alter the sensitivity of M1 and S1 to p7 
inhibitors when compared with H77 and the other Seattle variants. In addition, for all 
isolates, the synonymous, hydrophobic substitutions may also have effects on 
inhibitor binding; the L20F substitution in GT1B is synonymous, but significantly 
reduces adamantane binding. 
This chapter aimed to characterise the role of p7 in the pathogenicity of the Seattle 
patient isolates, by cloning the sequences into the H77 chimera and investigating the 
effects of the p7 polymorphisms on the production of infectious virus. The changes in 
pH-gating phenotype observed in vitro may also have an effect on the role of p7 in 
preventing endosomal acidification during virus assembly and egress, and the effect 
of transient exposure to reduced pH on the H77 chimera and the Seattle isolates was 
also investigated. Finally, p7 inhibitors have previously been found to have genotype-
specific effects on virus production, and the effect of the Seattle isolate 
polymorphisms on inhibitor sensitivity was also investigated. 
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4.2 Results 
4.2.1 Cloning of virus constructs 
Examination of the sequence of the GT1A/JFH1 chimera pJ3-5 identified two unique 
restriction sites, MauBI and AfeI, up- and downstream of the p7 sequence. Three of 
the patient isolate p7 sequences, M1, M2 and S1, had sufficient flanking sequence to 
use simple PCR to amplify the cloning insert sequence required. The S2, S3-1 and 
S3-2 sequences comprised only the coding region for p7 and none of the flanking 
sequences. In order to generate the flanking sequences incorporating the restriction 
sites, a long forward primer (for sequences see Appendix 1) was used for the 5’ end. 
The 3’ flanking sequence required was longer, and overlap PCR using the H77 NS2 
sequence as a template for the missing 3’ section was used to generate this section 
(Fig. 4.1). Incorporation of the patient isolate p7s into the pHJ3-5 plasmid was 
confirmed by commercial sequencing using the short forward and reverse primers 
flanking the p7 sequence.  
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Figure 4.1 Cloning strategy for insertion of Seattle patient isolate p7s into the 
HJ3-5 chimera 
Diagram showing the restriction endonuclease sites MauBI and AfeI close to the p7 
coding region of the H77-JFH1 chimera HJ3-5. The sequence of the H77 chimeric 
virus was analysed for the presence of restriction endonuclease cleavage sites using 
pDRAW32, and MauBI and AfeI sites identified in proximity to the p7 coding region. 
Primers were designed to allow amplification of the sequence. For M1, M2 and S1, 
the cDNA had sufficient flanking sequence for a simple PCR amplification. For S2, 
S3-1 and S3-2, a long forward primer and overlap PCR of the region downstream of 
p7 had to be used to generate sufficient sequence to reach the restriction 
endonuclease sites.  
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4.2.2 Effects of patient isolate p7s on viral titres 
4.2.2.1 Genotype prototypes JFH1 and H77 show expected viral titres 
Initial work established the infectivity levels of the prototype viruses, JFH1 and H77. 
After optimisation of the timecourse of virus infectivity, JFH1, H77 and the replication-
null mutant GND were assayed for their infectivity every 24 hrs for a period of 72 hrs. 
This timecourse was also used to compare the infectivity of the patient isolates. 
Secreted virus was harvested by removal of the cell media, and intracellular virus was 
harvested by freeze-thaw lysis of the infected cells. The results are shown in Fig. 4.2 
(a) and Fig. 4.3 (a). As expected, the GND mutant did not produce infectious virus, 
whilst both parental strains secreted infectious virus; with JFH1 titres of 1.1 x 104 
focus forming units per ml (FFU/ml) at 24 hrs, 2.3 x 104 FFU/ml at 48 hrs and 3.8 x 104 
FFU/ml at 72 hrs. The H77 virus showed similar infectious titres at 24 and 48 hrs (7.6 
x 103 FFU/ml and 2.6 x 104 FFU/ml respectively). At 72 hrs however, the infectious 
titres dropped to 5.5 x 103 FFU/ml.  
The intracellular virus (Fig. 4.3 (a)) showed consistently higher values for the H77 
chimera, which produced 1.9 x 103 FFU/ml at 24 hrs compared with 1.1 x 103 FFU/ml 
for JFH1. At 48 hrs the separation was higher; 1 x 104 FFU/ml for H77 and 1.8 x 103 
FFU/ml for JFH1. At 72 hrs however, the infectivity of the H77 intracellular virus 
dropped to 2.9 x 103 FFU/ml, while JFH1 increased to 4.2 x 103 FFU/ml. The overall 
ratios of secreted: intracellular virus, (Fig. 4.4 (a)) shows that at each timepoint, JFH1 
has a higher ratio of intra-to extracellular infectivity, indicating a greater efficiency of 
virus release. The most efficient release of virus was observed at 24 hrs for the H77 
chimera and at 48 hrs for JFH1. For both viruses, the cell media showed signs of 
acidification at 72 hrs. The loss of H77 chimeric virus infectivity when the media 
becomes acidified is investigated further in section 4.3.2. 
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Figure 4.2 Infectivity of secreted virus over 72hr 
Infectivity of secreted virus for JFH1, the replication-null mutant JFH1-GND, the 
H77/JFH1 chimera (H77) and the H77/JFH1 chimera with the p7 sequence 
substituted for the Seattle patient isolate p7 sequences. Secreted virus was harvested 
by the removal of media from infected cells. Infectivity was assessed by focus forming 
assay, where virus was serially diluted into a titre plate and allowed to infect cells for 
48 hours. The infected cells were fixed and stained, then the foci counted. Each panel 
shows the GND and H77 controls, with the following additions: Panel (a) JFH1, (b) M1 
(S21P), (c) M2 (H17R), (d) S1 (Y31H), (e) S2 (H17N), (f) S3-1 (A16T), (g) S3-2 
(A16T, R35G). Experiments were performed in triplicate. Error bars = standard error 
of the mean (SEM) 
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Figure 4.3 Timecourse of intracellular virus infectivity over 72hr 
Intracellular infectivity of JFH1, JFH1-GND H77 and the H77/JFH1 chimera with 
substituted p7 sequences. For each Seattle patient isolate, intracellular virus was 
harvested by freeze-thaw lysis and infectivity assessed by focus forming assays 
48  hrs post-infection. Each panel shows the GND and H77 controls, with the following 
additions: Panel (a) JFH1, (b) M1 (S21P), (c) M2 (H17R), (d) S1 (Y31H), (e) S2 
(H17N), (f) S3-1 (A16T), (g) S3-2 (A16T, R35G). Experiments were performed in 
triplicate. Error bars = SEM 
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Figure 4.4 Ratio of secreted: intracellular virus over 72hr 
Ratio of secreted: intracellular virus was calculated from Figs. 4.2 and 4.3. Each panel 
shows GND and H77 controls, with the following additions: Panel (a) JFH1, (b) M1 
(S21P), (c) M2 (H17R), (d) S1 (Y31H), (e) S2 (H17N), (f) S3-1 (A16T), (g) S3-2 
(A16T, R35G).   
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4.2.2.2 Seattle isolate p7s produce infectious virus 
To investigate the effects of the Seattle variations on the production of infectious virus, 
the cloned Seattle isolate p7 viruses were analysed in the same manner as the 
parental strains.  
M1 with its significant S21P mutation showed slightly higher extracellular titres than 
H77, with 8.9 x 103 FFU/ml at 24 hrs, 3.5 x 104 FFU/ml at 48 hrs and 8.5 x 103 FFU/ml 
at 72 hrs (Fig 4.2 (b)) The intracellular infectivity (Fig. 4.3 (b)) was also close to H77 
(2.1 x 103 FFU/ml at 24 hrs, 8.4 x 103 FFU/ml at 48 hrs, and 5.5 x 103 FFU/ml at 
72 hrs). The secreted: intracellular ratio at 24 hrs was similar for both, M1 4.1 and H77 
4.0, but the slight increase in secreted viral titres and decrease in intracellular titres at 
48 hrs results in a higher intra/extracellular infectivity ratio at 48 hrs (M1= 4.1 vs. 
H77 = 2.5). 
M2 (H17R) shows reduced extracellular titres compared to H77 (3.1 x 103 FFU/ml at 
24 hrs, 1.3 x 104 FFU/ml at 48 hrs and 4.2 x 103 FFU/ml at 72 hrs) (Fig. 4.2 (c)). The 
intracellular titres were also lower, (2.3 x 102 FFU/ml at 24 hrs, 3.6 x 103 FFU/ml at 
48 hrs and 3.1 x 103 FFU/ml at 72 hrs (Fig. 4.3 (c)). The lower intracellular infectious 
titres increased the secreted: intracellular ratio to a peak of 13.4 at 24 hrs compared 
with 4.0 for H77 at the same timepoint. 
S1 (Y31H) is the sole Seattle isolate that in virus shows a significant reduction in the 
production of infectious virus. (Fig. 4.2 (d)), The S1 secreted infectious titres were 1.7 
x 102 FFU/ml at 24 hrs, 1.2 x 103 FFU/ml at 48 hrs and 1.6 x 103 FFU/ml at 72 hrs. 
The intracellular titres were also reduced (3.0 x 101 FFU/ml at 24 hrs, 7.3 x 102 
FFU/ml at 48 hrs and 1.2 x 103 FFU/ml at 72 hrs). This is the only GT1A virus that did 
not show a drop in virus titres at 72 hrs. Interestingly, whilst both secreted and 
intracellular virus titres were considerably lower than for any other GT1A chimeric 
virus tested, the secreted: intracellular ratio was slightly higher at 24 hrs than for H77, 
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(5.8 for S1 vs. 4.0 for H77), suggesting that the release of infectious virus progeny 
may be more efficient for S1.  
S2 (H17N) shows an increase in secreted viral titres compared with H77 (Fig. 4.2 (e)), 
(1.3 x 104 FFU/ml at 24 hrs, 3.7 x 104 FFU/ml at 48 hrs and 8.0 x 103 FFU/ml at 
72 hrs). When intracellular virus infectivity was assessed (Fig. 4.3 (e)), a reduction in 
virus titres at 24 hrs (5.6 x 102 FFU/ml) was observed, but the intracellular infectious 
virus titres increased to similar levels to H77 intracellular titres at 1 x 104 FFU/ml at 
48 hrs, before dropping to 5.8 x 103 FFU/ml at 72 hrs. The increase in secreted virus 
and decreased intracellular virus at 24 hrs resulted in a high secreted: intracellular 
ratio of 24.0 at 24 hrs, which decreased to 3.7 at 48 hrs, higher than H77 (that 
displayed a ratio of 2.5 at 48 hrs) (Fig. 4.4 (e)). The high ratio at 24 hrs and increased 
infectivity at 48hrs compared to H77 may indicate more efficient virus release for S2.  
S3-1 (A16T) displayed lower secreted infectious titres than H77 (4.2 x 103 FFU/ml at 
24 hrs) but increased higher than H77 at 48 hrs (3.1 x 104 FFU/ml), before dropping to 
1.0 x 104 FFU/ml at 72 hrs (Fig 4.2 (f)). The intracellular titres (Fig 4.3 (f)) were lower 
than H77 at 24 and 48 hrs, (1.2 x 103 FFU/ml and 8.8 x 103 FFU/ml respectively), 
dropping to 5.8 x 103 FFU/ml at 72 hrs. The ratio of secreted: intracellular virus was 
only slightly lower than H77 at 24 hrs: (3.5 vs. 4.0), but the ratio increased at 48 hrs to 
3.6 vs. H77 which decreased to 2.5 (Fig. 4.4 (f)) suggesting that a higher efficiency of 
virion release is maintained during the later stages of infection.  
S3-2 (A16T, R35G) showed a reduction in virus infectivity over time, with titres of 2.3 x 
103 FFU/ml at 24 hrs, 1.2 x 104 FFU/ml at 48 hrs and 4.7 x 103 FFU/ml at 72 hrs (Fig 
4.2 (g)). The intracellular titres were also lower than H77 at 24 and 48 hrs, with titres 
of 1.7 x 103 FFU/ml and 4.1 x 103 FFU/ml respectively. Unusually, the intracellular 
titres did not decrease at 72 hrs, but further increased to 4.7 x 103 FFU/ml. The 
secreted: intracellular ratio is low at 24 hrs at 1.3, but increases at 48 hrs to 3.0 before 
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dropping to 1.0 at 72 hrs. This shift in the peak ratio could indicate a delay in the 
release of infectious virus progeny from S3-2 infected cells.  
4.2.2.3 Assessment of the expression of virus proteins of the Seattle patient 
isolate p7 viruses  
To investigate any effects of the Seattle p7 variations on viral protein expression and 
polyprotein cleavage, samples of the infected cells were harvested for intracellular 
virus as in Fig. 4.3, and assessed for virus protein expression by western blot analysis 
(Fig 4.5). Expression of the viral proteins p7, NS2, E2, Core, and NS5A were 
assessed, and the cellular protein GAPDH probed as a loading control. The blots for 
E2, p7 and NS2 were carried out to assess if polyprotein processing around p7 was 
affected by the sequence variations. Core and NS5A blots were performed to assess 
general viral protein expression, and to investigate the correlation between the 
release of infectious virus and levels of structural and non-structural proteins within 
the cell. The GAPDH blots were carried out to check the health of the infected cells, 
and to ensure that any reductions in infectious virus production were not due to 
cytotoxic effects. Samples for p7 and NS2 western blots were run on Tris-tricine gels, 
as they were previously found to show good band resolution for small proteins, as well 
as reduced background staining for one of the antibodies used in this study (the 1055 
TB antibody for GT1B p7). All other blots were run on Tris-glycine gels; 10% for E2, 
12% for Core, NS5A and GAPDH. As expected, the GND virus showed no viral 
protein expression. The consistent levels of GAPDH expression confirmed the Huh7 
cells were healthy. JFH1 shows the expression of viral proteins at all 3 timepoints, 
while H77 and the Seattle viruses display only show minimal NS5A expression at 
24 hrs, with no detectable expression at 24 hrs for any of the other viral proteins. The 
expression of viral proteins at 48 hrs is often noticeably higher than at 72 hrs, 
indicating that the acidification of the media may be reducing viral protein expression 
as well as the production of infectious virus.  
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The 2716 p7 antibody for JFH1 p7 was found to be cross-reactive with H77 p7. As this 
antibody was originally raised against the N-terminal 13 residues of JFH1 p7, the H77 
and Seattle p7 expression levels cannot be directly compared to each other due to 
sequence variation in this region (Fig. 3.2). While M1 shows low apparent expression 
levels, this could also be due to sequence variations at position 6 and 7 (V6I I7V). M2 
possesses an identical sequence to H77 in this region, and the p7 expression levels 
were comparable with H77. S1 and S2 are also identical in this N-terminal region with 
an I7L variant, and S1 shows lower p7 expression levels than S2. S3-1 and S3-2 are 
also identical in this region with an I7V variant, and S3-2 shows very low p7 
expression levels when compared with S3-1.  
The NS2 sequence is identical between the H77 and Seattle viruses, but variations in 
its expression levels between the viruses were observed. H77, M2 and S3-1 all show 
slightly lower expression levels than M1, S1, S2 and S3-2. E2, also identical between 
the viruses, also shows some variations, with S1 and S3-2 showing higher E2 levels, 
possibly indicating an intracellular accumulation of E2, due to reduced virus export, or 
improper E2 folding.  
Core levels also show some variation, with S1 showing lower expression levels. This 
could correlate with the reduced production of infectious virus for S1, as reduced Core 
expression will limit the amount of infectious virus that can be produced. NS5A does 
not show a significant variation in expression between the viruses, indicating that the 
changes in p7 do not influence NS5A expression/stability. GAPDH also shows no 
variation between the viruses or the GND control, showing that the viruses have not 
increased any virus specific cytopathic effects, and that the acidification of the media 
that most likely impacted the H77 and Seattle viruses at 72 hrs, did not affect the 
overall health of the infected cells.  
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Figure 4.5 Expression of viral proteins over 72 hrs 
Infected cells were harvested and assessed for virus protein expression by Western 
blot analysis. Western blots for p7 and NS2 were run on 10% Tris-tricine SDS-PAGE 
gels, E2 blots on 10% Tris-glycine SDS-PAGE gels and Core, NS5A and GAPDH 
blots were run on 12% Tris-glycine SDS-PAGE gels. All gels were transferred to 
PVDF membranes using the standard protocol. For each virus, 24, 48 and 72 hr 
timepoints are shown.  
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4.2.3 Exposure to low pH impairs genotype 1a viral infectivity 
Both H77 and the Seattle patient chimeras showed a consistent loss of virus infectivity 
at 72 hours. This loss is most likely due to the build-up of metabolites such as lactic 
acid in the cell media, which is sufficient to cause a reduction of extracellular pH. The 
effect of exposure of GT1A virions to low pH was therefore investigated. Previous 
work in JFH1 identified that intracellular virus particles were rendered non-infectious 
by transient exposure to low pH, whilst secreted virions appeared to have undergone 
a maturation step during virus assembly/release that rendered them resistant to pH-
mediated inactivation (Wozniak et al., 2010). The transient pH reduction protocol used 
in these studies was adapted and optimised, and the results are shown in Fig 4.6. The 
relative insensitivity of secreted JFH1 particles to transient exposure to low pH was 
reproduced, with a drop of only 25% in infectivity when the pH was reduced to 4.0, 
compared to an 85% reduction of infectivity in intracellular particles. H77, as 
hypothesised, displayed a loss in infectivity following exposure to low pH of both 
secreted and intracellular virions, with secreted virions showing a 49% loss of 
infectivity at pH 6.2, 69% at pH 5.2 and 78% at pH 4.0, which were statistically 
significant differences from JFH1 at all 3 reduced pH values. The loss of infectivity of 
intracellular virus was also greater for H77 than JFH1, with JFH1 showing an 85% 
loss of infectivity at pH 4.0, while H77 showed a 97% loss.  
As p7 is not thought to be present in the HCV virion, the effect of low pH exposure on 
the infectious virions is most likely mediated by the envelope glycoproteins E1 and E2 
that control acid-dependent fusion during virus entry. If this is the case, then the 
secreted Seattle isolate p7 viruses would be predicted to show the same pH 
sensitivity as the H77 chimera, as the structural proteins are identical between these 
viruses.  
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Figure 4.6 Infectivity of JFH1 and H77 viruses after transient exposure to 
reduced pH. 
Secreted virus was concentrated by sucrose-cushion centrifugation and resuspended 
in PBS. Intracellular virus was harvested by freeze-thaw lysis of infected cells in PBS. 
Virus in PBS was then mixed 1:1 with HEPES-MES buffers to produce a final pH of 4, 
5.2, 6.2 and 7.4 at 37 °C for 10 minutes. Samples were restored to neutral pH using 1 
M NaOH. Samples were titred for infectivity by focus forming assays. Experiments 
were performed in triplicate and normalised to the infectivity at pH 7.4. Error 
bars = SEM. A Student T test was used to compare each pH point, * = p≤ 0.05, 
** = p≤ 0.01. 
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4.2.4 Seattle isolates M1, S1 and S2 show apparent secreted virion pH 
sensitivity closer to JFH1 than H77  
Due to the marked differences in pH sensitivity of JFH1 and H77 virions, the effect of 
any changes in the M1, S1, and S2 Seattle patient isolates were assessed for their pH 
sensitivity as in Fig. 4.6. If the virion pH sensitivity is mediated entirely by the 
structural proteins, then no differences would be expected to be observed between 
the parental H77 and the Seattle patient isolate viruses. M1 and S1 both display a 
low-pH activation profile in vitro, and while S1 had low viral titres compared with the 
other viruses, it was also the only GT1A virus that did not show a drop in the infectivity 
of secreted virus at 72 hr during the timecourse of infection.  
All 3 of the Seattle viruses tested showed a pH sensitivity pattern that was closer to 
that of JFH1 than H77 (Fig 4.7). Due to limited time, only one experiment was 
performed, and this resulted in low statistical significance for some data-points. While 
M1 shows a similar pattern to JFH1, it did not show statistically significant differences 
with H77 at each pH point. S1, however, did show statistically significant differences 
from H77 at all 3 of the reduced pH points. S2 also showed statistically significant 
differences from H77 at all the reduced pH points, but at pH 4.0 it also displayed 
significant differences from JFH1, showing intermediate pH sensitivity between JFH1 
and H77.  
The intracellular virus pH sensitivity, however, showed levels closer to that of H77 
than JFH1, although fewer of the data-points showed any statistical significance. 
Once again, M1 did not show a statistical significance. However, the data-points at 
pH 6.2 and 5.2 are close to those of H77, whilst the sensitivity to pH 4.0, was similar 
to that of JFH1. For S1, the pH sensitivity again matched that of H77, and at pH 6.2 
shows a statistically significant difference from the JFH1 value. S2, which showed an 
intermediate sensitivity for secreted virus at pH 4.0, showed a reduction in infectivity 
at pH 6.2 that was significantly greater than both JFH1 and H77.  
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Thus, while these were initial experiments and were not repeated to the same extent 
as the JFH1 and H77 virus pH assays shown in Fig. 4.6, the changes in pH sensitivity 
from H77 may indicate that the pH sensitivity of the virion is mediated by more than 
genotype variations in the envelope glycoproteins. These data point to a role of 
changes in p7 affecting the glycoprotein maturation process that is hypothesised to 
render secreted JFH1 virions insensitive to transient reductions in pH.  
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Figure 4.7 Infectivity of M1, S1 and S2 H77 viruses after transient exposure to 
reduced pH  
Secreted virus from M1, S1 and S2 viruses were concentrated and assessed for 
sensitivity to pH as in Fig. 4.6. Experiments were performed in duplicate and 
normalised to the infectivity at pH 7.4. Error bars = SD. A Student T test was used to 
compared the parental virus to the Seattle virus, * = p≤ 0.05, ** = p≤ 0.01. 
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4.2.5 JFH1 and H77 show similar sensitivity to temperature 
One possible reason why GT1A virus particles display greater sensitivity to transient 
exposure to low pH may be due to a greater overall instability of the viral particles, 
perhaps due to weaker non-covalent associations between Core protein units in the 
capsid, or between E1 and E2 heterodimers. One relatively simple way to test the 
stability of virions is to assess their thermal stability. JFH1 particles have been shown 
to be rendered non-infectious by exposure to high temperature; 54 °C was sufficient 
to reduce infectivity to undetectable levels over a period of 40 minutes (Song et al., 
2010). Thus, to assess their thermal stability, JFH1 and H77 virions were exposed to 
temperatures of 54 °C and samples removed at 5 minute intervals over a period of 1 
hour. The infectivity of these samples was then assessed by focus forming assays. 
The results are shown in Fig 4.7. 
The relative infectivity of each virus stock was normalised to the T=0 timepoint for 
each virus isolate. After 5 minutes of high temperature treatment, H77 showed a 55% 
drop in infectivity, compared with a 34% drop for JFH1. At T=10, JFH1 infectivity had 
dropped a further 30%, while H77 remained constant. For the remainder of the 
timecourse the percentage of JFH1 infectivity remained below that of H77. Taken 
together, these data suggest that the enhanced sensitivity of the H77 virions to 
decreased pH was not due to the H77 virions possessing lower stability than their 
JFH1 counterparts.  
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Figure 4.8 Thermostability of JFH1 and H77 viruses 
Secreted JFH1 and H77 virus were incubated at 54 °C and assessed for infectivity by 
focus forming assay. Experiments were performed in triplicate and normalised to the 
initial levels of infectivity. Error bars = SEM. 
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4.2.6 M1 and S2 show H77-like responses to p7 inhibitors, S1 shows 
high sensitivity to rimantadine 
Previous work comparing the effect of p7 inhibitors on HCV genotypes found a 
number of phenotypes. H77 was found to be resistant to adamantanes, JFH1 was 
sensitive to rimantadine but not amantadine, Jc1 (J6) was sensitive to all 
characterised p7 inhibitors, as was J4, and the GT3A p7 452 was resistant to NNDNJ. 
The in vitro work with the Seattle patient isolate p7s showed that M1 and S1 had low-
pH activation phenotypes more typical of J4 or JFH1 than H77. Thus, whether the 
change in gating phenotype also mediated an alteration to p7 inhibitor sensitivity was 
investigated. Due to time constraints, only selected Seattle viruses were investigated; 
these included M1 and S1 due to their low-pH activated gating phenotypes, and S2 
due to its high activity and the Jc1-like H17N variation. 
To assess the effects of p7 inhibition on the production of infectious virus for M1, S1 
and S2 isolates, Seattle viruses were incubated in media containing rimantadine and 
NNDNJ at 20, 40 and 80 μM from 4-48 hrs post-transfection. The results for 
rimantadine are shown in Fig. 4.9. As expected, JFH1 showed greater sensitivity to 
rimantadine than H77, with a 48% drop in infectivity at 20 μM, 64% at 40 μM and 67% 
at 80 μM. H77 showed only a slight response to rimantadine, with an 18% drop in 
infectivity at both 20 μM and 40 μM, and at 80 μM increased to 5% higher than the no-
drug control. This increase in infectivity may be due to the basic nature of rimantadine 
adding an extra buffering effect to the media, preventing the acidification that impacts 
on H77 infectivity. Of the Seattle p7 viruses, M1 and S2 both followed the same 
pattern as H77, with M1 showing a 15% drop at 20 μM rimantadine, 17% at 40 μM 
and an increase above the no-drug control of 26% at 80 μM. S2 displayed a 21% drop 
at 20 μM and 40 μM, increasing to 5% below the no-drug control at 80 μM. S1, 
however, displayed increased sensitivity to rimantadine with a 45% drop at 20 μM, 
46% at 40 μM and 53% at 80 μM.  
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The results for NNDNJ are shown in Fig. 4.10. Both JFH1 and H77 viruses were 
sensitive to NNDNJ, with JFH1 showing greater sensitivity than H77. JFH1 displays a 
63% drop in infectious virus production at 20 μM, 78% at 40 μM and 91% at 80 μM, 
while H77 has a 26% drop at 20 μM, 47% at 40 μM and 71% at 80 μM. Again, M1 and 
S2 show a similar sensitivity to H77, with M1 showing a 29% drop at 20 μM, 52% at 
40 μM and 74% at 80 μM, and S2 showing a 33% drop at 20 μM, 46% at 40 μM and 
76% at 80 μM. S1 showed greater sensitivity to NNDNJ than both H77 and JFH1, with 
a 91% drop at 20 μM, 95% at 40 μM and 98% at 80 μM. It is thus possible that the 
changes in p7 inhibitor sensitivity are due to the synonymous hydrophobic residue 
substitutions in p7 sequence.  
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Figure 4.9 Effect of rimantadine on JFH1, H77, M1, S1 and S2 viruses 
Virus electroporations were aliquoted into 12-well plates. 4 hrs post-electroporation, 
infected cells were treated with rimantadine (20-80 μM) for a further 48 hrs. Secreted 
virus was harvested and virus infectivity titred. Experiments were performed in 
triplicate. Error bars = SE of the mean. 
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Figure 4.10 Effect of NNDNJ on JFH1, H77, M1, S1 and S2 viruses. 
Virus electroporations were aliquoted into 12-well plates. 4 hrs post-electroporation, 
infected cells were treated with NNDNJ (20-80 μM) for 48 hrs. Secreted virus was 
harvested and virus infectivity titred by focus forming assay. Experiments were 
performed in triplicate. Error bars = SEM 
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4.3 Discussion 
The substitution of p7 sequences between viral constructs has previously been used 
to identify p7-specific effects on the production of infectious virus (Steinmann et al., 
2007; Sakai et al., 2003). While the lumenal tails of p7 have been shown to display 
genotype specific effects, substitution of p7 into the same genotype where the 
lumenal tails are identical or closely conserved, should rule out effects on polyprotein 
cleavage at the E2-p7-NS2 junctions and protein-protein interactions. The Seattle 
patient isolate sequences were thus substituted into a H77 chimera to assess the 
effects of their sequence variations on the overall production of infectious virus. In the 
course of this work, genotype-specific differences in pH sensitivity of the virus 
particles were identified.  
While the major virus system for HCV is entirely based on JFH1 and its chimeric 
derivatives, this does have advantages when comparing the effect of an individual 
protein on the production of infectious virus. As pHJ3-5 is a chimera of H77, the RNA 
replication machinery, with the exception of its interactions with the structural proteins, 
cannot be implicated in any loss of infectivity. By substituting the Seattle patient 
isolate p7 sequences into the H77/JFH1 chimera, any possible compensatory 
mutations that occurred in the full virus of the patient isolate can be ruled out, and any 
overall change in the production of infectious virus can be attributed to differences in 
p7 function. As these sequences were derived from patients, and thus originated from 
infectious viruses, the problems of any non-specific effects of the mutations, such as 
the effect of mutation of the basic loop residues causing the incorrect processing of 
NS2, can also be ruled out. The N and C terminal lumenal tails of each p7 are also 
unchanged in the patient isolates when compared with the H77 sequence. As these 
regions mediate the non-viroporin activity of p7, it is likely that any effects on the 
production of infectious virus are due to changes in the viroporin activity of p7.  
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4.3.1 Effects of Seattle variations on infectious virus production 
High levels of p7 activity are hypothesised to enhance the protection of nascent 
virions against the exposure to a reduced endosomal pH during virus assembly and 
release. However, this may also lead to enhanced cytopathic effects as any 
perturbation of normal endosome activity would also be enhanced. Low levels of p7 
activity, or changes in the gating phenotype, could result in a reduced production of 
infectious virus when the substituted Seattle patient isolates are present. This may be 
due to the virions in this study consisting of the structural proteins of H77 with no 
compensatory mutations that may have occurred in the original Seattle isolates to 
compensate for changes in p7 activity. This would include the protection from 
endosomal acidification.  
The two isolates that showed a low-pH activation profile in vitro displayed very 
different phenotypes in virus. M1 showed comparable titres to H77, while S1 showed 
a ~1.5 log10 drop for secreted virus and a ~1 log10 drop for intracellular virus. Thus, the 
change in gating phenotype alone cannot account for specific changes in the 
production of infectious virus.  
 M1 showed comparable expression levels of all H77 viral proteins, with the exception 
of p7: the apparent low p7 expression levels may simply be a result of the antibody 
specificity, as two residue variations between M1 and H77 are present in the N 
terminal 13 residues targeted by the antibody (V6I and I7V). 
M2, with its H17R variant, showed slightly lower activity than H77 p7 in vitro although 
the differences were not found to be statistically significant. The viral titres were lower 
for M2 than for H77 for both secreted and intracellular virus, with the lower 
intracellular titres resulting in an increase in the secreted: intracellular ratio. Thus, 
while virus titres may be reduced, it is possible that the changes in p7 increased the 
efficiency of virus release. The western blot results showed comparable expression 
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levels of Core, E2 and NS5A, but with slightly reduced NS2 levels. Mutations of p7 in 
a GT1B replicon containing p7 and NS2 were previously shown to have variable 
effects on NS2 levels, with H17A showing no impact on NS2 expression, while G39A 
caused a reduction. The K33A R35A mutation displayed a complete loss of NS2 
(Tedbury et al., 2011). This suggests that the reduction in NS2 levels, in this study, 
were most likely due to the changes in p7. The reduced levels of NS2 may explain the 
reduction in infectious virus production observed.  
S1 p7, with its Y31H variation, showed the greatest reduction in viral titres of all the 
Seattle patient isolate viruses. S1 showed the lowest p7 viroporin activity in vitro and 
when the pH was reduced to 6.2 its activity never exceeded that of H77. The reduced 
p7 activity, in addition to the lack of activity shown at pH 7.4, may account for this 
isolate p7 displaying a significant effect on viral infectivity.  
Despite the high activity of the S2 isolate observed in in vitro liposome assays, it 
displayed no phenotype in virus systems, with the virus timecourse displaying only a 
modest increase in the production of infectious virus in comparison with H77. Jc1, 
which has the highest production of infectious virus of any HCV construct yet created, 
also possesses an H17N variation, and substitution of Jc1 p7 alone into the JFH1 
background has previously been shown to increase titres by ~1.5 log10. While S2 only 
shows a slight increase in comparison (42% higher than H77 at 48 hrs) this sequence 
variation may enhance the production of infectious virus. Previous work with Jc1 p7 
(J6 p7) showed in vitro activity levels in liposome assays below that of J4 and JFH1 
p7 (Griffin et al., 2008), meaning the high level of in vitro activity shown by S2 cannot 
be directly correlated with the H17N variation.  
S3-2 showed slightly reduced viral titres when compared with H77 and with its close 
partner S3-1. As the major mutation in this isolate is in one of the two basic loop 
residues, this result was surprising. Previous work in JFH1 found that single mutations 
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to either of the two loop residues to the polar glutamine rather than the hydrophobic 
alanine, resulted in a 1 log10 drop in the production of infectious virus The double-
alanine loop mutation in both JFH1 and a GT1B replicon containing p7 has previously 
been shown to perturb E2-p7-NS2 processing, with uncleaved E2-p7-NS2 found in 
virus (Steinmann et al., 2007) and no detectable NS2 in the replicon (Tedbury et al., 
2011). Despite this, the R33Q R35Q mutation in virus did not show a defect in p7 
processing (Steinmann et al., 2007). Thus, while it is surprising that the R35G variant 
in S3-2 only caused a slight drop in the production of infectious virus, previous work 
shows that protein processing may not be affected. The presence of at least one 
charged basic residue may still allow this region to mediate membrane insertion of p7, 
and the lower activity shown in vitro may mean enhanced endosomal p7 accumulation 
is required to raise the endosomal pH to similar levels to WT p7, maintaining the 
stability and infectivity of virions. This may account for why, unlike the other Seattle 
isolates, S3-2 shows a peak secreted: intracellular ratio at 48 hrs rather than 24 hrs.  
S3-1 and S3-2, which originated from the same patient and are the most closely 
matched pair of all the Seattle isolate p7s, show some interesting variations in protein 
expression levels. The Core and NS5A levels are closely matched, but S3-1 shows 
lower levels of NS2 and E2, and higher levels of p7 than S3-2. The R35G mutation, 
while not showing a severe impact on viral titres, as might have been expected based 
on all previous work involving mutations to the basic loop residues, clearly has major 
effects on protein levels. No detectable uncleaved precursors were found by western 
blot so these effects are unlikely to be due to polyprotein processing defects. 
All Seattle patient isolate viruses showed expression of the viral proteins p7, NS2, E2, 
Core and NS5A by western blot, but there were some variations evident. Some of the 
variations observed for p7 may be accounted for by the specificity of the antibody, as 
it was originally raised against the N-terminal 13 residues of JFH1. However, as some 
of the H77 and Seattle p7 sequences are matched in the first 13 residues it is possible 
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to perform a comparison of p7 expression. M1 shows low apparent p7 levels, but 
possesses two residues that differ from H77 (V6I and I7V) and so this may be 
attributed to reduced antibody binding. M2 is identical to H77 in this region, and the 
expression levels are comparable. S1 and S2 however, are identical in their 
sequences for the first 13 residues and do show reduced expression for S1 – 
combined with the lower expression levels observed for Core protein. This reduced 
expression may account for why the titres are much lower for S1 than for any of the 
other Seattle isolate viruses.  
The variations in E2 levels shown between the different viruses seem to have a 
reverse-correlation with the production of infectious virus – the viruses with the lowest 
titres show the highest levels of E2. With the lower in vitro activity of both of these 
p7s, the E2 levels could be explained by an accumulation of non-functional E2 
protein, possibly as a result of reduced p7 viroporin activity. This is unlikely to be due 
to polyprotein processing defects, however, as no uncleaved proteins were detected 
for any of the Seattle isolate p7 viruses.  
4.3.2 Secreted H77 virions are more sensitive to transient exposure to 
reduced pH than JFH1  
The persistent reduction in infectivity of secreted H77 virus and all but S1 of the 
Seattle isolate viruses at 72 hrs suggested that experimental conditions at this 
timepoint were causing the reduction in infectivity. At the 72 hr timepoint, the cell 
media displayed signs of acidification, with the phenol red fading to an orange colour. 
This acidification is due to the accumulation of cell metabolites, most likely lactic acid 
as many tumour cell lines primarily use glycolysis for respiration (Moreno-Sánchez et 
al., 2007). JFH1 secreted virions have previously been shown to be insensitive to 
transient exposure to reduced pH, while the intracellular virions were sensitive to 
intracellular pH (Wozniak et al., 2010). This assay was adapted to compare the 
relative pH sensitivity of JFH1 and H77 virions. The observed increased pH sensitivity 
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of secreted H77 virions may provide a reason why H77 p7 shows higher activity at pH 
7.4 in vitro; with more sensitive virions, p7 may have to act earlier in the virus life cycle 
and prevent even slight alterations to endosomal acidification 
The drop in infectivity also seen with the intracellular H77 virus and many of the 
Seattle p7 viruses may be accounted for by an effect shown in section 5.2.3. An 
endosome-targeted pH sensor protein fused to the endosomal protein VAMP2 
(Miesenbock et al., 1998) was shown to be highly responsive to external buffer pH in 
Huh7 cells, and so the acidification of the media may also result in acidification of 
intracellular compartments, thus overriding any ability of p7 to raise endosomal pH.  
4.3.3 Virions from Seattle variants M1, S1 and S2 show possible 
intermediate pH sensitivities 
If the virion pH sensitivity were mediated entirely by the structural proteins that form 
the virion, particularly the E1 and E2 envelope glycoproteins that mediate acid-
dependent membrane fusion (Hsu et al., 2003), then it would be expected that the 
virions produced by the Seattle p7 viruses would be identical to those produced by the 
parental H77 chimera. However, as this was not the case it raises the intriguing 
possibility of p7 mediating a process of virus maturation that renders the virions 
resistant to transient exposure to reduced pH. Another possibility is that p7 could be 
present in the virions in very low numbers, and the variations in p7 may affect the 
resistance of the virions to reduced pH. p7 has never been detected in virions, so this 
possibility can be considered unlikely. 
However, these experiments were not repeated due to reasons of time and so further 
repeats would be advisable before it can be stated with certainty that the changes in 
p7 have altered the pH sensitivity of the virions, as the initial timecourse assays 
showed that all Seattle viruses but S1 had reduced infectivity at 72 hrs.  
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4.3.4 JFH1 and H77 virus particles show similar thermal stability 
A possible explanation for the greater sensitivity of H77 virions to transient reductions 
in pH could be that the virion components Core, E1 and E2 formed less stable 
interactions than in JFH1 virions. If the non-covalent associations between these 
proteins were weaker, then it would be expected that H77 virions would be heat 
inactivated more quickly than JFH1. The thermal inactivation of JFH1 virus infectivity 
had previously been shown over a 40 minute period at 54 °C (Song et al., 2010), and 
so secreted virions were tested at this temperature. It was found that JFH1 and H77 
virions had no major differences in the speed at which they were heat inactivated. 
Thus, the pH-sensitivity of the secreted virions is not dictated by the overall stability of 
the virus particles. 
4.3.5 p7 inhibitor sensitivities changed in S1 (Y31H) 
4.3.5.1 S1 (Y31H) shows an increased sensitivity to rimantadine, M1 and S2 are 
comparable to H77 
The increased sensitivity of S1 to rimantadine is surprising when the sequences of 
H77, M1 and S2 are compared. Of the 3 Seattle isolate viruses tested, S1 has the 
least total deviation from the H77 sequence, with a single non-synonymous variant 
Y31H, and three synonymous changes I7L, V41A and F45V. This compares with 9 
variant residues between M1 and H77, and 8 variants between S2 and H77. The 
mutations previously found to confer adamantane resistance in J4 p7 were L20F 
(Foster et al., 2011), and amantadine resistance with L50-55A (StGelais et al., 2009). 
S1, like H77 has a valine at position 20 and no alterations to L50-55. A leucine-rich 
binding pocket was identified in J4 p7 as the rimantadine binding site (Foster et al., 
2011), but the sole additional leucine residue in S1 is at position 7, predicted to lie in 
the N-terminal lumenal tail rather than adjacent to other leucine residues in the TMDs. 
Also the same I7V variant is present in S2, which showed no increased sensitivity to 
rimantadine. Thus, the increase in rimantadine sensitivity observed does not conform 
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to any known precedent in previously-studied p7 resistance mutations, and may be 
due to its gating phenotype. 
M1 also shows a low-pH activation profile, but no sensitivity to rimantadine. M1 has 
just under half the initial rate of H77 at pH 7.4 in the liposome assay, while the very 
low activity of S1 at pH 7.4 may indicate that the S1 channel is almost completely 
inactive at this pH. The Y31H variation may cause this low channel activity, both as an 
additional barrier to ion passage through the channel, and as a relatively hydrophobic 
residue at pH 7.4.  
4.3.5.2 S1 shows greater NNDNJ inhibition 
NNDNJ was included as a control drug that inhibits both JFH1 and H77 p7. However, 
S1 p7 viruses possessed an enhanced sensitivity to this drug on the production of 
infectious virus. F25A is known to confer NNDNJ resistance (Foster et al., 2011), but 
both H77 and all the Seattle variants also have phenylalanine at this position and so 
this cannot explain the increased sensitivity to NNDNJ observed. One possibility is 
that the low levels of p7 expression with S1 when compared with S2 could mean that 
there are proportionately fewer p7 channels present in the cell. This may enhance the 
effectiveness of NNDNJ on the production of infectious virus.  
4.4 Conclusions 
All the Seattle isolate p7 sequences were able to produce infectious virus when 
cloned into an H77 chimeric background, although S1 resulted in a significant drop in 
viral titres. The R35G variant in S3-2 caused only a slight drop in viral titres, and a 
delay in virus release shown by the peak in the secreted: intracellular ratio at 48 hrs 
rather than 24 hrs. Once again, no differences were observed between the ‘mild’ M 
and ‘severe’ S isolates. H77 virions are more sensitive to transient exposure to 
reduced pH.  
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 Chapter 5: The development of cell 
based assays to measure p7 activity. 
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5.1 Introduction 
p7 has been shown to increase the pH of intracellular compartments. Blocking this 
process using p7 inhibitors significantly reduces virus infectivity (Wozniak et al., 2010). 
Whilst live cell imaging is an effective method to characterise the cellular effects of p7 
during virus infection, the use of live cell microscopy on cells infected with the JFH-1 
infectious clone presents a number of challenges. As no fluorescence microscope was 
available in the CL3 facility during the course of this study, cell based p7 assays 
suitable for a CL2 containment microscope required development. p7 alone and in the 
context of subgenomic replicons has previously been expressed in a number of cell-
based systems.  
Intracellular pH can be measured using a number of techniques. Lysosensor yellow-
blue DND-160 (Lysosensor Y/B) (Invitrogen Molecular Probes) was used in previous 
studies to determine that p7 raised endosomal pH, and that this effect could be blocked 
by the p7 inhibitor rimantadine (Wozniak et al., 2010). Fig. 5.1 shows the excitation (a) 
and emission (b) spectra for Lysosensor Y/B, with excitation peaks at 340 and 380 nm, 
and a major emission peak at 540 nm, with increased tailing towards 400  nm as the 
pH is increased. Previous work used dual excitation at 340 and 380  nm with emission 
readings taken at 440 and 525  nm respectively, and compared the ratio of these 
emission readings to a standard curve of Lysosensor Y/B in free solution to determine 
vesicular pH (Wozniak et al., 2010). 
Other investigations of intracellular pH have made use of a pH-sensitive GFP, 
ratiometric pHluorin, targeted to specific cellular compartments by tagging with 
appropriate cellular proteins of known specific endosomal distribution (Miesenbock et 
al., 1998). pHluorin was developed by targeted mutagenesis of fluorophore-adjacent 
residues to histidine, the only residue with a pKa in the physiological pH range, 
followed by random mutagenesis with selection for fluorescence and protein stability. 
This resulted in a single histidine substitution (S202H), and 8 compensatory mutations 
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for ratiometric pHluorin. Fig. 5.2 shows the excitation spectra for both native GFP and 
ratiometric pHluorin, both showing excitation peaks at 400 and 470 nm, with the 
emission read at 508 nm. Native GFP shows a slight reduction in excitation as the pH 
is reduced, but ratiometric pHluorin shows alterations in the ratio between the peaks 
(strongest peak = 400 nm at pH 7.5, at pH 5.5, strongest peak = 470 nm). VAMP2-
tagged pHluorin has previously been used to specifically measure endosomal pH as 
VAMP2 is known to distribute to sorting endosomes, late endosomes, or lysosomes 
(Smith & Lippiat, 2010). 
As it was not possible to use the full length virus for live-cell imaging, a number of p7-
expression constructs were considered and tested. p7-containing replicons were 
previously generated (Tedbury et al., 2011), although the function and localisation of p7 
in these replicons (where p7 is dispensable for replication) was not determined. A p7-
NS5B replicon represents the most physiologically-relevant system to assess p7 
cellular functions, where infectious live-virus cannot be used. To allow the investigation 
of the effect of p7 on intracellular pH through live cell imaging techniques, bicistronic 
constructs that express both SPp7 and mCherry as a marker protein were generated, 
as both pHluorin and Lysosensor Y/B display spectra emission in the green 
fluorescence wavelength while mCherry can be viewed at red emission wavelengths.  
A third cell-based system for measuring p7 activity is through two-electrode voltage 
clamp of Xenopus laevis oocytes. Rather than using fluorescent proteins or compounds 
to measure intracellular vesicle pH, the whole-cell two-electrode voltage clamp 
technique allows the measurement of ion flow across the cell, following the injection of 
oocytes with mRNA encoding JFH-1 p7 and subsequent ion channel formation in the 
oocyte plasma membrane. This system is widely used for measuring the activity of 
mammalian ion channels. Also, oocyte electrophysiology was successfully used to 
characterise many of the properties of the prototype viroporin, IAV M2. While this 
system has less physiological relevance to the normal p7 viroporin activity to increase 
endosomal pH, it can allow the detailed analysis of channel conductance.  
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In this chapter, three techniques were utilised to measure p7 function in cellular 
assays. Lysosensor Y/B and ratiometric pHluorin were used to measure the effect of p7 
on vesicular pH, and electrophysiological recordings allowed a detailed analysis of p7 
channel function, as previously performed with IAV M2.  
  
 
 
166 
 
 
Figure 5.1 Excitation and emission spectra of Lysosensor Yellow/Blue DND-160 
Panel (a) shows the excitation spectrum of Lysosensor Y/B between 275 nm and 
475 nm with the emission measured at 490 nm. Panel (b) shows the emission 
spectrum of Lysosensor Y/B between 380 nm and 700 nm with excitation at 360 nm. 
Lysosensor in free solution was titrated to the indicated pH for each spectrum. Image 
copyright: Invitrogen Molecular Probes. 
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Figure 5.2 Excitation spectrum of GFP and ratiometric pHluorin between pH 5.5 
and 7.5 
The excitation spectrum of (a) GFP and (b) ratiometric pHluorin between wavelengths 
350 and 500 nm, with emission read at 508 nm. GFP and Ratiometric pHluorin in free 
solution were titrated to the indicated pH points and results normalised to native GFP at 
pH 7.5. Taken from Miesenbock et al., 1998. 
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5.2 Results  
5.2.1 Live-cell imaging optimisation 
Both pHluorin and Lysosensor yellow/blue require the use of light wavelengths at or 
below 400 nm. It was found that ordinary tissue-culture dishes led to high background 
fluorescence at these wavelengths. Alternative systems were tested including glass-
bottomed 2 cm dishes (Iwaki), but these experiments were both time-consuming and 
low throughput. More high-throughput assays were attempted, utilising glass-bottomed 
96-well plates (Iwaki), but these displayed poor cell adhesion, even after poly-lysine 
treatment of the glass surface prior to cell seeding. After testing a number of options, 8-
well microscopy slides (Ibidi) were determined as the most suitable for subsequent 
assays. These slides allowed the best compromise for the experimental conditions 
under investigation and maintained the health of cells, allowing an effective number of 
images to be taken to give high N numbers for statistical significance, that could be 
captured in a reasonable timeframe before the fluorophores became bleached or, in 
the case of Lysosensor, trafficked out of the endosomal pathway. All fluorescence 
experiments herein were performed with 8-well slides, with the exception of the initial 
flow chamber pHluorin experiments which were carried out in fluorodishes (WPI) that 
could be fixed firmly to the confocal microscope.  
5.2.2 Lysosensor Y/B  
5.2.2.1 Lysosensor calibration 
Lysosensor Y/B has previously been used to measure the effect of p7 on intracellular 
pH. Previous recordings were performed on a confocal microscope with excitation 
wavelengths of 340nm and 380nm, with emission wavelengths read at 440nm and 
510nm respectively (Wozniak et al., 2010). These conditions could not be replicated 
with the facilities available, meaning a new system was developed that was able to 
approximate these conditions. A whole-cell fluorescence microscope was attached to a 
monochromator that was able to generate an excitation wavelength between 250-
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750 nm. Appropriate filters and dichroic mirrors were added to the system to allow 
measurements of blue (440 nm), green (530 nm) and red (615 nm) emission 
wavelengths. Initial work with Lysosensor Y/B found that an excitation wavelength of 
340nm produced a high background level of fluorescence; whilst a single excitation 
wavelength at 380nm produced a small but recordable signal in the blue emission 
channel. As the ratio between green/blue emissions was required for the ratiometric 
measurement of pH, the midpoint excitation wavelength of 360 nm – where the 
excitation spectra shown in Fig. 5.1 converge – was found to produce sufficient blue 
signal above the background levels to allow accurate readings to be performed.  
The pH dependent behaviour of Lysosensor Y/B was next established using this 
system. The dye was diluted to 100 nm in HEPES cell buffer at a range of pH values, 
and a curve of the ratiometric change in response to changes in pH was generated. An 
equation relating the Lysosensor Y/B ratio at each pH value was then generated from 
this curve (Fig 5.3). If experimental conditions were altered, this curve had to be re-
determined in order to allow an accurate pH calculation in each experiment. 
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Figure 5.3 Control curve for Lysosensor Y/B ratios in response to changes in pH 
Lysosensor Y/B at 10nm in free solution in HEPES cell buffer was titrated to the pH 
points shown and fluorescence readings taken at emission wavelengths of 420 nm and 
530 nm with excitation at 360 nm. Fluorescence intensity was measured using Image J 
analysis software, and the 530 nm signal divided by the 420 nm signal to generate the 
Green/blue ratio. Microsoft Excel was used to calculate the natural log of the 
Green/blue emission ratio, a linear regression line calculated and the equation shown 
to allow the calculation of pH values from green/blue ratio. Ratios were taken from 10 
images for each data point. Error bars = SD 
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5.2.2.2 Positive control and p7 inhibitor concentration calibration 
Lysosensor Y/B has been previously used to show that p7 prevents endosomal 
acidification (Wozniak et al., 2010). In order to assess the correct function of the 
Lysosensor Y/B, compounds previously shown to alkalinise endosomes were used as 
positive controls. Bafilomycin A (BafA) is an inhibitor of the cellular vATPase that drives 
protons into the lumen of endosomes, the inhibition of which prevents endosomal 
acidification and has previously been used with Lysosensor Y/B (Wozniak et al., 2010). 
Chloroquine (CQ) is a drug originally used to treat malaria, which preferentially 
accumulates in acidic cellular compartments and increases their pH (Homewood et al., 
1972). Ammonium chloride (AmCl) and chloroquine (CQ) are both lysomotropic 
amines, which are membrane permeable until protonated in the low pH of lysosomes 
and other acidic cellular compartments (Dijkstra et al., 1984). Sodium bicarbonate 
(NaHCO3) has also previously been used to induce endosomal alkalinisation (Jamel 
Mankouri, unpublished observations). 
Each of these drugs was tested at their characterised inhibitory concentrations (Fig. 5.4 
(a)). AmCl is not shown, as it was found to either inhibit lysosensor uptake or cause cell 
death, meaning no Lysosensor Y/B staining was visible. BafA at 100 pM showed no 
effects on cellular pH compared to untreated controls. CQ and NaHCO3 both influenced 
the lysosensor ratios, and these two compounds were taken forwards into subsequent 
experiments (Fig. 5.4 (b)). This second experiment found that, of the two compounds, 
CQ was the most effective at inducing a change in the lysosensor ratio. Further 
calibrations with CQ titration over a range of 2-20 μM showed a dose-dependent effect 
on endosomal pH (Fig. 5.4 (c)) 
To assess the effects of p7 inhibition on intracellular pH, a reversible effect on the 
Lysosensor ratio would be expected with the specific p7 inhibitor rimantadine. It was 
first important to investigate any non-specific effects of rimantadine on the Lysosensor 
Y/B ratio, as rimantadine is a basic compound that, in high enough concentrations, 
could non-specifically elevate endosomal pH. Consistent with this, 100 μM rimantadine 
 
 
172 
 
increased the measured endosomal pH from 3.8 to 5.6. At lower concentrations known 
to maintain p7 inhibition, (50 μM) rimantadine displayed a lesser effect, increasing the 
endosomal pH from 3.8 to 4.7 (Fig. 5.5).  
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Figure 5.4 Positive controls for Lysosensor calibration 
Panel (a): Huh 7.5 cells were incubated with 20 μM chloroquine (CQ), 10 μM sodium 
bicarbonate (NaHCO3) and 100 pM bafilomycin A (Baf A) to test their ability to 
alkalinise endosomal compartments. Chemicals were applied for 2 hours prior to 
imaging, with cells also incubated with 2 μM Lysosensor Y/B for 30 minutes before 
immediate imaging. Panel (b). Chloroquine and sodium bicarbonate were tested 
further. Panel (c): titration of chloroquine from 2 μM to 20 μM. For all data-points N = 20 
cells. A Student T test was used to compare all chemicals with the cell-only control, * = 
p≤ 0.05, ** = p≤ 0.01  
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Figure 5.5 Effect of the p7 inhibitor rimantadine on vesicular pH 
Huh 7.5 cells were incubated with 1-100 μM rimantadine for 2 hrs minutes prior to 
Lysosensor Y/B imaging. Fluorescence intensity was measured using ImageJ, data 
processed and pH values calculated using Microsoft Excel.  
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5.2.2.3 SPp7-NS5B replicons 
Live-cell imaging could not be performed on virus-infected cells as no suitable 
microscopes were available for use in the CL3 facility. The next most physiologically 
relevant system was the SPp7-NS5B subgenomic replicon (SGR). The SGR does not 
typically include p7, as it is not required for genome replication, but previous work had 
developed a number of replicons containing NS2-5b and SPp7-5b, in both a GT1B 
background (Con1/FK5.1) and JFH1 (Tedbury et al., 2011). The preceding signal 
peptide from E2 was found to be required, as without it the replicon was not functional 
(Phillip Tedbury, unpublished observations).  
These replicons were developed to study NS2 localisation and function, and p7 
expression was not characterised at the time. Analysis of the two replicons found that 
p7 expression was not detectable in the Con1/FK5.1 replicon, but could be detected by 
western blot analysis in the JFH1 SPp7-5B system (Fig. 5.6 (a)). The effect of p7 
expression on vesicular pH was therefore analysed using Lysosensor Y/B comparing 
the vesicular pH of naive Huh 7.5 cells to that of the JFH1 SPp7-5b replicon, with the 
JFH1 NS2-5B replicon included as a control for any non-specific effects of the replicon 
on endosomal pH.  
The results, shown in Fig. 5.6 (b), show the vesicular pH of untransfected Huh 7.5 was 
averaged at 4.4, with the positive control CQ increasing the endosomal pH to 7.3. Cells 
harbouring the NS2-5B SGR displayed a lower endosomal pH than untransfected cells 
(pH 3.8) that increased to pH 5.1 following treatment with 50 μM rimantadine. Both 
these data-points showed statistically significant differences to the normal endosomal 
pH of Huh 7.5 cells. The SPp7-5B replicon-harbouring cells showed a pH of 4.1, 
increasing to 4.9 following treatment with 50 μM rimantadine. Neither of these two data-
points showed statistically significant differences to Huh 7.5 cells. These results 
indicate that despite the p7 expression detected by western blot, p7 fails to increase 
endosomal pH in replicon harbouring cells.   
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Figure 5.6 Vesicular pH in JFH1 SPp7 replicon cells 
Panel (a): Western blots for GAPDH and p7, for Huh 7.5 cells, and Huh 7.5 cells 
harbouring the JFH1 NS2-5B and SPp7-5B replicons. p7 was run on 10% Tris-tricine 
gels and probed with the 2716 p7 antibody. GAPDH was run on 12% Tris-glycine. 
Panel (b): pH values generated by the green/blue Lysosensor Y/B ratios for each cell 
line, with and without 50 μM rimantadine. Lysosensor Y/B was incubated at 5 μM for 30 
minutes prior to imaging. Fluorescence intensity was measured using ImageJ and data 
processed using Microsoft Excel. N = 20 cells for each data-point. A Student T test was 
used to compare each value with that of the Huh 7.5 cells, * = p≤ 0.05, ** = p≤ 0.01 
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5.2.2.4 Bicistronic SPp7-IRES-mCherry 
A number of mammalian cell p7 expression constructs, containing a variety of epitope 
tags, have previously been generated. The majority of these constructs were epitope 
insertions that allowed visualisation of p7 by fixed-cell immunofluorescence. For live 
cell imaging experiments, bicistronic constructs expressing both p7 and the red 
fluorescent protein mCherry were cloned. These were based on previously 
characterised constructs containing IAV M2 and mCherry. Previous work had shown 
that the inclusion of the preceding signal-peptide sequence of E2 (SP) improved the 
expression of p7. The pLXV-M2-IRES-mCherry construct proved difficult to clone, and 
so PCR was used to amplify the region containing the IRES and mCherry sequences, 
allowing successful cloning into the mammalian expression construct pCDNA3.1+. The 
p7 sequence was then cloned into the pCDNA3-IRES-mCherry constructs and p7 
expression assessed by Western blot analysis, shown in Fig. 5.7 (a). 
Huh 7 cells were transfected with the pCDNA3-SPp7-IRES-mCherry (SPp7 ImC) 
construct and incubated for 24 hours. Images showing red fluorescent cells were 
analysed for the effect of p7 expression on the Lysosensor Y/B ratio. Analysis of the 
Lysosensor Y/B ratio for non-transfected cells showed a mean pH of 3.3, which 
increased to 5.9 when the cells were treated with 20 μM chloroquine. The cells 
expressing SPp7 ImC showed a mean pH of 3.0, which was slightly lower than the 
non-transfected cells, but showed no statistically significant difference. Thus, while p7 
expression in cells has been shown with this construct, no effects of p7 on vesicular pH 
in this system were observed. 
  
 
 
178 
 
 
Figure 5.7 Vesicular pH in Huh7 cells transfected with SPp7-ImC 
Huh 7 cells were transfected with pCDNA3-SPp7-IRES-mCherry (SPp7-ImC). Panel 
(a): transfected cells were harvested at 24 and 48 hours post-transfection and analysed 
by western blot. Samples were run on 10% Tris-tricine gel and probed with 1055 TB p7 
antibody. Panel (b): vesicular pH values generated by the green/blue Lysosensor Y/B 
ratios. Transfected cells were incubated with Lysosensor Y/B as before and imaged. N 
= 15 cells, pH values were compared with Huh7 cells using Student T test, * = p≤ 0.05 
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5.2.3 Ratiometric pHluorin 
5.2.3.1 The effects of FCCP treatment on endosomal pH 
In collaboration with Dr. Jonathan Lippiat, who had previously used the VAMP2-
pHluorin construct to measure endosomal pH (Smith & Lippiat, 2010), initial control 
experiments were performed in HEK 293T cells transfected for 24 hrs with the 
construct. Cells were viewed on a confocal microscope with excitation at 488 nm, and a 
buffer flow system that continuously flushed the glass-bottomed dish with HEPES cell 
buffer was constructed. Under this system, the protonophore FCCP – an ionophore 
that allows protons to cross lipid bilayers – could be transiently added to the cells and 
washed away, with any perturbation to the endosomal pH shown by a reduction, 
followed by recovery of the green emission signal. Only one emission wavelength could 
be read during the timecourse, but this was sufficient to qualitatively measure the 
changes in endosomal pH.  
Initial control experiments showed promising results (Fig. 5.8 (a)), with a 40% decrease 
of pHluorin fluorescence emission following an influx of FCCP at the 3 minute 
timepoint, and a recovery of the signal following the removal of FCCP at the 8 minute 
timepoint recorded. However, 6 subsequent experiments failed to show any response 
to FCCP. A representative example of one of these experiments is shown in Fig. 5.8 
(b). 
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Figure 5.8 Real-time drop in pHluorin signal in response to FCCP at pH 7.4 in 
293T cells 
HEK293T cells were plated onto glass-bottomed dishes and transfected with VAMP2-
pHluorin. 24 hrs post-transfection cells were bathed in HEPES cell buffer under a 
gentle flow rate. pHluorin was imaged every 15 seconds at 530 nm with 488nm 
excitation. After 3 minutes, the ionophore FCCP (4 μM) was washed into the cell dish, 
and after 8 minutes was removed. Panel (a) shows the results of an initial experiment. 
N = 5 cells. Panel (b) is a representative example of 6 experiments performed to repeat 
the experiment shown in Panel (a). N= 6 cells. Error bars = SD 
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5.2.3.2 Whole-cell fluorescence microscopy  
The whole-cell fluorescence microscope set up for Lysosensor Y/B could also be 
utilised to measure ratiometric pHluorin. However, 293T cells were not suitable for use 
in this system due to their rounded shape, resulting in images of poor resolution. Huh7 
cells were utilised as the most physiologically relevant cell line for HCV studies, 
particularly for comparison to virus/replicon harbouring cells. Cos7 cells were also 
selected due to their flat and defined nature, and the high expression levels of this cell 
line following transfection.  
Control experiments were carried out to generate the pH-response curve of the ratio of 
green: blue excitation, and to determine if the external pH buffer affects endosomal pH. 
Immediately prior to imaging, the cell media was replaced with HEPES cell buffer 
titrated to the pH points shown, in the absence or presence of the protonophore FCCP 
to equalise the endosomal pH with the external buffer. The results are shown in Fig. 
5.9. Both Huh7 and Cos7 cells displayed identical pH response curves in the presence 
and absence of FCCP. For Huh7 cells at pH 7.4, the green/blue excitation ratio was 
1.1, and at pH 5.1 the ratios were 2.5 for untreated cells, and 2.4 for FCCP treated 
cells. For Cos7 cells, at pH 7.4 the ratios were 1.2 for untreated and 1.0 for FCCP 
treated, and at pH 5.2 the ratios were 1.9 for untreated and 2.2 for FCCP treated. This 
indicates that, even without the presence of a protonophore to facilitate the transport of 
hydrogen ions across cell membranes, the endosomal pH of the cells is equilibrating 
with the external buffer pH. Thus, the VAMP2-pHluorin construct was deemed 
unsuitable as a measure of the ability of p7 to increase endosomal pH.  
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Figure 5.9 Control experiments of pHluorin in Huh7/Cos7 cells over the pH range, 
with and without FCCP 
Huh7 and Cos7 cells were transfected with the VAMP2-pHluorin construct in 8-well 
microcroscopy slides and imaged 16 hrs post-transfection. Cells were imaged in 
HEPES cell buffer titrated to the indicated pH points ± FCCP (4 μM). Panel (a) Huh7 
cells, Panel (b) Cos7 cells. Each data-point represents the mean from 10-30 cells. 
Error bars = SD 
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5.2.4 Xenopus oocyte two-electrode voltage clamp 
In collaboration with Dr. Jonathan Lippiat, attempts were made to use the Xenopus 
oocyte system to measure p7 activity. Xenopus laevis oocytes can be injected with 
mRNA encoding the protein of interest, with the protein typically trafficked at high levels 
to the plasma membrane, where its activity can be measured using two electrode 
voltage clamp recordings. This system has been frequently utilised for the high 
throughput assessment of the function of mammalian cell ion channel activity.  
To allow Xenopus oocyte expression of p7, the J4 FLAG-p7 sequence was cloned into 
the vector pBF+, and capped mRNA synthesised using an SP7 transcription kit 
(Ambion). The mRNA was then micro-injected into prepared oocytes and incubated for 
24 hrs to allow protein expression prior to patch clamp recordings. When recordings 
were performed at pH 7.4, no channel activity was detectable above that of the mock-
injected (water) controls, suggesting no functional p7 activity was present (Fig 
5.10 (b)). However, when the pH of the oocyte bathing solution was reduced to pH 6.2 
a voltage dependent increase in the currents was observed, that peaked at ~3 μA at 
100 mV. No currents above those of endogenous channels were observed in the mock-
injected oocytes.  
Attempts to repeat this work, however, were unsuccessful as the health of the oocytes 
consistently deteriorated during the 24 hour incubation period post-microinjection. This 
was attributed to the poor-quality oocytes which were also observed in similar 
experiments in the laboratory. Within the scope of this PhD it was not possible to 
repeat this work.  
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Figure 5.10 Electrophysiology analysis of J4 FLAG-p7 expressed in Xenopus 
laevis oocytes 
mRNA transcribed from the pBF+ vector containing the J4 FLAG-p7 sequence was 
injected into prepared Xenopus laevis oocytes as described in section 2.10. After 
24 hrs to allow protein expression, patch clamp recordings were performed. Panel (a) 
shows the mRNA and p7 western blot, Panel (b) shows the ion channel activity of mock 
injected and J4 p7 mRNA injected oocytes at pH 7.4, Panel (c) shows the ion channel 
activity of mock injected and J4 p7 mRNA injected oocytes at pH 6.2. N = 6 oocytes. 
Error bars = SEM. All electrophysiology experiments were performed by Dr. Jonathan 
Lippiat.  
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5.3 Discussion 
5.3.1 Lysosensor Y/B  
Previous studies that used Lysosensor Y/B to measure the effect of p7 on vesicular pH 
used a full-length H77 replicon system (Wozniak et al., 2010), and confocal microscopy 
with dual-excitation wavelengths. It was not possible to replicate these conditions as 
the use of the full-length virus would have required the use of a confocal microscope in 
a CL3 facility. Thus, attempts were made to replicate both the microscopy conditions 
and a suitable p7 expression system for CL2 analysis. The control experiments show 
that it was possible to measure the vesicular pH of Huh7/7.5 cells using this system. In 
addition, the lysomotropic drug chloroquine was able to raise endosomal pH in a 
statistically significant manner. However, in contrast to previously published data, the 
ability of the ability of p7 to raise vesicular pH in these systems was not observed.  
5.3.2 Ratiometric pHluorin  
The lack of response of VAMP2-pHluorin to alterations in the external pH was unlikely 
to be due to incorrect distribution of the protein, as cells showed a punctate, 
cytoplasmic VAMP-2 like distribution consistent with an endosomal distribution.  
The limitations found with pHluorin may have been overcome with extensive testing in 
other tumour derived cell lines. As HCV has been shown only to replicate in hepatocyte 
derived cell lines and cell lines of neuronal lineage, the physiological representation of 
p7 activity in non-permissive cells would have been questionable. The single working 
control experiment with VAMP2-pHluorin in 293T cells where FCCP showed a transient 
effect showed some potential, but the lack of reproducibility made it unsuitable as an 
experimental method.  
5.3.3 Xenopus laevis oocyte two-electrode voltage clamp 
The Xenopus laevis oocyte experiments showed the highest potential of all the 
methods tested in this chapter, and indeed this method has been used in recent 
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published studies with GT2A p7 (OuYang et al., 2013). IAV M2 viroporin activity, with 
its pH gating and directionality of proton flux has been well characterised in this 
system, with M2 activity shown in the positive voltage range, with no detectable 
currents in the negative voltage range. The measured J4 p7 activity at pH 6.2 provides 
further evidence for low-pH activation of this channel, and recent studies manipulating 
this system have demonstrated reduced function for inhibitory p7 mutations (OuYang et 
al., 2013). Further assessment of p7 activity using non-functional mutants, the inclusion 
of p7 inhibitors to block measured p7 currents, and comparison of the functionality of 
p7 across genotypes will be further required to verify the Xenopus system as a more 
physiological assay for p7 activity than previously described liposome assays. 
Expression of native p7 in bacteria is known to be toxic to bacterial cells, but the lack of 
current above control levels shown at pH 7.4 means that for J4 FLAG-p7, the channel 
is unlikely to be active during the 24 hr expression period prior to readings, therefore p7 
activity is unlikely to be killing the cells during this period. If this was the case, other p7 
isolates that do not display a low-pH activation profile and are thus more active at pH 
7.4 may prove more toxic, and it can be speculated that the addition of p7 inhibitors to 
the bathing media during this time period may improve cell survival. 
5.4 Conclusions 
Attempts to develop a cell-based assay for the effects of p7 on endosomal pH using 
Lysosensor Y/B and ratiometric pHluorin were unsuccessful. Xenopus oocyte 
electrophysiology showed strong potential as a technique to analyse p7 channel 
function, but was not reproducible within the scope of this project. 
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 Chapter 6 – General discussion and 
future perspectives  
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This study demonstrates that the natural HCV quasispecies sequence variation that 
occurs within patients is capable of generating significant changes in the behaviour of 
the HCV viroporin p7 protein in vitro. According with the known roles of p7 in the HCV 
lifecycle, these sequence variations also lead to changes in the production and 
secretion of infectious virus and the response to p7 inhibitors (Chapter 4). p7 is a 
potential target for direct-acting antiviral drugs (Griffin, 2010). Understanding how 
changes in the p7 sequence affect both the function of the protein, and its sensitivity 
to characterised p7 inhibitors, will aid in the development of new anti-HCV 
compounds. Current HCV therapy includes only one type of direct acting anti-viral that 
targets the NS3-4A viral protease (Lange et al., 2010). Further drugs targeting other 
viral proteins and stages in the virus life cycle may significantly increase the efficacy 
of treatment, as is the case with HIV. A number of p7 structural studies have now 
been published (Foster et al., 2014; Cook et al., 2013), including an NMR structure of 
a GT5a p7 oligomer (OuYang et al., 2013), and these structures could allow much 
more accurate modelling of how changes in the amino acid sequence of the protein 
affect the function and inhibitor sensitivity.  
The use of patient isolate sequences has advantages over previous studies that 
performed targeted mutagenesis of p7 residues predicted to be important for normal 
p7 activity. By definition, the p7 sequences investigated in this study came from 
functional viruses that were able to replicate, assemble and release infectious 
progeny within human patients. Thus, it is less likely that any of these patient 
mutations would lead to protein processing defects that can occur with targeted 
mutagenesis. The observed phenotypes for the Seattle isolate p7 proteins, either in 
vitro or in virus did, however, fail to show any correlation to the disease severity of the 
patients (Chapters 3 and 4). This may argue against the level of p7 functionality 
directly contributing to the levels of disease pathogenesis in an in vivo system.  
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In this study, the p7 inhibitor assays and pH responsiveness of the Seattle isolate 
virions were only performed with 3 out of the 6 isolates under investigation (section 
4.6.2). Continuation of this work to determine if the reduced sensitivity of Seattle 
isolate virions compared with the parental H77 virions is consistent across more than 
one experiment and for all 6 isolates may determine whether p7 is involved in a 
glycoprotein maturation process that renders secreted virus insensitive to transient 
reductions in pH, as is the case with JFH1 (Wozniak et al., 2010). This may provide 
insight into further roles of p7 during assembly and egress of the virions, in addition to 
its prevention of endosomal acidification. S3-1 and S3-2 would make an interesting 
comparison in this case, as it can be speculated that the reduced p7 expression levels 
observed in S3-2 could may hinder such a maturation process and produce virions 
that are sensitive to transient exposure to reduced pH, as with the H77 chimera.  
The other possible reason for the observed change in virion pH sensitivity could be 
due to the presence of p7 in the virion, where it may serve to mediate virion uncoating 
during acid-dependent membrane fusion during virus entry, as previously 
demonstrated for M2 in influenza (Shimbo et al., 1996). Large-scale bulk preparation 
of secreted virus and p7 analysis by western blot or mass spectrometry could finally 
identify if indeed this is the case and p7 is present in the virion, in previously 
undetectable levels.  
Of the cell-based assays developed to study p7 function, Xenopus laevis oocyte 
electrophysiology showed the most potential for the detailed study of p7 function, and 
was recently used to confirm p7 viroporin activity in an NMR structural study (OuYang 
et al., 2013). Further work to standardise the Xenopus oocyte system, with known 
non-functional mutants and the application of known p7 activators/inhibitors are 
currently under investigation in the laboratory. This will further develop this system as 
a reliable and high throughput method to study p7 functionality.  
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The calibration and controls for Lysosensor Y/B showed that this system was able to 
measure changes in vesicular pH, but its use is limited by the lack of a suitable cell-
based p7 expression system for CL2 facilities. Future studies applying this method in 
the context of virus infected cells imaged under CL3 conditions, now possible with the 
recent acquisition of a confocal microscope in the CL3 facility, would allow p7 function 
to be studied in the context of the fully infectious virus system. This would allow a full 
temporal investigation into the role of p7 during the full course of HCV infection. 
Recently, a number of new HCV infectious clones have been developed. These 
include another GT 2A clone designated JFH2 (Date et al., 2012), three GT 2B clones 
(Ramirez et al., 2014) and a GT 1A clone that produces much higher titres than the 
previous H77 clone (Li et al., 2012b). The development of a wider range of HCV 
constructs that can be cultured as infectious virus will allow further investigation of the 
role of p7 in the whole virus lifecycle, and how changes in p7 structure between 
different genotypes affect the production of infectious virus.  
Recent further evidence of the role of p7 in assembly and release of infectious 
extracellular virus has been shown by studies of cell-cell transmission of HCV, where 
the p7 inhibitors BIT225, NNDNJ and Rimantadine caused a 50% reduction in 
transmission, while a GT 5A/JFH1 chimeric virus showed no effect of p7 inhibitors on 
reducing cell-cell virus transmission (Meredith et al., 2013). This raises the intriguing 
possibility that p7 may be involved in cell-cell transmission of the virus in some HCV 
isolates but not others, and is worth further investigation.  
The structural studies that have been published since this work was completed may 
also provide new avenues of investigation for the study of p7. As well as the NMR 
structure of the J4 monomer in methanol, a second monomer structure of the 
monomer in detergent micelles has also been published (Cook et al., 2013). This 
second monomer structure shows some differences with the methanol structure, the 
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slight kink in TMD1 is more pronounced, and the N-terminus without the FLAG-tag 
sequence does not form an α-helix. A further study used a GT 5A p7 to generate an 
NMR structure of the oligomer in detergent micelles (OuYang et al., 2013), and 
showed a more complex structure than previous computer models of the p7 oligomer 
structure had suggested. Each monomer is spread out, so that it not only interacts 
with its two immediate neighbours but also comes into contact with a further two 
monomers. The most constricted part of the channel is at the lumenal rather than the 
cytosolic side of the pore, with proposed channel gating residues at I6 and N9. 
However, the sequence of GT 5A shows low conservation with the previously-studied 
p7s, with only 25 residues out of 63 shared with J4 p7, so more work will be required 
to determine if this structure is applicable to other HCV isolates. It is noted in the 
oligomer study that this HCV isolate was chosen due to its ability to produce high-
quality NMR data unlike all other isolates that were tested, and this may perhaps be 
due to this isolate solely forming hexamers, whereas a mixture of hexamers and 
heptamers could explain why attempts to determine the oligomer structure of J4 p7 
have not been successful (T. Foster, unpublished observations).  
A possible adamantane binding site was also identified in the GT 5A oligomer 
structure which includes residue 20, which work in J4 p7 has previously shown to map 
to adamantane resistance when this residue was mutated (Foster et al., 2011). Thus, 
while there are substantial amino acid sequence differences between GT 5A and J4 
p7 that may result in significant structural differences, there may also be common 
elements between the structures that can potentially be targeted by p7 inhibitors. 
Further structural work on p7 isolates from across the genotypes could show why 
there is such a wide variation in inhibitor sensitivities, and potentially use any common 
structures as better inhibitor targets. This structural work can also be used as a 
starting point for further targeted mutagenesis of p7 in other genotypes to investigate 
how the channel gating mechanism may change as the p7 protein sequence evolves.  
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In conclusion, there are many further avenues of investigation that can be pursued 
from this work and from the work of others. This work, if continued, may lead to viable 
p7 inhibitors joining the ranks of the newly-developed directly-targeted drugs against 
HCV. 
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Appendix 1 – PCR oligonucleotides 
GST-FLAG-p7 cloning 
H77_EcoRI_FLAGp7for: 
ATATATGAATTCGCGGCCATGGATTACAAGGATGACGACGATAAGGCTTTGGAG
AACCTCGTAATACTCAATGCAGC  
H77_p7_NotIrev: ATATATACTGCAGGCGGCCGCTGCGTATGCCCGCTGAGGC  
S235_EcoRI_FLAGp7for: 
ATATATGAATTCGCGGCCATGGATTACAAGGATGACGACGATAAGGCTTTGGAAA
ACCTTGTATTGCTTAATGCGGC  
S235_p7_NotIrev: ATATATACTGCAGGCGGCCGCCGCGTATGCCCGTTGGGGC 
 
Virus cloning  
Seattle_long_for: 
GCAGACGCGCGCGTCTGCTCCTGCTTGTGGATGATGTTACTCATATCCCAAGCG
GAGGCGGCTTTGGAGAACCTCGT 
Seattle_short_for: GACGCGCGCGTCTGCTCCTGCTTGTGGATGATGTTACtc 
Seattle_short_rev: CCATAAGCACCAGCTGATATAGCGCTTG 
Seattle_chim_for: GCCTCAGCGGGCATACGCACTGGACACGGAGGTGGCCGCG 
Seattle_chim_rev: CGCGGCCACCTCCGTGTCCAGTGCGTATGCCCGCTGAGGC 
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IRES-mCherry cloning 
IRES_mCherryXhoI_for: ATATATCTCGAGCCTAACGTTACTGGCCGAAGC 
IRES_mCherryXbaI_rev: TAGATATCTAGAGGTTGATTGTTCCAGACGC 
EcoRI_SPp7_J4_for: 
ATATATGAATTCGCGGCCATGGATTACAAGGATGACGACGATAAGGCGCGCGTG
TGTGCCTGCTTGTGG 
BamHI_STOP_J4p7_rev: 
ATATATCCTAGGTTATTAGGCGTAAGCTCGTGGTGGTAACG 
 
pBF+ cloning 
EcoRI_FLAG-J4p7-fwd: 
ATATATGAATTCGCGGCCATGGATTACAAGGATGACGACGATAAGGCCTTAGAG
AACTTGGTGGTCC  
EcoRI_J4p7_rev: ATATATGAATTCTTAGGCGTAAGCTCGTGGTGGTAACGCC 
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Appendix 2 – ImageJ macro 
rename("Image1"); 
run("Duplicate...", "title=Image1-1"); 
run("Gaussian Blur...", "sigma=2"); 
run("Find Maxima...", "noise=10 output=[Single Points]"); 
run("Dilate"); 
run("Dilate"); 
run("Invert"); 
selectWindow("Image1-1"); 
setAutoThreshold("RenyiEntropy"); 
run("Convert to Mask"); 
imageCalculator("AND create", "Image1-1","Image1-1 Maxima"); 
selectWindow("Result of Image1-1"); 
run("Analyze Particles...", "size=3-Infinity circularity=0.00-
1.00 show=Outlines exclude add"); 
selectWindow("Image1"); 
roiManager("Show All"); 
roiManager("Measure"); 
run("Tile"); 
 
